The O
primary O
effectiveness O
measure O
, O
the B-Prim
horizontal I-Prim
VAS I-Prim
according I-Prim
to I-Prim
Jensen I-Prim
, O
has O
been O
analyzed O
at O
each O
follow-up O
moment O
by O
a O
t-test O
. O

Principal O
outcomes O
related O
to O
the O
person O
with O
dementia O
are O
behavioural B-Prim
and I-Prim
psychological I-Prim
symptoms I-Prim
of I-Prim
dementia I-Prim
( I-Prim
Neuropsychiatric I-Prim
Inventory I-Prim
– I-Prim
NPI-Q I-Prim
) I-Prim
80 I-Prim
and O
quality B-Prim
of I-Prim
life I-Prim
( I-Prim
DEMQoL I-Prim
) I-Prim
102 I-Prim
. O

The O
second O
question O
was O
what O
the O
primary O
end O
point O
would O
be O
. O

The O
guidelines O
contained O
14 O
recommendations O
on O
antibiotics O
, O
asthma O
/ O
COPD O
drugs O
and O
cholesterol O
drugs O
The O
main O
outcome O
measures O
were O
prescription B-Prim
data I-Prim
of I-Prim
a I-Prim
three-year I-Prim
period I-Prim
( I-Prim
one I-Prim
year I-Prim
before I-Prim
and I-Prim
2 I-Prim
years I-Prim
after I-Prim
guideline I-Prim
dissemination I-Prim
) I-Prim
and O
proportion B-Prim
of I-Prim
change I-Prim
according I-Prim
to I-Prim
recommendations I-Prim
. O

Primary O
outcome O
measure O
The O
changes O
on O
the O
primary O
outcome O
measurement O
, O
the B-Prim
CCQ I-Prim
, O
will O
be O
analysed O
with O
the O
repeated O
measurements O
ANOVA O
technique O
. O

The O
primary O
outcome O
of O
this O
study O
is O
clinical B-Prim
improvement I-Prim
of I-Prim
incontinence I-Prim
as I-Prim
measured I-Prim
with I-Prim
the I-Prim
validated I-Prim
Dutch I-Prim
version I-Prim
of I-Prim
the I-Prim
Urinary I-Prim
Distress I-Prim
Inventory I-Prim
( I-Prim
UDI I-Prim
) I-Prim
. O

Primary O
Outcome O
birth B-Prim
< I-Prim
37 I-Prim
weeks I-Prim
gestation I-Prim
following I-Prim
spontaneous I-Prim
onset I-Prim
of I-Prim
labour I-Prim
or I-Prim
following I-Prim
preterm I-Prim
prelabour I-Prim
rupture I-Prim
of I-Prim
membranes I-Prim
. O

Main O
variables O
: O
Utilization B-Prim
of I-Prim
health I-Prim
services I-Prim
, O
number B-Prim
and I-Prim
severity I-Prim
of I-Prim
somatic I-Prim
symptoms I-Prim
. O

Primary O
and O
secondary O
measures O
are O
completed O
at O
baseline O
( O
T0 O
) O
before O
the O
iCST O
programme O
, O
first O
follow-up O
at O
13 O
weeks O
after O
baseline O
( O
T1 O
) O
and O
second O
follow-up O
and O
primary O
endpoint O
at O
26 O
weeks O
after O
baseline O
( O
T2 O
) O
. O

Final O
inclusion O
criterion O
: O
scoring O
3 O
or O
more O
on O
a O
disability O
case-finding O
tool O
. O

The O
primary O
iQuit O
trial O
outcome O
is O
whether B-Prim
or I-Prim
not I-Prim
participants I-Prim
have I-Prim
abstained I-Prim
from I-Prim
smoking I-Prim
( I-Prim
self-reported I-Prim
three I-Prim
months I-Prim
prolonged I-Prim
abstinence I-Prim
) I-Prim
and O
the O
primary O
research O
question O
is O
whether O
or O
not O
tailored O
materials O
are O
more O
effective O
than O
generic O
materials O
in O
helping O
participants O
achieving O
this O
. O

Because O
POD O
is O
associated O
with O
worse O
outcomes O
in O
the O
future O
, O
some O
may O
argue O
that O
hospital O
mortality O
or O
longer-term O
mortality O
assessments O
be O
considered O
as O
the O
primary O
outcome O
to O
judge O
the O
efficacy O
of O
critical O
care O
interventions O
2 O
. O

The O
clinical O
significance O
of O
0.6 O
in O
the O
main O
outcome O
score O
is O
based O
on O
the O
estimation O
of O
discriminant O
validity O
showing O
that O
patients O
with O
diabetes O
, O
who O
could O
be O
compared O
with O
patients O
with O
CHD O
in O
terms O
of O
life-long O
disease O
, O
who O
reported O
poor O
self-rated O
health O
scored O
around O
3 O
in O
several O
subscales O
of O
SWE-DES O
– O
23 O
scale O
; O
corresponding O
figures O
for O
those O
who O
reported O
good O
self-rated O
health O
was O
around O
0.6 O
above O
3 O
31 O
. O

The O
primary O
outcome O
will O
be O
the B-Prim
proportion I-Prim
of I-Prim
patients I-Prim
with I-Prim
a I-Prim
reduction I-Prim
in I-Prim
systolic I-Prim
blood I-Prim
pressure I-Prim
≥ I-Prim
10 I-Prim
mmHg I-Prim
at I-Prim
eight I-Prim
months I-Prim
after I-Prim
the I-Prim
start I-Prim
of I-Prim
the I-Prim
trial I-Prim
. O

Statistical O
analysis O
Sample O
size O
and O
power O
With O
regard O
to O
re-visits B-Prim
to I-Prim
the I-Prim
program I-Prim
( O
first O
primary O
outcome O
measure O
) O
, O
it O
is O
estimated O
that O
approximately O
50 O
% O
of O
the O
respondents O
of O
the O
no-prompting O
condition O
will O
visit O
the O
site O
more O
often O
than O
four O
times O
( O
after O
the O
baseline O
, O
and O
the O
first O
three O
post O
tests O
after O
six O
, O
twelve O
and O
eighteen O
months O
) O
. O

Sample O
size O
The O
sample O
size O
is O
based O
on O
the O
primary O
outcome O
parameter O
and O
the O
primary O
analysis O
. O

Primary O
outcomes O
are O
autonomic B-Prim
and I-Prim
neuroendocrine I-Prim
regulation I-Prim
and O
affective B-Prim
responses I-Prim
. O

Linear O
regression O
models O
, O
adjusting O
for O
baseline O
covariates O
, O
will O
be O
used O
to O
compare O
the O
treatment O
groups O
at O
6 O
weeks O
for O
the O
primary O
outcome O
, O
and O
any O
other O
continuous O
secondary O
outcomes O
that O
fit O
the O
assumptions O
. O

To O
assess O
the O
primary O
outcome O
, O
patients O
are O
asked O
to O
perform O
a O
straining O
maneuver O
in O
a O
sitting O
position O
( O
patients O
not O
able O
to O
sit O
will O
be O
assessed O
in O
a O
lateral O
decubitus O
position O
) O
. O

The O
functional O
exercise O
intervention O
begins O
at O
week O
12 O
and O
all O
patients O
will O
complete O
the O
Primary O
and O
Secondary O
outcome O
assessments O
at O
this O
point O
. O

Principal O
outcomes O
related O
to O
the O
caregiver O
are O
caregiver B-Prim
role I-Prim
strain I-Prim
( I-Prim
Zarit I-Prim
caregiver I-Prim
burden I-Prim
interview I-Prim
) I-Prim
, O
psychological B-Prim
distress I-Prim
( I-Prim
SRQ I-Prim
20 I-Prim
) I-Prim
, O
and O
quality B-Prim
of I-Prim
Life I-Prim
( I-Prim
the I-Prim
17 I-Prim
item I-Prim
WHO-QoL I-Prim
Bref I-Prim
) I-Prim
101 I-Prim
. O

The O
primary O
parameters O
in O
the O
model O
( O
V O
c O
, O
k O
12 O
, O
and O
k O
21 O
) O
were O
estimated O
by O
applying O
a O
non-linear O
least-squares O
regression O
routine O
( O
fminsearch O
) O
by O
using O
Matlab O
R2010a O
software O
( O
The O
MathWorks O
, O
Inc. O
, O
Natick O
, O
MA O
, O
USA O
) O
, O
whereas O
k O
10 O
was O
calculated O
as O
a O
secondary O
parameter O
as O
follows O
: O
k O
10 O
= O
∑ O
urine O
volume O
/ O
AUC O
for O
( O
v O
c O
- O
V O
c O
) O
, O
where O
AUC O
is O
the O
area O
under O
the O
curve O
. O

Primary O
outcome O
The O
primary O
outcome- O
perinatal B-Prim
mortality- I-Prim
will O
be O
evaluated O
using O
surveillance O
data O
. O

Randomisation O
takes O
place O
after O
the O
whole O
assessment O
has O
been O
completed O
, O
so O
that O
the O
first O
assessment O
is O
not O
dependent O
on O
the O
participant’s O
knowledge O
of O
treatment O
condition O
. O

It O
was O
also O
decided O
to O
change O
the O
principal O
outcome O
for O
subgroup O
analyses O
to O
look O
at O
the O
effects O
of O
fenofibrate O
in O
subjects O
with O
and O
without O
prior O
cardiovascular O
disease O
( O
CVD O
) O
( O
originally O
those O
with O
and O
without O
prior O
MI O
) O
. O

The O
primary O
outcome O
is O
Health-Related B-Prim
Quality I-Prim
of I-Prim
Life I-Prim
at I-Prim
12 I-Prim
months I-Prim
, I-Prim
measured I-Prim
using I-Prim
the I-Prim
Assessment I-Prim
of I-Prim
Quality I-Prim
of I-Prim
Life I-Prim
instrument I-Prim
. O

Primary O
endpoint O
was O
the B-Prim
Sum I-Prim
of I-Prim
Pain I-Prim
Intensity I-Prim
Differences I-Prim
( I-Prim
SPID I-Prim
) I-Prim
of I-Prim
the I-Prim
CSTP I-Prim
Intensity I-Prim
scale I-Prim
by I-Prim
the I-Prim
child I-Prim
. O

The O
measurement O
of O
the O
main O
variables O
of O
the O
study O
relies O
on O
three O
strategies O
: O
video O
recording O
of O
facial O
actions O
, O
monitoring O
of O
cardio-respiratory O
measures O
and O
oxygen O
saturations O
, O
collection O
of O
salivary O
cortisol O
and O
chart O
review O
( O
Table O
1 O
) O
. O

The O
primary O
outcome O
from O
our O
double-blind O
RCT O
is O
that O
amoxicillin O
significantly O
increased O
the O
proportion O
of O
children O
achieving O
normal O
middle O
ears O
( O
bilaterally O
aerated O
) O
at O
consecutive O
monthly O
examinations O
. O

The O
precise O
relation O
between O
the O
primary O
endpoint O
and O
the O
time O
between O
start O
of O
symptoms O
and O
start O
of O
EN O
will O
be O
analyzed O
using O
a O
generalized O
linear O
model O
with O
logarithmic O
link O
function O
and O
Bernouilli O
distribution O
, O
with O
independent O
variables O
time O
( O
between O
start O
of O
symptoms O
and O
start O
of O
EN O
) O
, O
time O
* O
time O
, O
APACHE-II O
score O
prior O
to O
randomization O
, O
hospital O
and O
co-morbidity O
( O
i.e. O

Power O
The O
sample O
size O
is O
based O
on O
power O
analysis O
, O
calculated O
on O
the O
basis O
of O
a O
change O
in O
the O
primary O
outcome O
during O
the O
period O
from O
the O
baseline O
to O
3 O
months O
post O
intervention O
. O

Primary O
outcomes O
will O
include O
: O
1 B-Prim
) I-Prim
pain I-Prim
severity I-Prim
at I-Prim
two-weeks I-Prim
, I-Prim
measured I-Prim
as I-Prim
the I-Prim
mean I-Prim
of I-Prim
average I-Prim
and I-Prim
worst I-Prim
pain I-Prim
and O
2 B-Prim
) I-Prim
pain-related I-Prim
impairment I-Prim
at I-Prim
2 I-Prim
weeks I-Prim
. O

Sample O
size O
The O
primary O
outcome O
in O
this O
trial O
is O
the B-Prim
change I-Prim
of I-Prim
the I-Prim
Visual I-Prim
Analogue I-Prim
Score I-Prim
( I-Prim
VAS I-Prim
) I-Prim
of I-Prim
average I-Prim
pain I-Prim
in I-Prim
the I-Prim
menstrual I-Prim
period I-Prim
between I-Prim
the I-Prim
baseline I-Prim
( I-Prim
Visit I-Prim
2 I-Prim
) I-Prim
and I-Prim
after I-Prim
treatment I-Prim
( I-Prim
Visit I-Prim
4 I-Prim
) I-Prim
. O

No O
significant O
difference O
in O
primary O
endpoint O
was O
found O
after O
1 O
year O
follow O
up O
( O
composite B-Prim
death I-Prim
, I-Prim
reinfarction I-Prim
, I-Prim
stroke I-Prim
, I-Prim
or I-Prim
new I-Prim
myocardial I-Prim
ischemia I-Prim
) O
. O

The O
primary O
outcome O
is O
dual-task B-Prim
effect I-Prim
on I-Prim
gait I-Prim
speed I-Prim
and O
cognition B-Prim
( I-Prim
reaction I-Prim
time I-Prim
and I-Prim
accuracy I-Prim
) I-Prim
during I-Prim
unobstructed I-Prim
walking I-Prim
at I-Prim
preferred I-Prim
and I-Prim
fastest I-Prim
comfortable I-Prim
walking I-Prim
speeds I-Prim
. O

The O
primary O
outcome O
measure O
is O
a B-Prim
5 I-Prim
% I-Prim
between-group I-Prim
difference I-Prim
in I-Prim
left I-Prim
ventricular I-Prim
ejection I-Prim
fraction I-Prim
measured I-Prim
by I-Prim
cardiac I-Prim
magnetic I-Prim
resonance I-Prim
imaging I-Prim
at I-Prim
12 I-Prim
months I-Prim
compared I-Prim
to I-Prim
baseline I-Prim
. O

The O
primary O
outcome O
is O
fatigue B-Prim
severity I-Prim
. O

While O
ideally O
we O
would O
have O
detection O
of O
melanoma O
as O
the O
primary O
outcome O
, O
this O
would O
require O
a O
much O
larger O
trial O
to O
have O
sufficient O
statistical O
power O
. O

Discussion O
We O
adopted O
the B-Prim
visual I-Prim
analogue I-Prim
scale I-Prim
for I-Prim
bothersomeness I-Prim
( I-Prim
not I-Prim
pain I-Prim
) I-Prim
as O
the O
primary O
outcome O
measurement O
. O

Outcomes O
Primary O
endpoints O
Two O
co-primary O
endpoints O
measuring O
number B-Prim
of I-Prim
antibiotic I-Prim
prescriptions I-Prim
and O
disease B-Prim
burden I-Prim
are O
considered O
. O

• O
An O
independent O
adjudication O
committee O
will O
be O
established O
to O
adjudicate O
all O
instances O
of O
a O
primary O
outcome O
( O
vaginal B-Prim
erosion I-Prim
or I-Prim
other I-Prim
serious I-Prim
adverse I-Prim
outcome I-Prim
) O
. O

Analytical O
plan O
Outcome O
1 O
- O
malaria B-Prim
morbidity I-Prim
The O
primary O
endpoint O
is O
a B-Prim
comparison I-Prim
of I-Prim
the I-Prim
incidence I-Prim
of I-Prim
clinical I-Prim
episodes I-Prim
of I-Prim
malaria I-Prim
in I-Prim
children I-Prim
in I-Prim
the I-Prim
2 I-Prim
intervention I-Prim
groups I-Prim
, I-Prim
measured I-Prim
by I-Prim
PCD I-Prim
. O

In O
case O
the O
primary O
endpoint O
is O
fulfilled O
, O
additional O
post-hoc O
analyses O
will O
be O
performed O
. O

Study O
population O
HbA1c B-Prim
was O
used O
as O
the O
principal O
variable O
for O
calculating O
the O
sample O
size O
. O

Hence O
, O
the O
participant O
may O
have O
been O
included O
by O
one O
member O
of O
the O
team O
; O
have O
been O
counselled O
by O
another O
; O
and O
have O
had O
final O
outcome O
assessed O
by O
a O
third O
member O
of O
the O
intervention O
team O
. O

There O
was O
no O
significant O
improvement O
in O
our O
primary O
outcome O
measure O
( O
the B-Prim
proportion I-Prim
with I-Prim
peak I-Prim
flow I-Prim
compared I-Prim
to I-Prim
best I-Prim
/ I-Prim
predicted I-Prim
) O
at O
either O
the O
6 O
or O
12 O
month O
time O
points O
after O
adjustment O
for O
baseline O
and O
practice O
effects O
. O

We O
did O
not O
correct O
for O
multiple O
testing O
; O
plasma O
cytokine O
data O
represent O
our O
primary O
endpoints O
with O
additional O
traits O
analyzed O
to O
provide O
complementary O
information O
regarding O
the O
model O
impact O
on O
diverse O
cardio-metabolic O
and O
biological O
pathways O
. O

Outcome O
measurements O
The O
primary O
endpoint O
shall O
be O
the B-Prim
prevalence I-Prim
of I-Prim
colorectal I-Prim
polyps I-Prim
and O
number B-Prim
of I-Prim
polyps I-Prim
after I-Prim
1-year's I-Prim
intervention I-Prim
. O

On O
the O
basis O
of O
an O
intention-to O
are O
measured O
with O
95 O
% O
confidence O
intervals O
at O
2 O
and O
12 O
weeks O
for O
both O
primary O
and O
secondary O
outcomes O
. O

After O
the O
intake O
procedure O
, O
which O
will O
include O
the O
first O
assessment O
of O
outcome O
variables O
, O
patients O
will O
be O
stratified O
in O
those O
with O
some O
dexterity O
and O
those O
with O
minimal O
control O
of O
paretic O
wrist O
and O
finger O
extension O
. O

To O
estimate O
the O
variance O
accounted O
for O
therapeutic O
relationship O
on O
the O
main O
outcome O
variable O
( O
IES-R B-Prim
) O
multiple O
regression O
analyses O
were O
used O
to O
further O
explore O
possible O
mediator O
or O
suppressor O
effects O
of O
the O
patients' O
ratings O
of O
the O
working O
alliance O
. O

To O
detect O
possible O
dose-response O
relationships O
, O
we O
used O
a O
logistic O
regression O
model O
to O
regress O
the O
primary O
outcome O
( O
prolonged B-Prim
abstinence I-Prim
) O
at O
t2 O
on O
the O
number O
of O
times O
logged O
in O
to O
the O
StopSite O
; O
only O
the O
respondents O
randomised O
to O
the O
StopSite O
( O
the O
experimental O
group O
) O
were O
included O
in O
the O
dose-response O
analyses O
. O

The O
relative O
effectiveness O
of O
self-management O
and O
patient O
education O
interventions O
for O
diabetes O
is O
varied O
9 O
and O
the O
primary O
outcomes O
similarly O
broad O
with O
some O
suggestion O
that O
only O
clinically O
relevant O
diabetes O
end-points O
( O
e.g. O

The O
primary O
outcome O
assessed O
was O
HSV-2 B-Prim
seroconversion I-Prim
during I-Prim
the I-Prim
study I-Prim
period I-Prim
. O

Further O
analysis O
plans O
The O
above O
analysis O
plans O
will O
be O
used O
for O
the O
analysis O
of O
intervention O
effects O
on O
the O
main O
outcome O
measures O
. O

Results O
Primary O
outcomes O
Significant O
differences O
in O
muscle O
strength O
were O
noted O
both O
in O
favour O
of O
Group O
I O
( O
PRE O
+ O
nutritional O
supplementation O
) O
and O
Group O
II O
( O
PRE O
+ O
placebo O
) O
, O
as O
compared O
to O
Group O
III O
( O
SE O
+ O
nutritional O
supplementation O
) O
and O
Group O
IV O
( O
SE O
+ O
placebo O
) O
. O

The O
primary O
outcome O
measure O
( O
change B-Prim
in I-Prim
waist I-Prim
circumference I-Prim
between I-Prim
T1 I-Prim
and I-Prim
T2 I-Prim
) O
will O
be O
compared O
between O
groups O
at O
T2 O
both O
crude O
( O
unadjusted O
) O
and O
adjusted O
for O
baseline O
waist O
circumference O
using O
analysis O
of O
covariance O
. O

Therefore O
, O
a O
second O
broader O
definition O
will O
include O
in O
the O
numerator O
all O
women O
with O
≥ O
500 O
mL O
measured O
blood O
loss O
OR O
women O
receiving O
a O
treatment O
dose O
of O
oxytocin O
( O
regardless O
of O
final O
measured O
blood O
loss O
) O
and O
will O
be O
assessed O
among O
all O
enrolled O
women O
. O

The O
primary O
endpoint O
is O
the B-Prim
rate I-Prim
of I-Prim
bowel I-Prim
obstruction I-Prim
within I-Prim
30 I-Prim
days I-Prim
after I-Prim
ileostomy I-Prim
closure I-Prim
. O

Data O
collection O
The O
main O
study O
outcome O
measures O
will O
be O
rates B-Prim
of I-Prim
performance I-Prim
of I-Prim
process I-Prim
of I-Prim
care I-Prim
and O
the B-Prim
patient I-Prim
based I-Prim
measures I-Prim
of I-Prim
functional I-Prim
and I-Prim
psychosocial I-Prim
wellbeing I-Prim
. O

Out O
of O
the O
100 O
patients O
who O
underwent O
the O
surgical O
intervention O
, O
91 O
were O
included O
in O
the O
final O
assessment O
at O
24 O
months O
( O
91 O
% O
) O
. O

Outcomes O
The O
primary O
outcome O
measure O
and O
endpoint O
will O
be O
the B-Prim
WOMAC I-Prim
Pain I-Prim
score I-Prim
measured I-Prim
1 I-Prim
year I-Prim
following I-Prim
knee I-Prim
arthroplasty I-Prim
63 O
64 O
65 O
66 O
67 O
. O

Results O
There O
was O
no O
significant O
effect O
of O
multivitamin O
supplementation O
on O
the O
primary O
endpoint O
of O
the O
trial O
: O
weight B-Prim
gain I-Prim
after I-Prim
eight I-Prim
weeks I-Prim
. O

During O
the O
first O
baseline O
measurement O
( O
T0 O
) O
, O
boys O
will O
try O
to O
fit O
the O
arm O
support O
under O
supervision O
of O
an O
experienced O
representative O
of O
Focal O
( O
the O
manufacturer O
of O
the O
TOP O
arm O
support O
) O
and O
the O
primary O
investigator O
. O

No O
primary O
outcome O
measure O
was O
determined O
, O
since O
the O
study O
has O
an O
exploratory O
character O
. O

The O
primary O
outcome O
measure O
is O
BMI B-Prim
; O
secondary O
outcomes O
measures O
are O
body B-Sec
fat I-Sec
from I-Sec
bioelectrical I-Sec
impedance I-Sec
, O
muscular B-Sec
fitness I-Sec
, O
objectively B-Sec
measured I-Sec
PA I-Sec
, O
dietary B-Sec
and I-Sec
sedentary I-Sec
behaviors I-Sec
and O
physical B-Sec
self-perception I-Sec
. O

We O
further O
examined O
the O
dose O
effects O
of O
statins O
on O
the O
primary O
and O
secondary O
outcomes O
by O
stratifying O
patients O
on O
the O
basis O
of O
doses O
equivalent O
to O
< O
40 O
mg O
and O
≥ O
40 O
mg O
of O
simvastatin O
. O

Primary O
outcome O
measures O
As O
in O
previous O
research O
by O
our O
team O
, O
the O
primary O
outcome O
measure O
for O
the O
study O
is O
the B-Prim
change I-Prim
in I-Prim
SADQ I-Prim
score I-Prim
at I-Prim
6 I-Prim
months I-Prim
post I-Prim
randomisation I-Prim
. O

The O
effects O
of O
baseline O
covariates O
expected O
to O
have O
an O
important O
influence O
on O
the O
primary O
outcome O
variables O
will O
be O
controlled O
for O
, O
by O
comparing O
covariate-adjusted O
analyses O
with O
unadjusted O
analyses O
. O

Although O
de O
facto O
a O
composite O
score O
of O
primary O
and O
secondary O
outcomes O
, O
' B-Prim
treatment I-Prim
response I-Prim
' I-Prim
is O
considered O
primary O
outcome O
as O
well O
. O

The O
primary O
outcome O
is O
to B-Prim
measure I-Prim
whether I-Prim
the I-Prim
child I-Prim
has I-Prim
become I-Prim
caries I-Prim
active I-Prim
( I-Prim
caries I-Prim
into I-Prim
dentine I-Prim
) I-Prim
. O

The O
primary O
outcome O
for O
this O
study O
was O
chosen O
to O
be O
mortality B-Prim
in I-Prim
the I-Prim
period I-Prim
from I-Prim
supplementation I-Prim
to I-Prim
6 I-Prim
months I-Prim
of I-Prim
age I-Prim
. O

Economic O
evaluation O
The O
economic O
evaluation O
will O
examine O
whether O
the O
intervention O
is O
associated O
with O
overall O
cost O
increases O
or O
cost O
decreases O
and O
will O
link O
the O
cost O
changes O
to O
incremental O
gains O
in O
effectiveness O
and O
primary O
outcomes O
. O

GRA1 O
will O
collect O
the O
socio-demographic O
and O
clinical O
characteristics O
, O
followed O
by O
primary O
outcome O
( O
HRQOL B-Prim
and O
physical B-Prim
function I-Prim
) O
and O
secondary O
outcome O
variables O
( O
physical B-Sec
fitness I-Sec
, O
psychosocial-cognitive B-Sec
functions I-Sec
, O
and O
physical B-Sec
activity I-Sec
) O
. O

Phase O
1 O
Nurses O
The O
first O
patient O
assessment O
will O
be O
discussed O
with O
a O
coach O
directly O
before O
and O
after O
completing O
the O
assessment O
. O

While O
the O
primary O
outcome O
composite O
score O
will O
provide O
a O
summary O
of O
the O
overall O
effectiveness O
of O
the O
intervention O
program O
, O
we O
will O
also O
examine O
each O
outcome O
component O
for O
a O
more O
detailed O
interpretation O
. O

Outcome O
measurements O
One O
primary O
and O
four O
secondary O
outcome O
measurements O
were O
used O
. O

Significant O
differences O
were O
observed O
in O
the O
decline O
of O
vital O
capacity O
( O
VC B-Prim
; O
primary O
endpoint O
) O
between O
placebo O
group O
and O
high-dose O
( O
1800 O
mg O
/ O
day O
) O
group O
; O
and O
in O
the O
secondary O
end O
point O
, O
the B-Sec
progression I-Sec
free I-Sec
survival I-Sec
( I-Sec
PFS I-Sec
) I-Sec
time I-Sec
, O
between O
the O
two O
groups O
. O

Primary O
outcome O
measures O
are O
symptoms B-Prim
of I-Prim
challenging I-Prim
behaviour I-Prim
( I-Prim
measured I-Prim
with I-Prim
the I-Prim
Cohen-Mansfield I-Prim
Agitation I-Prim
Inventory I-Prim
( I-Prim
CMAI I-Prim
) I-Prim
and I-Prim
the I-Prim
Neuropsychiatric I-Prim
Inventory-Nursing I-Prim
Home I-Prim
version I-Prim
( I-Prim
NPI-NH I-Prim
) I-Prim
) I-Prim
, O
and O
pain B-Prim
( I-Prim
measure I-Prim
with I-Prim
the I-Prim
Dutch I-Prim
version I-Prim
of I-Prim
the I-Prim
Pain I-Prim
Assessment I-Prim
Checklist I-Prim
for I-Prim
Seniors I-Prim
( I-Prim
PACSLAC-D I-Prim
) I-Prim
and I-Prim
the I-Prim
Minimum I-Prim
Data I-Prim
Set I-Prim
of I-Prim
the I-Prim
Resident I-Prim
Assessment I-Prim
Instrument I-Prim
( I-Prim
MDS-RAI I-Prim
) I-Prim
pain I-Prim
scale I-Prim
) I-Prim
. O

Primary O
outcome O
The O
primary O
outcome O
of O
this O
study O
is O
the B-Prim
psychological I-Prim
health I-Prim
of I-Prim
mothers I-Prim
in I-Prim
terms I-Prim
of I-Prim
anxiety I-Prim
and I-Prim
depression I-Prim
as I-Prim
measured I-Prim
by I-Prim
the I-Prim
Hospital I-Prim
Anxiety I-Prim
and I-Prim
Depression I-Prim
Scale I-Prim
( I-Prim
HADS I-Prim
) I-Prim
. O

The O
primary O
outcome O
is O
change B-Prim
in I-Prim
wheal I-Prim
and I-Prim
flare I-Prim
responses I-Prim
. O

Sample O
size O
was O
calculated O
based O
on O
an O
overall O
difference O
between O
participants O
in O
the O
intervention O
and O
control O
groups O
in O
the O
primary O
outcome O
measure O
of O
depression B-Prim
scores I-Prim
at I-Prim
6 I-Prim
months I-Prim
, O
where O
a O
sample O
size O
of O
n O
= O
100 O
was O
sufficient O
to O
detect O
a O
difference O
in O
mean O
CDS O
scores O
of O
6.8 O
, O
assuming O
a O
between-patient O
SD O
of O
12 O
29 O
. O

There O
were O
two O
main O
outcome O
parameters O
in O
this O
study O
: O
change B-Prim
in I-Prim
SBP I-Prim
and O
change B-Prim
in I-Prim
HOMA I-Prim
index I-Prim
, I-Prim
from I-Prim
week I-Prim
0 I-Prim
( I-Prim
pre-treatment I-Prim
) I-Prim
to I-Prim
week I-Prim
6. I-Prim

Balance O
performance O
on O
the O
two O
primary O
outcome O
measures O
and O
the O
secondary O
outcome O
measures O
will O
be O
made O
using O
repeated O
measures O
ANOVA O
between O
the O
two O
groups O
, O
with O
variables O
differing O
between O
groups O
at O
baseline O
being O
used O
as O
covariates O
. O

Statistical O
analysis O
Because O
the O
distribution O
of O
the O
main O
outcome O
was O
skewed O
and O
groups O
were O
small O
, O
continuous O
variables O
were O
compared O
using O
the O
Mann-Whitney O
U O
test O
. O

With O
a O
planned O
number O
of O
138 O
patients O
providing O
post-baseline O
data O
, O
a O
drop O
out O
rate O
for O
the O
primary O
outcome O
of O
less O
than O
5 O
% O
and O
an O
expected O
screening O
to O
inclusion O
ratio O
of O
5 O
: O
1 O
, O
750 O
patients O
will O
have O
to O
be O
assessed O
for O
eligibility O
in O
all O
8 O
centers O
, O
and O
150 O
will O
be O
allocated O
for O
trial O
participation O
. O

The O
primary O
endpoint O
will O
be O
analysed O
also O
at O
the O
end O
of O
the O
follow-up O
period O
. O

Outcome O
measures O
Our O
primary O
study O
endpoint O
will O
be O
the B-Prim
proportion I-Prim
of I-Prim
women I-Prim
reporting I-Prim
a I-Prim
live I-Prim
birth I-Prim
defined I-Prim
as I-Prim
the I-Prim
delivery I-Prim
of I-Prim
one I-Prim
or I-Prim
more I-Prim
living I-Prim
infants I-Prim
, I-Prim
> I-Prim
20 I-Prim
weeks I-Prim
gestation I-Prim
or I-Prim
400 I-Prim
g I-Prim
or I-Prim
more I-Prim
birth I-Prim
weight I-Prim
. O

Setting O
Primary O
Care O
Outcomes O
Primary O
outcome O
the B-Prim
therapeutic I-Prim
adherence I-Prim
considered I-Prim
as I-Prim
the I-Prim
percentage I-Prim
of I-Prim
patients I-Prim
classified I-Prim
as I-Prim
good I-Prim
adherent I-Prim
. O

The O
primary O
outcome O
measure O
is O
the B-Prim
time I-Prim
between I-Prim
study I-Prim
inclusion I-Prim
and I-Prim
first I-Prim
competitive I-Prim
employment I-Prim
that I-Prim
lasted I-Prim
three I-Prim
months I-Prim
or I-Prim
longer I-Prim
. O

Sample O
size O
Power O
calculations O
are O
based O
on O
the O
primary O
outcome O
measurement O
PACIC B-Prim
. O

At O
the O
12-month O
follow-up O
, O
all O
groups O
will O
be O
re-examined O
regarding O
the O
primary O
outcome O
variable O
and O
all O
secondary O
variables O
. O

A O
separate O
paper O
17 O
reports O
the O
design O
, O
methodology O
, O
and O
main O
service O
user O
outcomes O
. O

The O
primary O
endpoint O
is O
the B-Prim
change I-Prim
in I-Prim
prevalence I-Prim
of I-Prim
atypical I-Prim
cells I-Prim
and O
cell B-Prim
proliferation I-Prim
( I-Prim
measured I-Prim
by I-Prim
Ki67 I-Prim
) I-Prim
in I-Prim
DL I-Prim
or I-Prim
fine I-Prim
needle I-Prim
aspirate I-Prim
samples I-Prim
, I-Prim
after I-Prim
12 I-Prim
months I-Prim
of I-Prim
treatment I-Prim
and I-Prim
12 I-Prim
months I-Prim
after I-Prim
treatment I-Prim
cessation I-Prim
. O

Binomial O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
were O
calculated O
for O
the O
difference O
between O
the O
2 O
groups O
in O
achieving O
the O
primary O
efficacy O
endpoint O
. O

A O
factorial O
or O
multiple-arm O
RCT O
design O
would O
have O
been O
optimal O
from O
the O
methodological O
perspective O
, O
and O
could O
shed O
light O
on O
the O
effectiveness O
of O
the O
individual O
ingredients O
of O
this O
multifaceted O
intervention O
in O
terms O
of O
the O
primary O
outcomes O
. O

A O
third O
measurement O
is O
performed O
if O
differences O
of O
0.1 O
cm O
and O
0.1 O
kg O
respectively O
are O
observed O
between O
the O
first O
and O
second O
measurements O
. O

To O
decrease O
the O
probability O
of O
finding O
positive O
results O
by O
chance O
as O
a O
result O
of O
multiple O
hypothesis O
testing O
28 O
, O
we O
limited O
our O
primary O
endpoints O
to O
a O
combination O
of O
one O
patient O
outcome O
and O
one O
organizational O
process O
measure O
. O

Repeated O
measures O
analysis O
of O
variance O
( O
RM-ANOVA O
) O
will O
be O
employed O
to O
compare O
the O
primary O
outcome O
variables O
( O
nutritional B-Prim
status I-Prim
and O
body B-Prim
composition I-Prim
) O
in O
participants O
with O
and O
without O
food O
supplements O
. O

Usual O
Care O
, O
Talk O
Study O
, O
TALK O
Plus O
) O
will O
be O
the O
main O
independent O
variable O
for O
intent-to-treat O
analysis O
23 O
. O

Outcome O
measures O
The O
primary O
outcome O
measures O
will O
be O
: O
The B-Prim
Simple I-Prim
Shoulder I-Prim
Test I-Prim
( I-Prim
SST I-Prim
) I-Prim
27 I-Prim
measuring I-Prim
shoulder I-Prim
function I-Prim
. O

The O
primary O
efficacy O
variable O
( O
mean B-Prim
PID I-Prim
3 I-Prim
– I-Prim
5 I-Prim
hours I-Prim
after I-Prim
dose I-Prim
) O
was O
similar O
to O
those O
used O
in O
other O
single-dose O
studies O
of O
COX-2 O
selective O
inhibitors O
in O
acute O
pain O
26 O
or O
in O
patients O
with O
OA O
flare O
27 O
. O

The O
primary O
endpoint O
of O
the O
trial O
was O
pulmonary B-Prim
or I-Prim
cardiac I-Prim
toxicity I-Prim
, O
and O
the O
secondary O
endpoint O
was O
locoregional B-Sec
recurrence I-Sec
. O

The B-Prim
Northwick I-Prim
Park I-Prim
Neck I-Prim
Pain I-Prim
Questionnaire I-Prim
( I-Prim
NPQ I-Prim
) I-Prim
is O
used O
as O
the O
primary O
outcome O
measure O
, O
and O
the B-Sec
McGill I-Sec
Pain I-Sec
Questionnaire I-Sec
( I-Sec
MPQ I-Sec
) I-Sec
and O
The B-Sec
Short I-Sec
Form I-Sec
( I-Sec
36 I-Sec
) I-Sec
Health I-Sec
Survey I-Sec
( I-Sec
SF-36 I-Sec
) I-Sec
are O
applied O
as O
secondary O
outcome O
measures O
. O

Study O
Outcomes O
Primary O
Outcome O
[ B-Prim
1 I-Prim
] I-Prim
Proportion I-Prim
of I-Prim
eligible I-Prim
patients I-Prim
enrolled I-Prim
in I-Prim
the I-Prim
CHAT I-Prim
pilot I-Prim
study I-Prim
. O

The O
primary O
outcome O
measure O
is O
a B-Prim
well-validated I-Prim
outcome I-Prim
measure I-Prim
for I-Prim
upper I-Prim
limb I-Prim
function I-Prim
and O
disability B-Prim
. O

The O
main O
desired O
outcomes O
of O
the O
SSS O
components O
were O
: O
empathy O
, O
venting O
and O
problem O
solving O
. O

Since O
all O
previous O
studies O
34 O
35 O
36 O
investigating O
the O
effect O
of O
PCOMS O
have O
used O
the O
Outcome O
Rating O
Scale O
( O
ORS O
) O
as O
primary O
outcome O
, O
we O
included O
the B-Sec
ORS I-Sec
and O
the B-Sec
Session I-Sec
Rating I-Sec
Scale I-Sec
( I-Sec
SRS I-Sec
) I-Sec
as O
secondary O
outcome O
measures O
30 O
. O

Main O
outcome O
variables O
Differences O
between O
treatment O
groups O
were O
not O
significant O
for O
any O
of O
the O
four O
main O
outcome O
variables O
( O
force B-Prim
platform I-Prim
variables I-Prim
PVF I-Prim
and O
impulse B-Prim
, O
the B-Prim
HCPI I-Prim
and O
rescue B-Prim
NSAIDs I-Prim
) O
. O

Oxidative O
stress O
and O
inflammation O
The O
primary O
outcome O
measure O
for O
oxidative O
stress O
will O
plasma B-Prim
isoprostanes I-Prim
measured I-Prim
using I-Prim
gas I-Prim
chromatography I-Prim
mass I-Prim
spectrometry I-Prim
39 I-Prim
and O
for O
inflammation O
, O
pentraxin B-Prim
3 I-Prim
using I-Prim
an I-Prim
ELISA I-Prim
assay I-Prim
40 I-Prim
. O

Measure O
and O
data O
collection O
procedures O
The O
primary O
outcome O
in O
this O
study O
is O
performance B-Prim
of I-Prim
functional I-Prim
tasks I-Prim
( I-Prim
mobility I-Prim
and I-Prim
self-care I-Prim
) I-Prim
as I-Prim
measured I-Prim
by I-Prim
the I-Prim
Pediatric I-Prim
Evaluation I-Prim
of I-Prim
Disability I-Prim
Inventory I-Prim
( I-Prim
PEDI I-Prim
) I-Prim
65 I-Prim
. O

The O
duration O
of O
the O
medical O
treatment O
is O
not O
restricted O
, O
but O
counted O
as O
treatment O
failure O
if O
medication O
is O
needed O
in O
the O
last O
three O
weeks O
before O
measurement O
of O
the O
primary O
endpoint O
in O
week O
26. O

The O
primary O
outcome O
measure O
was O
claim B-Prim
duration I-Prim
( I-Prim
in I-Prim
days I-Prim
) I-Prim
during I-Prim
12 I-Prim
months I-Prim
follow-up I-Prim
. O

The O
magnitude O
of O
any O
observed O
rates O
of O
primary O
outcome O
differences O
by O
treatment O
status O
and O
what O
to O
consider O
a O
" O
substantial O
" O
difference O
will O
be O
revisited O
at O
each O
interim O
looks O
. O

Recruitment O
and O
retention O
The O
study O
successfully O
recruited O
526 O
individuals O
in O
from O
4 O
sites O
in O
just O
over O
29 O
months O
, O
with O
the O
primary O
outcome O
recorded O
for O
372 O
individuals O
. O

Primary O
inclusion O
criterion O
is O
the O
GP's O
suspicion O
of O
LRTI O
being O
the O
primary O
cause O
of O
the O
acute O
cough O
episode O
. O

Multiple O
imputation O
was O
used O
to O
construct O
primary O
ITT O
assessments O
of O
relative O
effectiveness O
that O
allowed O
inclusion O
of O
all O
randomized O
subjects O
with O
comparable O
results O
. O

a O
) O
Ease O
of O
Care O
The O
primary O
outcome O
to O
assess O
ease O
of O
care O
and O
comfort O
will O
be O
the B-Prim
Canadian I-Prim
Occupational I-Prim
Performance I-Prim
Measure I-Prim
( I-Prim
COPM I-Prim
) I-Prim
44 I-Prim
. O

The O
primary O
outcome O
measure O
for O
the O
cost-effectiveness O
analysis O
is O
depression B-Prim
measured I-Prim
by I-Prim
the I-Prim
BDI-II I-Prim
, O
and O
for O
the O
cost-utility O
analysis O
the B-Prim
QALY I-Prim
based I-Prim
on I-Prim
the I-Prim
EQ-5D I-Prim
. O

Intervention O
and O
control O
group O
will O
be O
compared O
on O
the O
main O
outcomes O
( O
place B-Prim
of I-Prim
death I-Prim
, O
number B-Prim
of I-Prim
transitions I-Prim
and O
out B-Prim
of I-Prim
hours I-Prim
contact I-Prim
, O
amount B-Prim
of I-Prim
identified I-Prim
patients I-Prim
) O
. O

Some O
patients O
may O
have O
remained O
in O
the O
trial O
because O
of O
other O
benefits O
apart O
from O
the O
primary O
outcome O
, O
such O
as O
sleeping O
better O
. O

The O
primary O
and O
secondary O
outcomes O
in O
LBW O
babies O
, O
the O
outcomes O
in O
all O
infants O
and O
their O
mothers O
, O
and O
the O
process O
outcomes O
( O
to O
be O
measured O
only O
in O
the O
intervention O
clusters O
) O
are O
shown O
in O
Table O
1 O
. O

To O
examine O
secondary O
outcomes O
, O
the O
differences O
between O
study O
groups O
will O
be O
assessed O
using O
Student's O
t-tests O
( O
as O
described O
above O
for O
primary O
outcome O
) O
. O

This O
is O
directly O
analogous O
to O
the O
primary O
endpoint O
of O
our O
study O
, O
the B-Prim
VTE I-Prim
threshold I-Prim
. O

For O
male O
patients O
, O
the O
first O
criterion O
had O
a O
K O
value O
of O
0.472 O
, O
a O
moderate O
level O
of O
agreement O
. O

For O
analysis O
of O
the O
primary O
variable O
, O
the O
study O
populations O
were O
analysed O
separately O
. O

The O
main O
outcomes O
were O
changes B-Prim
in I-Prim
pain I-Prim
as I-Prim
measured I-Prim
on I-Prim
a I-Prim
verbal I-Prim
rating I-Prim
scale I-Prim
from I-Prim
0 I-Prim
to I-Prim
10 I-Prim
during I-Prim
a I-Prim
flexion-extension I-Prim
range I-Prim
of I-Prim
motion I-Prim
evaluation I-Prim
and O
changes B-Prim
in I-Prim
disc I-Prim
height I-Prim
as I-Prim
measured I-Prim
on I-Prim
CT I-Prim
scans I-Prim
. O

Primary O
outcomes O
are O
headache B-Prim
days I-Prim
and O
medication B-Prim
days I-Prim
per I-Prim
month I-Prim
comparing I-Prim
the I-Prim
two I-Prim
arms I-Prim
and I-Prim
change I-Prim
compared I-Prim
to I-Prim
baseline I-Prim
. O

Efficacy O
end-point O
criteria O
The O
primary O
end-point O
criteria O
used O
to O
determine O
the O
efficacy O
of O
treatment O
were O
absence B-Prim
of I-Prim
parasites I-Prim
and O
clinical B-Prim
signs I-Prim
on I-Prim
days I-Prim
14 I-Prim
and I-Prim
28 I-Prim
, O
and O
good B-Prim
clinical I-Prim
and I-Prim
biological I-Prim
tolerability I-Prim
. O

Primary O
outcome O
: O
Table O
2 O
presents O
the O
results O
of O
the O
logistic O
regressions O
. O

These O
issues O
include O
the O
choice O
of O
intermediate O
and O
final O
outcome O
measures O
, O
sample O
size O
calculations O
and O
the O
impact O
of O
varying O
the O
assumptions O
, O
the O
process O
for O
moving O
between O
trial O
stages O
, O
stopping O
accrual O
to O
each O
trial O
arm O
and O
overall O
, O
and O
issues O
around O
perceived O
trial O
complexity O
. O

The O
primary O
outcome O
measure O
will O
be O
the B-Prim
proportion I-Prim
of I-Prim
inappropriate I-Prim
antibiotic I-Prim
prescription I-Prim
in I-Prim
each I-Prim
group I-Prim
. O

Primary O
Study O
Endpoints O
Serious B-Prim
adverse I-Prim
outcomes I-Prim
for I-Prim
the I-Prim
infant I-Prim
defined I-Prim
as I-Prim
: I-Prim
Perinatal I-Prim
/ I-Prim
Neonatal I-Prim
Mortality I-Prim
( I-Prim
defined I-Prim
as I-Prim
any I-Prim
fetal I-Prim
death I-Prim
after I-Prim
study I-Prim
entry I-Prim
or I-Prim
death I-Prim
of I-Prim
a I-Prim
liveborn I-Prim
infant I-Prim
within I-Prim
28 I-Prim
days I-Prim
of I-Prim
age I-Prim
( I-Prim
excluding I-Prim
lethal I-Prim
congenital I-Prim
anomalies I-Prim
) I-Prim
; O
or O
Serious B-Prim
neonatal I-Prim
morbidity I-Prim
( I-Prim
defined I-Prim
as I-Prim
one I-Prim
or I-Prim
more I-Prim
of I-Prim
the I-Prim
following I-Prim
, I-Prim
excluding I-Prim
lethal I-Prim
congenital I-Prim
anomalies I-Prim
: I-Prim
birth I-Prim
trauma I-Prim
( I-Prim
subdural I-Prim
or I-Prim
intracerebral I-Prim
haemorrhage I-Prim
, I-Prim
spinal I-Prim
cord I-Prim
injury I-Prim
, I-Prim
basal I-Prim
skull I-Prim
fracture I-Prim
, I-Prim
other I-Prim
fracture I-Prim
, I-Prim
peripheral I-Prim
nerve I-Prim
injury I-Prim
present I-Prim
at I-Prim
discharge I-Prim
from I-Prim
hospital I-Prim
) I-Prim
; O
seizures B-Prim
at I-Prim
< I-Prim
24 I-Prim
hours I-Prim
age I-Prim
or I-Prim
requiring I-Prim
two I-Prim
or I-Prim
more I-Prim
drugs I-Prim
to I-Prim
control I-Prim
; O
Apgar B-Prim
score I-Prim
< I-Prim
4 I-Prim
at I-Prim
5 I-Prim
minutes I-Prim
; O
cord B-Prim
pH I-Prim
< I-Prim
7.18 I-Prim
; O
base B-Prim
deficit I-Prim
< I-Prim
-8 I-Prim
( I-Prim
arterial I-Prim
or I-Prim
venous I-Prim
cord I-Prim
blood I-Prim
) I-Prim
; O
neonatal B-Prim
encephalopathy I-Prim
stage I-Prim
3 I-Prim
( I-Prim
Sarnat I-Prim
& I-Prim
Sarnat I-Prim
1976 I-Prim
) I-Prim
; O
admission B-Prim
to I-Prim
the I-Prim
neonatal I-Prim
intensive I-Prim
care I-Prim
unit I-Prim
( I-Prim
NICU I-Prim
) I-Prim
> I-Prim
4 I-Prim
days I-Prim
; O
severe B-Prim
neonatal I-Prim
lung I-Prim
disease I-Prim
( I-Prim
defined I-Prim
as I-Prim
MAP I-Prim
> I-Prim
10 I-Prim
and I-Prim
or I-Prim
FiO I-Prim
2 I-Prim
> I-Prim
0.80 I-Prim
with I-Prim
need I-Prim
for I-Prim
ventilation I-Prim
) I-Prim
; O
proven B-Prim
necrotising I-Prim
enterocolitis I-Prim
; O
proven B-Prim
systemic I-Prim
infection I-Prim
in I-Prim
first I-Prim
48 I-Prim
hours I-Prim
of I-Prim
life I-Prim
treated I-Prim
with I-Prim
antibiotics I-Prim
) I-Prim
. O

Primary O
outcome O
measure O
was O
HbA1c B-Prim
. O

For O
each O
performance O
indicator O
potential O
effects O
on O
our O
primary O
outcomes O
will O
be O
measured O
. O

The O
primary O
outcome O
measures O
will O
be O
assessed O
by O
the O
same O
researcher O
( O
AN O
) O
for O
all O
participants O
at O
each O
location O
. O

Statistics O
The O
primary O
outcome O
was O
the B-Prim
hands-on I-Prim
time I-Prim
during I-Prim
the I-Prim
first I-Prim
three I-Prim
minutes I-Prim
of I-Prim
the I-Prim
cardiac I-Prim
arrest I-Prim
. O

It O
was O
assumed O
≥ B-Prim
Grade I-Prim
2 I-Prim
( I-Prim
G2 I-Prim
) I-Prim
toxicity I-Prim
incidence I-Prim
as O
primary O
end O
point O
. O

Assessment O
of O
muscle O
mass O
Muscle O
mass O
was O
evaluated O
with O
US O
, O
by O
measuring O
the O
Cross O
Sectional O
Diameter O
( O
CSD O
) O
of O
the O
quadriceps O
muscle O
( O
rectus O
femoris O
- O
vastus O
intermedius O
) O
26 O
27 O
28 O
on O
the O
day O
of O
randomization O
( O
second O
day O
of O
admission O
) O
and O
seven O
or O
eight O
days O
after O
the O
first O
assessment O
29 O
. O

The O
primary O
outcome O
measure O
is O
the' O
Medication B-Prim
Appropriateness I-Prim
Index' I-Prim
. O

In O
Part O
B O
, O
the O
data O
set O
used O
for O
analysis O
of O
the O
primary O
efficacy O
end O
point O
included O
all O
Part O
B O
randomized O
patients O
who O
participated O
in O
the O
WOMAC O
study O
( O
n O
= O
145 O
) O
. O

Main O
outcome O
measures O
included O
coma B-Prim
recovery I-Prim
time I-Prim
; O
time B-Prim
to I-Prim
sit I-Prim
unsupported I-Prim
, O
begin B-Prim
oral I-Prim
intake I-Prim
; O
duration B-Prim
of I-Prim
hospitalization I-Prim
; O
death B-Prim
and O
adverse B-Prim
effects I-Prim
. O

The O
primary O
outcomes O
are O
disability B-Prim
( I-Prim
patients I-Prim
) I-Prim
and O
strain B-Prim
( I-Prim
carers I-Prim
) I-Prim
. O

They O
showed O
that O
an O
electronic O
key O
feature O
assessment O
is O
feasible O
and O
can O
produce O
reliable O
assessment O
results O
. O

One O
year O
primary O
outcome O
will O
be O
mobility B-Prim
limitation I-Prim
assessed I-Prim
by I-Prim
interviewing I-Prim
the I-Prim
subjects I-Prim
for I-Prim
the I-Prim
ability I-Prim
to I-Prim
getting I-Prim
in I-Prim
and I-Prim
out I-Prim
of I-Prim
bed I-Prim
, I-Prim
rising I-Prim
from I-Prim
a I-Prim
chair I-Prim
, I-Prim
walking I-Prim
across I-Prim
a I-Prim
room I-Prim
, I-Prim
walking I-Prim
one I-Prim
block I-Prim
, I-Prim
and I-Prim
climbing I-Prim
stairs I-Prim
10 I-Prim
. O

The O
primary O
outcome O
measure O
, O
change B-Prim
in I-Prim
insulin I-Prim
sensitivity I-Prim
, O
is O
measured O
at O
3 O
, O
6 O
and O
12 O
months O
. O

Additionally O
, O
although O
this O
study O
examined O
potential O
baseline O
patient O
/ O
disease O
characteristics O
and O
key O
treatment O
outcomes O
that O
may O
influence O
treatment O
satisfaction O
, O
data O
on O
other O
important O
ongoing O
treatment O
factors O
such O
as O
burden O
and O
compliance O
were O
not O
collected O
. O

Although O
there O
is O
a O
concern O
that O
generic O
measures O
may O
be O
less O
responsive O
than O
disease O
specific O
measures O
, O
the O
physical O
functioning O
and O
bodily O
pain O
scales O
of O
the O
SF-36 O
( O
which O
contribute O
most O
of O
the O
variation O
in O
the B-Prim
PCS I-Prim
summary I-Prim
measure I-Prim
used O
as O
the O
primary O
outcome O
in O
this O
trial O
) O
compare O
reasonably O
well O
with O
disease O
specific O
measures O
in O
patients O
with O
musculoskeletal O
problems O
40 O
41 O
42 O
43 O
. O

Outcomes O
HbA1c O
The O
primary O
outcome O
of O
the O
DIAPERIO O
trial O
will O
be O
the B-Prim
difference I-Prim
in I-Prim
change I-Prim
of I-Prim
HbA1c I-Prim
from I-Prim
V1 I-Prim
to I-Prim
V4 I-Prim
between I-Prim
the I-Prim
two I-Prim
groups I-Prim
. O

A B-Prim
comparison I-Prim
of I-Prim
intra- I-Prim
and I-Prim
post-dialytic I-Prim
complications I-Prim
among I-Prim
study I-Prim
groups I-Prim
constitutes O
the O
primary O
endpoint O
. O

Statistical O
issues O
Sample O
size O
The O
sample O
size O
is O
calculated O
based O
on O
the O
primary O
outcome' B-Prim
bad I-Prim
neonatal I-Prim
outcome' I-Prim
. O

Calculating O
effect O
size O
for O
the O
primary O
outcome O
using O
Cohen's O
method O
and O
a O
standardised O
mean O
difference O
( O
SMD O
) O
to O
draw O
comparisons O
with O
the O
2010 O
Cochrane O
review O
8 O
, O
the O
effect O
size O
of O
0.71 O
is O
larger O
than O
the O
moderate O
, O
non-significant O
SMD O
reported O
previously O
; O
exercise O
of O
preferred O
intensity O
appears O
to O
promote O
greater O
benefits O
. O

Our O
primary O
outcome O
is O
refractive B-Prim
predictability I-Prim
, I-Prim
which I-Prim
is I-Prim
one I-Prim
of I-Prim
several I-Prim
standard I-Prim
refractive I-Prim
outcomes I-Prim
, I-Prim
defined I-Prim
as I-Prim
the I-Prim
proportion I-Prim
of I-Prim
eyes I-Prim
achieving I-Prim
a I-Prim
postoperative I-Prim
spherical I-Prim
equivalent I-Prim
( I-Prim
SE I-Prim
) I-Prim
within I-Prim
± I-Prim
0.50 I-Prim
D I-Prim
of I-Prim
the I-Prim
intended I-Prim
target I-Prim
. O

Of O
particular O
interest O
is O
the O
effect O
on O
the O
principal O
outcome O
, O
knowledge B-Prim
, O
thereby O
allowing O
an O
assessment O
of O
knowledge O
retention O
. O

Statistical O
analysis O
The O
main O
outcome O
is O
the B-Prim
proportion I-Prim
of I-Prim
persons I-Prim
with I-Prim
at I-Prim
least I-Prim
one I-Prim
fall I-Prim
and O
will O
be O
analysed O
by O
using O
a O
chi-square O
test O
adjusted O
for O
cluster O
randomisation O
17 O
. O

Results O
of O
this O
trial O
showed O
that O
the O
intervention O
had O
favourable O
effects O
on O
all O
primary O
outcomes O
: O
fear B-Prim
of I-Prim
falling I-Prim
, O
avoidance B-Prim
of I-Prim
activity I-Prim
, O
and O
daily B-Prim
activity I-Prim
. O

ITT O
analysis O
( O
n O
= O
85 O
intervention O
, O
n O
= O
70 O
control O
) O
showed O
improvement O
of O
physical O
performance O
( O
intervention O
+8 O
% O
; O
control O
−7 O
% O
) O
and O
no O
differences O
on O
other O
primary O
and O
secondary O
outcome O
measures O
. O

The O
first O
variable O
is O
branching O
pathways O
through O
the O
VP O
, O
present O
or O
absent O
. O

Adverse O
events O
Sample O
size O
determination O
The O
primary O
endpoint O
for O
this O
study O
was O
the B-Prim
mean I-Prim
number I-Prim
of I-Prim
detected I-Prim
polyps I-Prim
. O

In O
study O
B O
, O
the O
primary O
efficacy O
endpoints O
were O
the B-Prim
slope I-Prim
of I-Prim
decline I-Prim
in I-Prim
FEV I-Prim
1 I-Prim
from I-Prim
2 I-Prim
hours I-Prim
post-dose I-Prim
, O
the B-Prim
area I-Prim
under I-Prim
the I-Prim
FEV I-Prim
1 I-Prim
curve I-Prim
( I-Prim
AUC I-Prim
) I-Prim
( I-Prim
0 I-Prim
– I-Prim
24 I-Prim
hours I-Prim
) I-Prim
and O
the B-Prim
mean I-Prim
change I-Prim
from I-Prim
pre-dose I-Prim
FEV I-Prim
1 I-Prim
at I-Prim
12 I-Prim
hours I-Prim
post I-Prim
dose I-Prim
. O

The O
primary O
effectiveness O
analyses O
will O
be O
conducted O
on O
an O
intention O
to O
treat O
basis O
, O
with O
secondary O
( O
explanatory O
) O
analyses O
conducted O
first O
comparing O
outcomes O
in O
all O
control O
schools O
to O
outcomes O
only O
in O
those O
schools O
that O
completed O
at O
least O
70 O
% O
of O
the O
lessons O
, O
and O
secondly O
employing O
instrumental O
variables O
regression O
models O
to O
address O
the O
question O
of O
causal O
effect O
if O
the O
intervention O
were O
applied O
as O
intended O
37 O
. O

The O
primary O
outcome O
was O
HbA1c B-Prim
, O
lipid B-Prim
levels I-Prim
, O
blood B-Prim
pressure I-Prim
, O
BMI B-Prim
after I-Prim
24 I-Prim
months I-Prim
of I-Prim
follow-up I-Prim
. O

Methods O
/ O
Design O
Objectives O
of O
the O
study O
The O
aim O
of O
this O
study O
is O
a O
first O
assessment O
of O
the O
safety O
of O
A-Part O
® O
Gel O
applied O
as O
an O
adhesion O
prophylaxis O
after O
major O
abdominal O
surgery O
, O
by O
specific O
observation O
of O
two O
major O
complications O
of O
abdominal O
surgery O
; O
wound O
healing O
impairment O
or O
peritonitis O
; O
in O
comparison O
to O
a O
non O
treated O
control O
group O
( O
primary O
objective O
) O
within O
28 O
( O
+10 O
) O
days O
after O
surgery O
( O
for O
definition O
see O
table O
1 O
) O
. O

Intra-cluster O
( O
practice O
) O
correlation O
coefficients O
will O
be O
determined O
and O
published O
for O
all O
primary O
outcome O
variables O
to O
assist O
future O
research O
. O

The O
sample O
size O
has O
been O
estimated O
to O
be O
sufficiently O
large O
to O
achieve O
significant O
results O
with O
concerns O
to O
the O
main O
outcome O
of O
the O
study O
. O

However O
, O
the O
results O
of O
the O
NSABP-C08 O
study O
published O
in O
2011 O
was O
negative O
for O
its O
primary O
endpoint O
. O

The O
primary O
endpoint O
was O
the B-Prim
percentage I-Prim
of I-Prim
patients I-Prim
who I-Prim
reached I-Prim
25 I-Prim
( I-Prim
OH I-Prim
) I-Prim
D I-Prim
levels I-Prim
of I-Prim
30 I-Prim
ng I-Prim
/ I-Prim
ml I-Prim
or I-Prim
above I-Prim
on I-Prim
day I-Prim
7. I-Prim

123 O
, O
which O
is O
based O
on O
this O
model O
, O
the O
primary O
target O
( O
and O
therefore O
a O
key O
outcome O
) O
of O
our O
intervention O
is O
optimal B-Prim
( I-Prim
physical I-Prim
) I-Prim
functioning I-Prim
. O

The O
primary O
endpoint O
bowel B-Prim
obstruction I-Prim
is O
relevant O
from O
the O
patient O
perspective O
as O
well O
as O
from O
a O
health O
care O
perspective O
. O

Because O
of O
the O
large O
number O
of O
parameters O
that O
are O
measured O
, O
it O
is O
important O
to O
distinguish O
the O
primary O
outcome O
measure O
from O
the O
aetiological O
factors O
that O
are O
studied O
. O

The B-Prim
frequency I-Prim
, O
duration B-Prim
and O
severity B-Prim
of I-Prim
exacerbations I-Prim
were O
combined O
as O
primary O
outcome O
measures O
for O
testing O
as O
multiple O
criteria O
. O

Preliminary O
information O
on O
the O
first O
measure O
designed O
to O
specifically O
capture O
the O
impact O
of O
antipsychotic-emergent O
weight O
gain O
on O
patients' O
psychosocial O
functioning O
was O
only O
recently O
published O
52 O
. O

The O
primary O
outcome O
measure O
will O
be O
the B-Prim
difference I-Prim
in I-Prim
NSCL I-Prim
/ I-Prim
P I-Prim
recurrence I-Prim
rates I-Prim
between I-Prim
the I-Prim
two I-Prim
groups I-Prim
and O
the B-Prim
associated I-Prim
confidence I-Prim
interval I-Prim
. O

Based O
on O
earlier O
studies O
7 O
10 O
11 O
14 O
and O
recommendations O
of O
an O
expert O
review O
15 O
, O
the B-Prim
15th I-Prim
percentile I-Prim
point I-Prim
was O
chosen O
as O
the O
parameter O
for O
the O
primary O
endpoint O
and O
expressed O
as O
the O
15th O
percentile O
lung O
density O
( O
PD15 O
) O
. O

Clinical O
outcomes O
measures O
The O
primary O
outcome O
is O
the B-Prim
number I-Prim
of I-Prim
participants I-Prim
with I-Prim
at I-Prim
least I-Prim
one I-Prim
fall I-Prim
at I-Prim
12 I-Prim
months I-Prim
. O

Sample O
size O
calculation O
A O
sample O
size O
calculation O
has O
been O
performed O
, O
based O
on O
the O
main O
outcome O
measure O
, O
i.e. O

Attempts O
to O
estimate O
sample O
size O
for O
a O
definitive O
trial O
were O
unproductive O
because O
of O
uncertainty O
in O
the O
distribution O
of O
the O
key O
variables O
. O

NHS O
Stop O
Smoking O
Study O
Helpline O
NHS O
Stop O
Smoking O
Study O
Helpline O
will O
provide O
call O
centre O
services O
: O
the O
consent O
call O
for O
participant O
enrollment O
, O
and O
the O
final O
call O
to O
determine O
the O
primary O
outcome O
( O
self B-Prim
reported I-Prim
smoking I-Prim
at I-Prim
34 I-Prim
to I-Prim
38 I-Prim
weeks I-Prim
gestation I-Prim
) O
. O

Systolic O
/ O
diastolic O
blood O
pressure O
was O
measured O
in O
a O
standard O
way O
( O
Omron O
705IT O
) O
: O
the O
first O
measurement O
was O
made O
after O
5 O
min O
rest O
in O
sitting O
position O
and O
the O
mean O
of O
the O
three O
measurements O
per O
visit O
was O
used O
. O

The O
pre-specified O
primary O
outcome O
measure O
of O
the O
trial O
was O
the B-Prim
proportion I-Prim
of I-Prim
pregnant I-Prim
women I-Prim
who I-Prim
attended I-Prim
ANC I-Prim
with I-Prim
their I-Prim
partners I-Prim
at I-Prim
the I-Prim
subsequent I-Prim
antenatal I-Prim
visit I-Prim
. O

But O
this O
study O
misses O
a O
clearly O
defined O
primary O
endpoint O
and O
a O
detailed O
sample O
size O
calculation O
and O
has O
the O
disadvantage O
of O
using O
sham-acupuncture O
instead O
of O
a O
real O
placebo O
acupuncture O
technique O
in O
the O
control O
group O
. O

The O
primary O
outcome O
measure O
for O
the O
participants O
with O
stroke O
is O
depressed B-Prim
mood I-Prim
, I-Prim
which I-Prim
will I-Prim
be I-Prim
assessed I-Prim
by I-Prim
the I-Prim
GDS-15 I-Prim
. O

Statistical O
Analysis O
Primary O
outcome O
Mortality B-Prim
at I-Prim
28 I-Prim
days I-Prim
post-randomisation I-Prim
will O
be O
compared O
between O
the O
groups O
by O
the O
risk O
ratio O
and O
95 O
% O
confidence O
interval O
. O

A O
p O
value O
< O
0.05 O
( O
2-sided O
) O
was O
considered O
significant O
for O
the O
primary O
outcome O
; O
p O
< O
0.01 O
was O
considered O
significant O
for O
secondary O
outcomes O
to O
account O
for O
multiple O
analyses O
in O
a O
small O
sample O
. O

In O
fact O
, O
all O
3 O
groups O
showed O
primary O
and O
secondary O
outcomes O
scores O
similar O
to O
those O
obtained O
following O
the O
non-randomised O
, O
symptomatic O
phase O
. O

Primary O
outcome O
measure O
was O
the B-Prim
proportion I-Prim
of I-Prim
eligible I-Prim
( I-Prim
aged I-Prim
≤ I-Prim
80 I-Prim
and I-Prim
symptom I-Prim
onset I-Prim
≤ I-Prim
6 I-Prim
hours I-Prim
) I-Prim
stroke I-Prim
patients I-Prim
referred I-Prim
to I-Prim
a I-Prim
stroke I-Prim
unit I-Prim
( I-Prim
SU I-Prim
) I-Prim
. O

Primary O
Outcome O
Measures O
The B-Prim
Conners' I-Prim
ADHD I-Prim
Index I-Prim
is O
used O
to O
distinguish O
ADHD O
children O
from O
non-clinical O
children O
, O
and O
is O
considered O
a O
good O
screening O
tool O
55 O
59 O
. O

Secondary O
endpoints O
• O
Progression-free B-Sec
survival I-Sec
will O
be O
analyzed O
analogously O
to O
the O
primary O
endpoints O
. O

In O
the O
first O
measurement O
, O
subjects O
will O
lay O
prone O
on O
a O
padded O
table O
. O

Primary O
outcome O
measures O
The O
primary O
outcomes O
will O
be O
change B-Prim
in I-Prim
pain I-Prim
and O
change B-Prim
in I-Prim
self-reported I-Prim
physical I-Prim
function I-Prim
at I-Prim
13 I-Prim
weeks I-Prim
( O
Table O
3 O
) O
. O

The O
primary O
efficacy O
outcome O
was O
all-cause B-Prim
mortality I-Prim
over I-Prim
3 I-Prim
years I-Prim
, O
regardless O
of O
whether O
patients O
withdrew O
from O
the O
study O
early O
. O

In O
order O
to O
maintain O
blindness O
the O
final O
research O
assessment O
will O
be O
carried O
out O
by O
a O
different O
person O
. O

The O
primary O
efficacy O
end O
point O
for O
the O
study O
was O
progression-free B-Prim
survival I-Prim
( I-Prim
PFS I-Prim
) I-Prim
per I-Prim
central I-Prim
radiology I-Prim
review I-Prim
, I-Prim
according I-Prim
to I-Prim
RECIST I-Prim
15 I-Prim
. O

Table O
1 O
Dependents O
variables O
to O
evaluate O
the O
primary O
and O
secondary O
outcomes O
. O

Other O
primary O
outcome O
measures O
are O
perceived B-Prim
recovery I-Prim
and O
intensity B-Prim
of I-Prim
leg I-Prim
pain I-Prim
and O
low B-Prim
back I-Prim
pain I-Prim
. O

Sample O
size O
Cognition B-Prim
( I-Prim
ADAS-Cog I-Prim
) I-Prim
will O
be O
the O
primary O
outcome O
measure O
. O

A O
key O
secondary O
outcome O
of O
the O
pilot O
RCT O
is O
to B-Sec
evaluate I-Sec
clinician I-Sec
acceptance I-Sec
of I-Sec
the I-Sec
weaning I-Sec
and I-Sec
sedation I-Sec
protocols I-Sec
. O

The O
primary O
endpoint O
is O
time B-Prim
to I-Prim
failure I-Prim
of I-Prim
strategy I-Prim
( I-Prim
TFS I-Prim
) I-Prim
. O

The B-Prim
FEV I-Prim
1 I-Prim
and O
exacerbations B-Prim
will O
be O
used O
as O
the O
primary O
outcome O
measures O
. O

Alas O
, O
our O
study O
failed O
to O
prove O
the O
primary O
outcome O
hypothesis O
of O
better O
clinical O
cure O
in O
the O
Infusion O
group O
( O
83 O
% O
vs. O
75 O
% O
; O
P O
= O
0.180 O
) O
. O

The O
primary O
outcome O
was O
the B-Prim
change I-Prim
in I-Prim
serum I-Prim
methylmalonic I-Prim
acid I-Prim
( I-Prim
MMA I-Prim
) I-Prim
levels I-Prim
after I-Prim
one I-Prim
month I-Prim
of I-Prim
treatment I-Prim
. O

Vaginal O
temperature O
was O
not O
affected O
by O
bST O
treatment O
, O
day O
relative O
to O
TAI O
, O
or O
interactions O
between O
these O
main O
effects O
and O
other O
variables O
. O

The O
perspective O
adopted O
will O
be O
that O
of O
the O
NHS O
, O
that O
is O
, O
the O
economic O
evaluation O
will O
only O
consider O
costs O
to O
the O
NHS O
and O
health O
benefits O
to O
patients O
Endpoints O
of O
the O
study O
Primary O
outcomes O
: O
Change B-Prim
in I-Prim
HbA1c I-Prim
between I-Prim
baseline I-Prim
and I-Prim
12 I-Prim
months I-Prim
and I-Prim
24 I-Prim
months I-Prim
post I-Prim
recruitment I-Prim
. O

There O
were O
no O
differences O
between O
the O
groups O
in O
the O
primary O
outcome O
at O
baseline O
( O
Table O
5 O
; O
17.7 O
% O
in O
the O
Intervention O
Group O
versus O
22.7 O
% O
in O
the O
Control O
Group O
) O
. O

Outcome O
measures O
Our O
primary O
outcome O
measure O
was O
percentage B-Prim
aggregation I-Prim
on I-Prim
day I-Prim
5 I-Prim
( I-Prim
2 I-Prim
hours I-Prim
after I-Prim
drug I-Prim
administration I-Prim
, I-Prim
) I-Prim
expressed I-Prim
as I-Prim
percentage I-Prim
of I-Prim
baseline I-Prim
, I-Prim
using I-Prim
1.1 I-Prim
μg I-Prim
/ I-Prim
ml I-Prim
collagen I-Prim
as I-Prim
an I-Prim
agonist I-Prim
. O

To O
avoid O
any O
possibility O
that O
the O
interviews O
could O
, O
themselves O
, O
affect O
the O
participants' O
responses O
to O
the O
main O
outcome O
measures O
, O
data O
from O
these O
participants O
will O
not O
be O
included O
in O
the O
main O
analysis O
. O

Sample O
size O
calculation O
regarding O
the O
main O
outcome O
measure O
OMAS B-Prim
showed O
that O
a O
sample O
size O
of O
51 O
individuals O
per O
group O
was O
needed O
to O
detect O
a O
difference O
of O
10 O
points O
between O
groups O
with O
an O
alfa O
level O
of O
0.05 O
and O
80 O
% O
power O
. O

The O
primary O
outcomes O
are O
educational B-Prim
achievement I-Prim
and O
anaemia B-Prim
. O

Trial O
participation O
payments O
In O
order O
to O
minimize O
loss O
to O
follow-up O
, O
particularly O
among O
control O
participants O
, O
£ O
25 O
will O
be O
given O
to O
all O
participants O
if O
they O
provide O
primary O
outcome O
information O
( O
and O
required O
samples O
to O
corroborate O
abstinence O
) O
at O
34 O
and O
38 O
weeks O
gestation O
. O

Typical O
symptoms O
for O
the O
primary O
outcome O
, O
bowel B-Prim
obstruction I-Prim
, O
like O
productive O
vomiting O
, O
gastric O
tube O
placement O
, O
severe O
constipation O
are O
detected O
during O
regular O
patient O
care O
and O
documented O
in O
the O
medical O
record O
. O

The O
main O
outcome O
measures O
were O
glycated B-Prim
hemoglobin I-Prim
A1c I-Prim
, O
body B-Prim
mass I-Prim
index I-Prim
( I-Prim
BMI I-Prim
) I-Prim
, O
blood B-Prim
pressure I-Prim
, O
lipids B-Prim
and O
control B-Prim
criteria I-Prim
during I-Prim
the I-Prim
2-year I-Prim
follow-up I-Prim
period I-Prim
. O

A O
descriptive O
analysis O
of O
the O
primary O
outcome O
variable O
is O
performed O
applying O
a O
Cox-regression O
model O
including O
the O
covariates O
RPA O
class O
, O
age O
, O
Karnofsky O
index O
and O
extent O
of O
previous O
surgery O
. O

Statistical O
analysis O
Analysis O
of O
the O
primary O
and O
secondary O
outcomes O
will O
be O
based O
on O
the O
intention-to-treat O
principle O
. O

Participants O
that O
show O
an O
improvement O
exceeding O
minimal O
clinically O
important O
difference O
for O
the O
primary O
outcomes O
( O
6 O
NDI O
% O
or O
15 O
NRS O
% O
) O
, O
at O
follow-up O
1 O
( O
one O
week O
after O
intervention O
) O
, O
will O
be O
classified O
as O
“ O
improved O
” O
. O

The O
consequent O
main O
outcomes O
are O
musculoskeletal B-Prim
disorders I-Prim
, O
work B-Prim
ability I-Prim
, O
physical B-Prim
capacity I-Prim
, O
body B-Prim
mass I-Prim
index I-Prim
( I-Prim
BMI I-Prim
) I-Prim
, O
kinesiophobia B-Prim
, O
rate B-Prim
of I-Prim
physical I-Prim
exertion I-Prim
during I-Prim
work I-Prim
and O
sickness B-Prim
absence I-Prim
. O

Clinical O
and O
parasitological O
efficacy O
: O
primary O
endpoint O
The B-Prim
PCR-corrected I-Prim
ACPR I-Prim
rate I-Prim
at I-Prim
follow-up I-Prim
on I-Prim
day I-Prim
28 I-Prim
after I-Prim
the I-Prim
first I-Prim
malaria I-Prim
episode I-Prim
for O
the O
ASAQ O
group O
was O
98.4 O
% O
versus O
96.2 O
% O
for O
the O
AL O
group O
in O
the O
intent-to O
( O
Table O
2 O
) O
. O

Microbial O
identification O
Microorganisms O
cultured O
from O
the O
skin O
of O
patients O
with O
a O
positive O
primary O
end O
point O
were O
identified O
by O
using O
VITEK-2 O
( O
BioMérieux O
, O
Boxtel O
, O
the O
Netherlands O
) O
and O
classic O
biochemical O
determination O
. O

Main O
parameters O
such O
as O
AUC O
, O
AUC O
120 O
or O
Cmax O
showed O
very O
small O
punctual O
differences O
( O
5 O
% O
or O
less O
) O
, O
but O
standard O
deviations O
, O
although O
similar O
between O
treatment O
groups O
, O
were O
large O
( O
coefficients O
of O
variation O
around O
50 O
% O
) O
. O

Primary O
outcome O
measure O
Roland B-Prim
Disability I-Prim
Questionnaire I-Prim
for I-Prim
Sciatica I-Prim
( I-Prim
RDQ I-Prim
) I-Prim
. O

Only O
if O
the O
adjudication O
committee O
agrees O
on O
both O
counts O
, O
will O
the O
adverse O
outcome O
be O
considered O
a O
primary O
outcome O
. O

Sample O
size O
For O
the O
power O
calculation O
, O
recurrent B-Prim
sickness I-Prim
absence I-Prim
days I-Prim
are O
considered O
the O
primary O
outcome O
measure O
. O

The O
primary O
study O
end O
point O
was O
a B-Prim
difference I-Prim
of I-Prim
≥ I-Prim
20 I-Prim
% I-Prim
in I-Prim
the I-Prim
microvascular I-Prim
flow I-Prim
index I-Prim
of I-Prim
small I-Prim
vessels I-Prim
among I-Prim
groups I-Prim
. O

Primary O
and O
secondary O
measures O
will O
be O
administered O
at O
all O
time O
points O
. O

Outcome O
measures O
The O
primary O
outcome O
measure O
was O
change B-Prim
in I-Prim
weight I-Prim
from I-Prim
randomization I-Prim
( I-Prim
0-M I-Prim
) I-Prim
to I-Prim
12 I-Prim
months I-Prim
post I-Prim
randomization I-Prim
. O

Primary O
outcome O
measures O
were O
' B-Prim
first-step' I-Prim
pain I-Prim
( I-Prim
measured I-Prim
on I-Prim
a I-Prim
100 I-Prim
mm I-Prim
Visual I-Prim
Analogue I-Prim
Scale I-Prim
) I-Prim
and O
the B-Prim
Foot I-Prim
Health I-Prim
Status I-Prim
Questionnaire I-Prim
domains I-Prim
of I-Prim
foot I-Prim
pain I-Prim
, I-Prim
foot I-Prim
function I-Prim
and I-Prim
general I-Prim
foot I-Prim
health I-Prim
. O

Study O
endpoints O
The O
primary O
endpoint O
of O
the O
study O
was O
28-day B-Prim
mortality I-Prim
from I-Prim
all I-Prim
causes I-Prim
. O

Measures O
Primary O
outcome O
measure O
: O
Moderate B-Prim
- I-Prim
Vigorous I-Prim
MET I-Prim
minutes I-Prim
of I-Prim
Physical I-Prim
Activity I-Prim
The O
primary O
outcome O
measure O
was O
the B-Prim
total I-Prim
MET I-Prim
minutes I-Prim
of I-Prim
moderate I-Prim
and I-Prim
vigorous I-Prim
physical I-Prim
activity I-Prim
accrued I-Prim
over I-Prim
the I-Prim
past I-Prim
7 I-Prim
days I-Prim
. O

Sample O
size O
Power O
calculation O
was O
performed O
on O
the O
primary O
outcome O
( O
all B-Prim
kind I-Prim
of I-Prim
surgeries I-Prim
together I-Prim
) O
. O

The O
primary O
outcome O
variable O
( O
number B-Prim
of I-Prim
falls I-Prim
) O
will O
be O
analysed O
using O
a O
linear O
mixed O
model O
, O
with O
the O
intervention O
specified O
as O
a O
fixed O
effect O
and O
care O
homes O
included O
as O
a O
random O
effect O
. O

Because O
this O
approach O
is O
novel O
, O
we O
will O
validate O
the O
primary O
outcome O
( O
preterm B-Prim
birth I-Prim
) O
by O
reviewing O
the O
medical O
records O
of O
all O
women O
identified O
in O
the O
computerised O
databases O
as O
delivering O
preterm O
, O
those O
where O
gestational O
age O
is O
missing O
( O
usually O
< O
1 O
% O
) O
and O
a O
random O
sample O
of O
those O
recorded O
as O
term O
deliveries O
. O

Primary O
outcome O
measures O
are O
BPD B-Prim
, I-Prim
described I-Prim
as I-Prim
oxygen I-Prim
dependency I-Prim
by I-Prim
day I-Prim
28 I-Prim
according I-Prim
to I-Prim
the I-Prim
definition I-Prim
of I-Prim
Jobe I-Prim
and I-Prim
Bancalari I-Prim
, O
and O
/ O
or O
mortality B-Prim
by I-Prim
day I-Prim
28. I-Prim

Primary O
outcome O
will O
be O
time B-Prim
to I-Prim
progression I-Prim
. O

The O
final O
outcome O
measures O
will O
be O
taken O
at O
Session O
5. O

Endpoint O
responsiveness O
The O
comparison O
between O
prednisone O
15 O
mg O
daily O
and O
placebo O
at O
Day O
15 O
in O
Panel O
A O
yielded O
a O
statistically O
significant O
treatment O
effect O
( O
effect O
size O
= O
1.17 O
, O
P O
= O
0.013 O
) O
in O
change O
from O
baseline O
in O
the O
primary O
endpoint O
, O
10 B-Prim
MCP I-Prim
Trans I-Prim
PDA I-Prim
, O
but O
not O
for O
Panel O
B O
( O
prednisone O
7.5 O
mg O
daily O
versus O
placebo O
) O
( O
effect O
size O
= O
0.61 O
, O
P O
= O
0.071 O
) O
. O

Three O
main O
outcome O
parameters O
for O
the O
assessment O
of O
efficacy O
are O
specified O
in O
the O
study O
protocol O
: O
change B-Prim
in I-Prim
waist I-Prim
circumference I-Prim
, O
change B-Prim
in I-Prim
subscapular I-Prim
skinfold I-Prim
thickness I-Prim
and O
change B-Prim
in I-Prim
6-min I-Prim
run I-Prim
performance I-Prim
, O
changes O
are O
calculated O
as O
differences O
between O
follow-up O
measurement O
and O
baseline O
measurement O
. O

Diagnosis B-Prim
of I-Prim
depression I-Prim
and O
Hamilton B-Prim
Depression I-Prim
Scale I-Prim
are O
the O
primary O
outcome O
measures O
. O

Written O
and O
face O
to O
face O
feedback O
focused O
on O
key O
trial O
outcomes O
but O
also O
provided O
information O
on O
inappropriate O
antibiotic O
use O
for O
non-bloody O
diarrhoea O
amongst O
many O
other O
indicators O
of O
quality O
of O
care O
. O

Primary O
Outcome O
Measure O
Aberrant B-Prim
Behaviour I-Prim
Checklist-Community I-Prim
( I-Prim
ABC-C I-Prim
) I-Prim
Our O
main O
outcome O
measure O
was O
the B-Prim
ABC I-Prim
Irritability I-Prim
subtest I-Prim
score I-Prim
because O
previous O
experience O
with O
patients O
in O
this O
population O
suggested O
that O
it O
would O
be O
the O
most O
sensitive O
to O
the O
benefits O
of O
minocycline O
. O

Sample O
Size O
and O
Power O
The O
primary O
outcome O
measure O
in O
this O
study O
is O
the B-Prim
DASH I-Prim
score I-Prim
. O

While O
the O
primary O
outcome O
of O
the O
present O
study O
is O
physical B-Prim
activity I-Prim
, O
dog-based O
interventions O
might O
in O
fact O
have O
a O
greater O
impact O
on O
other O
outcomes O
of O
considerable O
public O
health O
importance O
, O
such O
as O
total O
time O
spent O
sedentary O
, O
or O
the O
patterning O
of O
sedentary O
behaviour O
34 O
47 O
48 O
49 O
50 O
. O

If O
they O
failed O
to O
return O
the O
primary O
outcome O
measure O
, O
the B-Prim
BDI-II I-Prim
, O
they O
were O
telephoned O
by O
the O
practice O
research O
nurse O
to O
prompt O
them O
to O
return O
the O
questionnaire O
. O

The O
primary O
efficacy O
variable O
is O
the B-Prim
percentage I-Prim
of I-Prim
patients I-Prim
with I-Prim
no I-Prim
vomiting I-Prim
over I-Prim
0 I-Prim
to I-Prim
72 I-Prim
h I-Prim
postoperatively I-Prim
across I-Prim
the I-Prim
two I-Prim
treatment I-Prim
groups I-Prim
. O

If O
the O
primary O
outcome O
is O
normally O
distributed O
it O
will O
be O
compared O
using O
a O
t O
-test O
, O
ANCOVA O
adjusting O
for O
the O
minimization O
factors O
( O
primary O
analysis O
) O
and O
ANCOVA O
with O
further O
adjustment O
for O
prognostic O
factors O
. O

In O
addition O
, O
conditional O
power O
/ O
stochastic O
curtailment O
method O
124 O
may O
be O
used O
if O
requested O
by O
the O
DSMB O
due O
to O
small O
observed O
differences O
in O
primary O
outcome O
rates O
between O
treatments O
. O

Study O
Endpoints O
The O
primary O
outcome O
was O
a B-Prim
composite I-Prim
endpoint I-Prim
of I-Prim
all-cause I-Prim
mortality I-Prim
or I-Prim
all-cause I-Prim
hospitalization I-Prim
. O

The O
primary O
outcome O
is O
the B-Prim
timed-up-and-go I-Prim
test I-Prim
( I-Prim
TUGT I-Prim
) I-Prim
, I-Prim
measured I-Prim
at I-Prim
baseline I-Prim
and I-Prim
14 I-Prim
weeks I-Prim
post-randomisation I-Prim
. O

Primary O
outcomes O
are O
time B-Prim
to I-Prim
first I-Prim
and I-Prim
second I-Prim
falls I-Prim
. O

The O
main O
outcome O
variables O
in O
this O
part O
of O
the O
study O
are O
: O
rate B-Prim
of I-Prim
complications I-Prim
, O
adverse B-Prim
events I-Prim
, O
near B-Prim
misses I-Prim
and O
information B-Prim
transfer I-Prim
between I-Prim
care I-Prim
providers I-Prim
. O

The O
primary O
outcome O
parameter O
will O
be O
the B-Prim
expansion I-Prim
of I-Prim
the I-Prim
visual I-Prim
field I-Prim
after I-Prim
3 I-Prim
and I-Prim
6 I-Prim
months I-Prim
of I-Prim
treatment I-Prim
as I-Prim
determined I-Prim
by I-Prim
static I-Prim
visual I-Prim
field I-Prim
perimetry I-Prim
and I-Prim
high I-Prim
resolution I-Prim
perimetry I-Prim
. O

Power O
and O
sample O
size O
We O
have O
powered O
our O
study O
to O
detect O
an O
0.5 O
SD O
effect O
size O
for O
the O
primary O
outcome O
. O

To O
ensure O
the O
highest O
possible O
follow-up O
the O
intention O
was O
to O
contact O
patients O
after O
18 O
months O
to O
be O
reminded O
of O
the O
2 O
year O
assessment O
, O
and O
if O
for O
any O
reason O
( O
eg O
being O
out O
of O
the O
country O
) O
, O
the O
final O
assessment O
might O
be O
made O
earlier O
. O

The O
primary O
outcome O
for O
this O
study O
is O
relapse B-Prim
of I-Prim
psychotic I-Prim
symptoms I-Prim
. O

Outcomes O
The O
primary O
outcome O
measure O
was O
objective B-Prim
functional I-Prim
capacity I-Prim
, I-Prim
assessed I-Prim
using I-Prim
a I-Prim
25 I-Prim
m I-Prim
walk I-Prim
test I-Prim
, I-Prim
a I-Prim
repeated I-Prim
chair I-Prim
rise I-Prim
test I-Prim
, I-Prim
and I-Prim
a I-Prim
stair I-Prim
climb I-Prim
test I-Prim
. O

The O
primary O
outcomes O
were O
the B-Prim
mean I-Prim
change I-Prim
in I-Prim
1 I-Prim
) I-Prim
the I-Prim
child's I-Prim
asthma I-Prim
control I-Prim
score I-Prim
, O
2 B-Prim
) I-Prim
the I-Prim
parent's I-Prim
quality I-Prim
of I-Prim
life I-Prim
score I-Prim
, O
and O
3 B-Prim
) I-Prim
the I-Prim
number I-Prim
of I-Prim
urgent I-Prim
care I-Prim
events I-Prim
assessed I-Prim
at I-Prim
12 I-Prim
and I-Prim
24 I-Prim
months I-Prim
. O

It O
should O
be O
noted O
that O
some O
patients O
( O
for O
both O
primary O
and O
secondary O
outcome O
measures O
) O
will O
become O
" O
at O
risk O
" O
between O
the O
time O
of O
the O
baseline O
data O
collection O
and O
the O
follow O
up O
data O
collections O
. O

The O
failure O
to O
find O
a O
significant O
difference O
on O
the O
primary O
efficacy O
measure O
at O
week O
8 O
could O
in O
part O
be O
explained O
by O
the O
small O
sample O
size O
as O
well O
as O
the O
heterogeneous O
study O
group O
. O

A O
table O
providing O
full O
definitions O
of O
acute O
respiratory O
infection O
for O
this O
study O
Click O
here O
for O
file O
Major O
secondary O
outcomes O
: O
▪ O
Rate B-Sec
of I-Sec
hospitalizations I-Sec
for I-Sec
ARI I-Sec
: O
same O
case O
definition O
as O
primary O
outcome O
measure O
. O

The O
primary O
outcome O
measures O
were O
adherence B-Prim
and O
participation B-Prim
. O

Quantitative O
data O
collection O
Primary O
outcome O
Smoking B-Prim
status I-Prim
at I-Prim
34 I-Prim
to I-Prim
38 I-Prim
weeks I-Prim
gestation I-Prim
, I-Prim
towards I-Prim
the I-Prim
end I-Prim
of I-Prim
pregnancy I-Prim
. O

Our O
primary O
outcome O
is O
based O
on O
self-report O
, O
which O
likely O
will O
falsely O
increase O
quit O
rates O
( O
as O
compared O
to O
biochemical O
verification O
) O
. O

The B-Prim
functional I-Prim
outcome I-Prim
of I-Prim
the I-Prim
patient I-Prim
, I-Prim
as I-Prim
assessed I-Prim
by I-Prim
the I-Prim
Roland I-Prim
Disability I-Prim
Questionnaire I-Prim
for I-Prim
Sciatica I-Prim
at I-Prim
8 I-Prim
weeks I-Prim
and I-Prim
1 I-Prim
year I-Prim
after I-Prim
treatment I-Prim
, O
is O
the O
primary O
outcome O
measure O
. O

In O
an O
additional O
multiple O
logistic O
regression O
model O
, O
the O
effect O
of O
treatment O
on O
the O
primary O
endpoint O
will O
be O
assessed O
in O
relation O
to O
important O
risk O
factors O
for O
pain O
( O
younger O
age O
, O
severe O
pain O
in O
the O
postoperative O
period O
and O
severe O
preoperative O
pain O
27 O
) O
. O

Sample O
size O
, O
power O
calculation O
, O
and O
statistical O
analysis O
The O
main O
endpoint O
of O
the O
study O
was O
the B-Prim
determination I-Prim
of I-Prim
the I-Prim
perioperative I-Prim
concentration I-Prim
of I-Prim
IL-1β I-Prim
in I-Prim
the I-Prim
patient's I-Prim
peritoneal I-Prim
fluid I-Prim
. O

Deciding O
on O
a O
primary O
outcome O
in O
OA O
research O
is O
challenging O
as O
it O
is O
common O
for O
OA O
patients O
to O
rate O
different O
domains O
of O
the O
disease O
experience O
, O
e.g. O

Women O
will O
receive O
incentive O
payments O
outlined O
below O
: O
£ O
50 O
for O
attending O
a O
face-to-face O
appointment O
with O
their O
NSPS O
adviser O
and O
setting O
a O
quit O
date O
; O
£ O
50 O
if O
quit O
4 O
weeks O
after O
their O
quit O
date O
corroborated O
by O
a O
carbon O
monoxide O
breath O
test O
result O
less O
than O
10 O
ppm O
collected O
by O
a O
research O
nurse O
; O
£ O
100 O
if O
quit O
after O
12 O
weeks O
corroborated O
by O
a O
carbon O
monoxide O
breath O
test O
collected O
by O
a O
research O
nurse O
; O
£ O
200 O
if O
they O
self O
report O
quit O
for O
at O
least O
2 O
months O
when O
contacted O
for O
primary O
outcome O
assessment O
by O
the O
Helpline O
at O
34 O
to O
38 O
weeks O
gestation O
. O

Results O
The O
primary O
outcome O
measurement O
was O
the B-Prim
precision I-Prim
of I-Prim
the I-Prim
final I-Prim
result I-Prim
set I-Prim
selected I-Prim
to I-Prim
answer I-Prim
the I-Prim
clinical I-Prim
question I-Prim
. O

Although O
patients O
, O
investigators O
, O
and O
therapists O
administering O
treatment O
will O
not O
be O
blinded O
, O
those O
assessing O
the O
patients O
for O
primary O
and O
secondary O
endpoints O
will O
be O
blinded O
to O
patient O
treatment O
assignment O
. O

Power O
calculations O
In O
this O
study O
, O
the B-Prim
PHQ-9 I-Prim
will O
be O
used O
as O
the O
primary O
outcome O
measure O
. O

no O
interim O
analyses O
are O
planned O
for O
the O
primary O
parameters O
. O

Thus O
, O
the O
proposed O
sample O
is O
sufficiently O
powered O
to O
detect O
clinically O
meaningful O
changes O
in O
this O
primary O
outcome O
of O
interest O
. O

The O
primary O
outcome O
is O
the B-Prim
incidence I-Prim
of I-Prim
PTS I-Prim
during I-Prim
follow-up I-Prim
. O

These O
variable O
results O
suggest O
that O
methacholine O
reactivity O
post O
allergen O
challenge O
is O
not O
a O
robust O
primary O
endpoint O
to O
evaluate O
drug O
effects O
. O

The O
primary O
endpoint O
is O
cure B-Prim
at I-Prim
day I-Prim
28 I-Prim
with O
secondary O
endpoint O
at B-Sec
day I-Sec
210 I-Sec
( I-Sec
6 I-Sec
months I-Sec
) I-Sec
. O

Main O
outcome O
measures O
after O
six O
weeks O
of O
treatment O
were O
Treatment B-Prim
Alliance I-Prim
Scale I-Prim
( I-Prim
TAS I-Prim
) I-Prim
40 I-Prim
and O
Client B-Prim
Satisfaction I-Prim
Questionnaire I-Prim
( I-Prim
CSQ I-Prim
) I-Prim
44 I-Prim
. O

Crossover O
is O
not O
allowed O
until O
after O
the O
outcome O
measures O
have O
been O
collected O
at O
the O
study O
primary O
endpoint O
of O
6 O
weeks O
; O
therefore O
, O
the O
primary O
results O
will O
reflect O
the O
treatment O
to O
which O
the O
participant O
was O
randomized O
. O

A O
final O
parameter O
investigated O
was O
the O
prevalence O
of O
Plasmodium O
falciparum O
in O
the O
target O
population O
, O
a O
factor O
that O
will O
determine O
the O
quantity O
of O
anti-malarial O
treatments O
used O
. O

The O
primary O
outcome O
measure O
is O
the B-Prim
change I-Prim
in I-Prim
the I-Prim
subscale I-Prim
bodily I-Prim
pain I-Prim
of I-Prim
the I-Prim
SF36 I-Prim
from I-Prim
M1 I-Prim
to I-Prim
M2 I-Prim
. O

The O
baseline O
questionnaire O
was O
then O
re-administered O
at O
the O
end O
of O
the O
study O
to O
all O
subjects O
( O
control O
and O
intervention O
) O
with O
change B-Prim
in I-Prim
score I-Prim
as O
the O
primary O
outcome O
, O
and O
difference B-Sec
in I-Sec
changes I-Sec
in I-Sec
score I-Sec
as O
the O
secondary O
outcome O
. O

Our O
aim O
is O
to O
assess O
whether O
UCR O
and O
/ O
or O
UTR O
are O
superior O
to O
conventional O
hemodialysis O
with O
respect O
to O
frequency B-Prim
of I-Prim
intra- I-Prim
and I-Prim
post-dialytic I-Prim
complications I-Prim
( O
primary O
outcome O
) O
, O
and O
improvement O
of O
various O
secondary O
outcome O
parameters O
, O
possibly O
related O
to O
improved O
hemodialysis O
stability O
and O
volume O
status O
. O

This O
absence O
of O
a O
beneficial O
effect O
of O
selenium O
treatment O
could O
theoretically O
be O
related O
to O
the O
small O
size O
of O
the O
study O
allowing O
conclusions O
only O
on O
the O
main O
endpoint O
. O

length O
of O
hospital O
stay O
) O
and O
total O
hospital O
costs O
per O
patient O
, O
alongside O
the O
primary O
clinical O
endpoint O
. O

Primary O
outcome O
measure O
is O
adherence B-Prim
to I-Prim
oral I-Prim
antidiabetics I-Prim
calculated I-Prim
from I-Prim
: I-Prim
1 I-Prim
) I-Prim
data I-Prim
collected I-Prim
with I-Prim
RTMM I-Prim
, I-Prim
as I-Prim
a I-Prim
percentage I-Prim
of I-Prim
medication I-Prim
taken I-Prim
as I-Prim
prescribed I-Prim
, I-Prim
and I-Prim
as I-Prim
percentage I-Prim
of I-Prim
medication I-Prim
taken I-Prim
within I-Prim
the I-Prim
correct I-Prim
time I-Prim
interval I-Prim
, O
2 B-Prim
) I-Prim
refill I-Prim
data I-Prim
, I-Prim
taking I-Prim
the I-Prim
number I-Prim
of I-Prim
days I-Prim
for I-Prim
which I-Prim
oral I-Prim
antidiabetics I-Prim
are I-Prim
dispensed I-Prim
during I-Prim
the I-Prim
study I-Prim
period I-Prim
divided I-Prim
by I-Prim
the I-Prim
total I-Prim
number I-Prim
of I-Prim
days I-Prim
of I-Prim
the I-Prim
study I-Prim
period I-Prim
. O

Measures O
Primary O
outcome O
measures O
The O
main O
outcome O
in O
the O
study O
is O
sick B-Prim
leave I-Prim
. O

Data O
analysis O
The O
primary O
outcome O
will O
be O
compared O
between O
each O
of O
the O
study O
arms O
using O
methods O
appropriate O
for O
cluster O
randomized O
trials O
. O

Phase O
II O
Primary O
endpoint O
The O
primary O
endpoint O
variable O
OS_12 B-Prim
m I-Prim
was O
planned O
to O
be O
analysed O
by O
a O
one O
sided O
logrank O
test O
of O
stratified O
by O
histology O
testing O
H O
0 O
: O
OS O
A O
-12 O
m O
= O
OS O
B O
-12 O
m O
versus O
H O
1 O
: O
OS O
A O
-12 O
m O
> O
OS O
B O
-12 O
m O
at O
the O
level O
of O
alpha O
= O
5 O
% O
. O

Primary O
outcome O
measure O
Alzheimer B-Prim
Disease I-Prim
Assessment I-Prim
Scale-Cognitive I-Prim
( I-Prim
ADAS-COG I-Prim
) I-Prim
13 I-Prim
is O
a O
frequently O
used O
measure O
of O
global O
cognitive O
functioning O
and O
assesses O
cognitive O
domains O
including O
orientation O
, O
memory O
, O
language O
, O
and O
praxis O
; O
common O
areas O
of O
impairment O
present O
in O
AD O
. O

The O
main O
outcome O
variable O
is O
the B-Prim
exclusive I-Prim
o I-Prim
predominant I-Prim
breastfeeding I-Prim
at I-Prim
6 I-Prim
moths I-Prim
of I-Prim
age I-Prim
. O
. O
Main O
effectiveness O
will O
be O
analyzed O
by O
comparing O
the O
percentage O
of O
infants O
with O
exclusive O
or O
predominant O
breastfeeding O
at O
6 O
months O
between O
the O
intervention O
group O
and O
the O
control O
group O
. O

Outcome O
measures O
Primary O
outcome O
Primary O
outcome O
will O
be O
presented O
by O
the B-Prim
mean I-Prim
percentage I-Prim
change I-Prim
of I-Prim
inflammatory I-Prim
lesion I-Prim
counts I-Prim
from I-Prim
baseline I-Prim
to I-Prim
the I-Prim
end I-Prim
of I-Prim
the I-Prim
trial I-Prim
29 O
33 O
. O

The O
primary O
outcome O
was O
the B-Prim
number I-Prim
of I-Prim
hospital I-Prim
days I-Prim
after I-Prim
surgery I-Prim
with O
cost-effectiveness B-Sec
as O
a O
secondary O
outcome O
. O

The O
primary O
outcome O
is O
presence B-Prim
/ I-Prim
absence I-Prim
of I-Prim
incontinence I-Prim
at I-Prim
six I-Prim
weeks I-Prim
post-stroke I-Prim
. O

First O
of O
all O
, O
blinding O
is O
not O
feasible O
in O
such O
studies O
and O
therefore O
a O
bias O
in O
the O
assessment O
of O
main O
and O
further O
outcomes O
cannot O
be O
ruled O
out O
( O
especially O
with O
subjective O
outcomes O
) O
. O

Primary O
and O
secondary O
outcomes O
will O
be O
evaluated O
within O
and O
between O
groups O
by O
comparing O
data O
from O
baseline O
, O
after O
completion O
of O
the O
visits O
, O
and O
again O
after O
a O
6-month O
follow-up O
. O

The O
primary O
study O
outcomes O
are O
muscle B-Prim
endurance I-Prim
and O
functional B-Prim
abilities I-Prim
, I-Prim
assessed I-Prim
with I-Prim
a I-Prim
Six-Minute I-Prim
Bicycle I-Prim
Test I-Prim
and I-Prim
the I-Prim
Motor I-Prim
Function I-Prim
Measure I-Prim
. O

The O
primary O
efficacy O
variables O
were O
analyzed O
using O
the O
Wilcoxon O
signed O
rank O
test O
to O
compute O
the O
within-group O
differences O
and O
the O
Wilcoxon O
rank O
sum O
test O
for O
between-group O
differences O
. O

The O
proportion O
of O
individuals O
in O
the O
two O
groups O
requiring O
more O
than O
six O
emergency O
interventions O
, O
first O
criterion O
for O
heavy O
use O
of O
MHS O
, O
did O
not O
differ O
at O
T24 O
( O
n O
= O
5 O
/ O
16 O
in O
the O
STM O
group O
and O
n O
= O
3 O
/ O
18 O
in O
the O
SB-APP O
group O
; O
chi O
-square O
= O
.443 O
; O
p O
< O
.311 O
) O
. O

Program O
evaluation O
and O
satisfaction O
questions O
will O
also O
be O
asked O
of O
each O
participant O
near O
the O
end O
of O
this O
final O
assessment O
. O

The O
aim O
will O
be O
to O
recruit O
78 O
patients O
in O
each O
group O
as O
this O
will O
provide O
sufficient O
participants O
to O
obtain O
a O
power O
of O
90 O
% O
for O
both O
primary O
outcome O
measures O
. O

Secondary O
outcome O
variables O
The B-Sec
change I-Sec
from I-Sec
baseline I-Sec
to I-Sec
final I-Sec
assessment I-Sec
of I-Sec
the I-Sec
study I-Sec
knee I-Sec
in I-Sec
self-reported I-Sec
knee I-Sec
pain I-Sec
and O
difficulty B-Sec
with I-Sec
physical I-Sec
function I-Sec
will O
be O
measured O
using O
the O
WOMAC O
Index O
32 O
. O

Outcomes O
The O
primary O
outcome O
is O
whether B-Prim
or I-Prim
not I-Prim
headache I-Prim
is I-Prim
present I-Prim
at I-Prim
24 I-Prim
hours I-Prim
after I-Prim
the I-Prim
start I-Prim
of I-Prim
treatment I-Prim
. O

The O
primary O
outcome O
is O
mortality B-Prim
at I-Prim
28 I-Prim
days I-Prim
after I-Prim
randomisation I-Prim
; O
secondary O
outcomes O
are O
mortality B-Sec
in I-Sec
ICU I-Sec
, O
mortality B-Sec
in I-Sec
hospital I-Sec
, O
number B-Sec
of I-Sec
ventilator-free I-Sec
days I-Sec
, O
number B-Sec
of I-Sec
non-pulmonary I-Sec
organ I-Sec
failure-free I-Sec
days I-Sec
, O
mortality B-Sec
at I-Sec
twelve I-Sec
months I-Sec
post-randomisation I-Sec
, O
quality B-Sec
of I-Sec
life I-Sec
at I-Sec
six I-Sec
and I-Sec
twelve I-Sec
months I-Sec
, O
length B-Sec
of I-Sec
stay I-Sec
in I-Sec
ICU I-Sec
, O
length B-Sec
of I-Sec
stay I-Sec
in I-Sec
hospital I-Sec
, O
adverse B-Sec
effects I-Sec
( O
e.g. O

Also O
, O
every O
effort O
will O
be O
made O
to O
ensure O
that O
the O
physician O
who O
is O
assessing O
the O
primary O
outcome O
is O
blinded O
to O
the O
treatment O
allocation O
. O

Univariate O
, O
multivariate O
and O
descriptive O
techniques O
are O
applied O
to O
estimate O
the O
effect O
of O
the O
intervention O
by O
comparing O
the O
experimental O
with O
the O
control O
groups O
with O
regard O
to O
the O
primary O
and O
secondary O
outcomes O
at O
the O
follow-up O
measurements O
and O
by O
comparing O
the O
pre-test O
( O
T1 O
) O
with O
post-tests O
( O
T3 O
and O
T4 O
) O
. O

Effect O
variables O
The O
primary O
effect O
variable O
was O
u-AQP2 B-Prim
CR I-Prim
, O
and O
the O
secondary O
effect O
variables O
were O
urinary B-Sec
sodium I-Sec
excretion I-Sec
rate I-Sec
( I-Sec
U I-Sec
Na I-Sec
) I-Sec
, O
FE B-Sec
Na I-Sec
, O
u-ENaC B-Sec
β-CR I-Sec
, O
urine B-Sec
volume I-Sec
( I-Sec
V I-Sec
) I-Sec
, O
C B-Sec
H20 I-Sec
, O
serum B-Sec
osmolality I-Sec
( I-Sec
s-osm I-Sec
) I-Sec
, O
urine B-Sec
osmolality I-Sec
( I-Sec
u-osm I-Sec
) I-Sec
, O
u-cAMP B-Sec
and I-Sec
u-PGE I-Sec
2 I-Sec
, O
plasma B-Sec
concentrations I-Sec
of I-Sec
AVP I-Sec
, O
PRC B-Sec
, O
Ang B-Sec
II I-Sec
, O
Aldo B-Sec
, O
ANP B-Sec
, O
BNP B-Sec
, O
sodium B-Sec
( I-Sec
p-Na I-Sec
) I-Sec
, O
and O
albumin B-Sec
( I-Sec
p-albumin I-Sec
) I-Sec
, O
systolic B-Sec
and I-Sec
diastolic I-Sec
blood I-Sec
pressure I-Sec
, O
heart B-Sec
rate I-Sec
, O
body B-Sec
weight I-Sec
, O
and O
glomerular B-Sec
filtration I-Sec
rate I-Sec
( I-Sec
GFR I-Sec
) I-Sec
. O

At O
the O
final O
assessment O
, O
participants O
were O
required O
to O
fill-out O
a O
Completion O
Questionnaire O
without O
the O
assessor O
present O
. O

Primary O
outcome O
measure O
The B-Prim
median I-Prim
RTDI I-Prim
for O
the O
whole O
study O
population O
was O
95.5 O
% O
( O
CECOG O
88.8 O
% O
, O
Mamma-1 O
95.6 O
% O
, O
Mamma-3 O
99.6 O
% O
) O
, O
whereas O
the O
mean O
RTDI O
overall O
was O
85.7 O
% O
( O
CECOG O
81.2 O
% O
, O
Mamma-1 O
85.6 O
% O
, O
Mamma-3 O
93.0 O
% O
) O
. O

The O
effect O
of O
acetylcysteine O
versus O
placebo O
on O
the O
primary O
endpoint O
, O
incidence B-Prim
of I-Prim
CIN I-Prim
between I-Prim
48 I-Prim
to I-Prim
96 I-Prim
hours I-Prim
, O
will O
be O
evaluated O
with O
a O
chi-square O
test O
. O

The O
primary O
outcome O
will O
be O
the B-Prim
total I-Prim
( I-Prim
non-maternity I-Prim
) I-Prim
cost I-Prim
per I-Prim
member I-Prim
as I-Prim
reported I-Prim
to I-Prim
the I-Prim
private I-Prim
health I-Prim
insurer I-Prim
( O
i.e. O

Other O
than O
the O
primary O
outcome O
, O
secondary O
outcomes O
and O
eligibility O
criteria O
agreed O
upon O
by O
the O
6 O
sites O
, O
each O
site O
was O
free O
to O
design O
a O
trial O
that O
was O
different O
in O
some O
way O
. O

Treatment O
effect O
was O
measured O
as O
the O
change O
on O
anthropometric O
and O
biochemical O
determinations O
within O
initial O
and O
final O
measures O
and O
mean O
change O
among O
groups O
comparison O
. O

Outcome O
measures O
The O
primary O
outcome O
measure O
is O
( B-Prim
unassisted I-Prim
) I-Prim
patency I-Prim
of I-Prim
the I-Prim
AVF I-Prim
at I-Prim
three I-Prim
months I-Prim
after I-Prim
randomisation I-Prim
. O

Effect O
of O
the O
intervention O
on O
primary O
outcome O
measures O
Lifestyle-related O
cardiovascular O
risk O
factors O
Table O
3 O
shows O
the O
effect O
of O
the O
intervention O
on O
lifestyle O
measures O
. O

If O
the O
differences O
between O
the O
centers O
are O
not O
significant O
, O
the O
subsequent O
comparison O
of O
the O
primary O
outcome O
will O
be O
performed O
between O
the O
two O
treatment O
groups O
across O
the O
centers O
, O
otherwise O
it O
will O
be O
stratified O
on O
center O
. O

Families O
were O
notified O
by O
means O
of O
a O
letter O
of O
their O
child's O
allocation O
to O
the O
intervention O
group O
or O
the O
control O
group O
prior O
to O
the O
first O
baseline O
assessment O
. O

We O
discussed O
in O
detail O
whether O
death O
before O
nursing O
home O
placement O
should O
be O
included O
in O
the O
primary O
endpoint O
or O
count O
as O
a O
censoring O
event O
. O

The O
primary O
outcome O
measure O
was O
the B-Prim
Roland I-Prim
Morris I-Prim
Disability I-Prim
Questionnaire I-Prim
( I-Prim
RDQ I-Prim
) I-Prim
41 I-Prim
, O
an O
established O
outcome O
measure O
for O
community O
based O
back O
pain O
studies O
46 O
. O

Whilst O
this O
interactive O
learning O
tool O
did O
not O
improve O
knowledge O
over O
and O
above O
self-directed O
learning O
, O
an O
improved O
tool O
might O
be O
more O
effective O
and O
efficiency O
might O
be O
a O
more O
appropriate O
primary O
outcome O
for O
further O
research O
. O

This O
outcome O
, O
compared O
with O
the O
principal O
study O
outcomes O
, O
will O
provide O
insight O
into O
the O
accuracy O
with O
which O
physicians O
' O
discern O
their O
own O
prescribing O
practices O
. O

These O
studies O
have O
used O
the B-Prim
ORS I-Prim
scale I-Prim
as O
the O
main O
outcome O
measure O
. O

Generalized O
Estimating O
Equations O
( O
GEE O
) O
84 O
will O
be O
used O
to O
fit O
regression O
models O
to O
describe O
the O
effects O
of O
the O
intervention O
on O
key O
outcome O
variables O
among O
children O
. O

Outcome O
measures O
Our O
primary O
outcome O
measure O
will O
be O
the B-Prim
IBS I-Prim
Symptom I-Prim
Severity I-Prim
Score I-Prim
( I-Prim
IBS I-Prim
SSS I-Prim
) I-Prim
. O

Since O
there O
was O
a O
lack O
of O
previous O
data O
to O
guide O
estimation O
of O
sample O
size O
based O
on O
our O
designated O
primary O
outcome O
, O
one O
purpose O
of O
this O
study O
was O
to O
determine O
feasible O
sample O
size O
for O
future O
study O
. O

Since O
the O
sequential O
application O
of O
treatment O
regimens O
is O
evaluated O
, O
time B-Prim
to I-Prim
failure I-Prim
of I-Prim
strategy I-Prim
( I-Prim
TFS I-Prim
) I-Prim
was O
chosen O
as O
the O
primary O
endpoint O
( O
Figure O
1 O
) O
. O

They O
will O
decide O
whether O
or O
not O
a O
primary O
end-point O
has O
occurred O
and O
classify O
strokes O
as O
thrombo-embolic O
, O
haemorrhagic O
, O
or O
uncertain O
. O

Biomarkers B-Prim
associated I-Prim
with I-Prim
oesophageal I-Prim
AC I-Prim
development I-Prim
will O
be O
measured O
as O
primary O
outcomes O
via O
blood O
samples O
. O

The O
primary O
outcome O
is O
the B-Prim
combined I-Prim
incidence I-Prim
of I-Prim
all I-Prim
cause I-Prim
hospitalization I-Prim
and I-Prim
death I-Prim
. O

Outcome O
Measures O
The O
primary O
outcome O
measure O
is O
depressive B-Prim
symptomology I-Prim
, I-Prim
which I-Prim
is I-Prim
being I-Prim
measured I-Prim
using I-Prim
the I-Prim
Edinburgh I-Prim
Postnatal I-Prim
Depression I-Prim
Scale I-Prim
32 I-Prim
. O

Statistical O
analyses O
The O
main O
outcome O
variable O
is O
the B-Prim
maximum I-Prim
SOFA I-Prim
score I-Prim
during I-Prim
ICU I-Prim
stay I-Prim
. O

Primary O
and O
secondary O
endpoint O
analysis O
The O
primary O
endpoint O
of O
this O
trial O
is O
overall B-Prim
survival I-Prim
, O
i.e. O

Outcome O
measures O
: O
Main O
outcome O
measure O
: O
Alteration B-Prim
of I-Prim
Pain I-Prim
intensity I-Prim
( I-Prim
VAS I-Prim
) I-Prim
; O
Secondary O
outcome O
measure O
: O
alteration B-Sec
of I-Sec
pain I-Sec
intensity I-Sec
/ I-Sec
frequency I-Sec
( I-Sec
evaluated I-Sec
by I-Sec
diary I-Sec
) I-Sec
; O
pain B-Sec
questionnaires I-Sec
( I-Sec
including I-Sec
: I-Sec
NPI I-Sec
, I-Sec
PDI I-Sec
, I-Sec
SES I-Sec
, I-Sec
please I-Sec
refer I-Sec
to I-Sec
Table I-Sec
3 I-Sec
) I-Sec
; O
quality B-Sec
of I-Sec
life I-Sec
( I-Sec
SF-36 I-Sec
) I-Sec
Sensoric B-Sec
perception I-Sec
evaluated I-Sec
through I-Sec
qualitative I-Sec
sensory I-Sec
testing I-Sec
( I-Sec
QST I-Sec
) I-Sec
; O
credibility B-Sec
assessment I-Sec
according I-Sec
to I-Sec
Vincent I-Sec
; O
cost B-Sec
effectiveness I-Sec
and O
safety B-Sec
aspects I-Sec
. O

The O
main O
outcome O
measures O
are O
changes B-Prim
in I-Prim
clinical I-Prim
practices I-Prim
that I-Prim
are I-Prim
recommended I-Prim
in I-Prim
RHL I-Prim
measured I-Prim
approximately I-Prim
a I-Prim
year I-Prim
after I-Prim
the I-Prim
first I-Prim
workshop I-Prim
. O

Sample O
size O
calculation O
The O
size O
of O
the O
study O
was O
based O
on O
the O
primary O
outcome O
measure O
HbA1c B-Prim
. O

Main O
outcomes O
include O
a B-Prim
) I-Prim
duration I-Prim
of I-Prim
breastfeeding I-Prim
measured I-Prim
at I-Prim
6 I-Prim
and I-Prim
12 I-Prim
months I-Prim
, O
b B-Prim
) I-Prim
introduction I-Prim
of I-Prim
solids I-Prim
measured I-Prim
at I-Prim
4 I-Prim
and I-Prim
6 I-Prim
months I-Prim
, O
c B-Prim
) I-Prim
nutrition I-Prim
, I-Prim
physical I-Prim
activity I-Prim
and I-Prim
television I-Prim
viewing I-Prim
measured I-Prim
at I-Prim
24 I-Prim
months I-Prim
, O
and O
d B-Prim
) I-Prim
overweight I-Prim
/ I-Prim
obesity I-Prim
status I-Prim
at I-Prim
age I-Prim
2 I-Prim
and I-Prim
5 I-Prim
years I-Prim
. O

The O
result O
of O
a O
sample O
size O
calculation O
with O
the O
primary O
outcome O
( O
NRS B-Prim
changes I-Prim
) O
of O
this O
study O
, O
adopting O
0.05 O
for O
α O
, O
0.2 O
for O
β O
and O
20 O
% O
for O
drop-out O
rate O
, O
suggested O
that O
115 O
participants O
in O
each O
group O
are O
an O
adequate O
sample O
size O
. O

Primary O
outcome O
The O
patients O
were O
well O
matched O
for O
baseline O
characteristics O
( O
Table O
1 O
) O
. O

The O
primary O
study O
outcome O
is O
the B-Prim
cumulative I-Prim
ongoing I-Prim
pregnancy I-Prim
rate I-Prim
resulting I-Prim
in I-Prim
live I-Prim
birth I-Prim
achieved I-Prim
within I-Prim
18 I-Prim
months I-Prim
after I-Prim
randomisation I-Prim
. O

The O
primary O
outcome O
will O
be O
change B-Prim
in I-Prim
depressive I-Prim
symptoms I-Prim
at I-Prim
6 I-Prim
months I-Prim
on I-Prim
the I-Prim
90-item I-Prim
Symptoms I-Prim
Checklist I-Prim
( I-Prim
SCL-90 I-Prim
) I-Prim
. O

Study O
objectives O
and O
outcome O
measures O
The O
primary O
objective O
is O
to O
ascertain O
whether O
there O
are O
equivalent O
changes O
in O
HbA1c B-Prim
( O
primary O
outcome O
measure O
) O
in O
people O
with O
newly O
diagnosed O
T2DM O
allocated O
to O
either O
a O
urine O
or O
a O
blood O
glucose O
monitoring O
strategy O
over O
18 O
months O
when O
incorporated O
as O
an O
integral O
part O
of O
a O
comprehensive O
self-management O
structured O
education O
programme O
( O
DESMOND O
) O
. O

Subgroup O
analyses O
for O
the O
primary O
outcome O
will O
be O
based O
on O
time O
from O
injury O
to O
randomization O
, O
the O
severity O
of O
TBI O
( O
moderate O
or O
severe O
) O
, O
the O
location O
of O
the O
intracranial O
bleeding O
, O
and O
baseline O
risk O
. O

The O
primary O
outcome O
measure O
will O
be O
the B-Prim
Disabilities I-Prim
of I-Prim
the I-Prim
Arm I-Prim
, I-Prim
Shoulder I-Prim
and I-Prim
Hand I-Prim
( I-Prim
DASH I-Prim
) I-Prim
score I-Prim
and O
the O
secondary O
outcome O
measures O
will O
be O
the B-Sec
EuroQol-5D I-Sec
( I-Sec
EQ-5D I-Sec
) I-Sec
value I-Sec
, O
OSS B-Sec
, O
Constant-Murley B-Sec
Score I-Sec
, O
VAS B-Sec
, O
and O
15D B-Sec
. O

The O
primary O
outcomes O
are O
depression B-Prim
and O
anxiety B-Prim
symptoms I-Prim
as I-Prim
measured I-Prim
by I-Prim
the I-Prim
Beck I-Prim
Depression I-Prim
and I-Prim
Anxiety I-Prim
Inventories I-Prim
. O

Primary O
outcome O
measure O
The O
primary O
outcome O
measure O
for O
the O
study O
is O
the B-Prim
score I-Prim
on I-Prim
the I-Prim
AUDIT I-Prim
screen I-Prim
at I-Prim
12 I-Prim
months I-Prim
post-consent I-Prim
. O

These O
data O
will O
be O
disclosed O
to O
the O
central O
office O
only O
after O
data O
on O
primary O
outcome O
have O
been O
collected O
. O

As O
illustrated O
in O
Figure O
2 O
, O
the O
study O
is O
designed O
to O
include O
a O
secondary O
data O
assessment O
12 O
months O
after O
baseline O
; O
the O
primary O
outcome O
assessment O
will O
be O
performed O
immediately O
after O
the O
intervention O
program O
4 O
months O
after O
baseline O
. O

A O
recent O
randomized O
controlled O
trial O
of O
an O
active O
video O
game O
( O
PlayStation O
EyeToy™ O
) O
intervention O
showed O
a O
statistically O
significant O
treatment O
effect O
on O
the O
primary O
outcome O
, O
change B-Prim
from I-Prim
baseline I-Prim
in I-Prim
body I-Prim
mass I-Prim
index I-Prim
( I-Prim
BMI I-Prim
) I-Prim
, O
which O
favored O
the O
intervention O
group O
at O
24 O
weeks O
1 O
. O

If O
serum O
phosphate O
remains O
below O
this O
level O
after O
6 O
weeks O
and O
/ O
or O
a O
dose O
reduction O
subjects O
will O
be O
withdrawn O
from O
the O
study O
after O
a O
final O
set O
of O
measurements O
. O

In O
addition O
, O
the O
primary O
outcome O
measure O
, O
reduction B-Prim
of I-Prim
depressive I-Prim
symptoms I-Prim
, O
is O
measured O
from O
three O
different O
perspectives O
. O

Sample O
Size O
Determination O
and O
Power O
Analysis O
The O
primary O
response O
variable O
for O
sample O
size O
calculation O
is O
the B-Prim
proportion I-Prim
( I-Prim
% I-Prim
) I-Prim
of I-Prim
patients I-Prim
who I-Prim
respond I-Prim
to I-Prim
treatment I-Prim
. O

Outcomes O
Effectiveness O
measures O
The O
primary O
effectiveness O
measures O
of O
the O
study O
consist O
of O
Roland B-Prim
Morris I-Prim
Disability I-Prim
Questionnaire I-Prim
( I-Prim
RDQ I-Prim
) I-Prim
31 I-Prim
32 I-Prim
( I-Prim
scale I-Prim
0-24 I-Prim
; I-Prim
lower I-Prim
score I-Prim
indicates I-Prim
lower I-Prim
disability I-Prim
) I-Prim
, O
Mc B-Prim
Gill I-Prim
Pain I-Prim
Questionnaire I-Prim
33 I-Prim
34 I-Prim
35 I-Prim
36 I-Prim
37 I-Prim
( I-Prim
including I-Prim
VAS I-Prim
1-10 I-Prim
; I-Prim
lower I-Prim
score I-Prim
indicates I-Prim
less I-Prim
pain I-Prim
) I-Prim
, O
and O
Goldberg B-Prim
questionnaire I-Prim
on I-Prim
anxiety I-Prim
and I-Prim
depression I-Prim
. O

The O
primary O
outcome O
, O
change B-Prim
in I-Prim
systolic I-Prim
blood I-Prim
pressure I-Prim
at I-Prim
6 I-Prim
months I-Prim
, O
will O
be O
compared O
between O
the O
two O
groups O
using O
a O
simple O
t-test O
against O
the O
usual O
null O
hypothesis O
of O
no O
difference O
. O

Measures O
The O
primary O
outcome O
is O
health-related B-Prim
quality I-Prim
of I-Prim
life I-Prim
for I-Prim
the I-Prim
carer I-Prim
. O

Assessments O
are O
re-reviewed O
by O
a O
second O
clinical O
investigator O
if O
the O
first O
assessment O
noted O
worsening O
HF O
as O
either O
' O
probably O
' O
or O
' O
probably O
not O
' O
a O
contributing O
factor O
to O
the O
admission O
or O
if O
it O
is O
marked O
' O
unsure O
' O
. O

Definition O
of O
endpoints O
The O
primary O
endpoint O
is O
biochemical B-Prim
progression-free I-Prim
survival I-Prim
( I-Prim
bPFS I-Prim
) I-Prim
. O

The O
primary O
measure O
for O
this O
task O
is O
the B-Prim
number I-Prim
of I-Prim
correct I-Prim
items I-Prim
. O

Primary O
outcome O
is O
the B-Prim
task I-Prim
performance I-Prim
measured I-Prim
with I-Prim
the I-Prim
Task I-Prim
Performance I-Prim
Scale I-Prim
six I-Prim
weeks I-Prim
post I-Prim
treatment I-Prim
. O

Outcome O
assessment O
Data O
collected O
at O
baseline O
, O
including O
primary O
and O
secondary O
outcome O
measures O
, O
will O
be O
collected O
again O
at O
12 O
and O
18 O
months O
post-intervention O
for O
both O
the O
intervention O
and O
control O
groups O
. O

Outcome O
measures O
Main O
objective O
The O
primary O
outcome O
measured O
is O
adherence B-Prim
, O
means B-Prim
of I-Prim
increasing I-Prim
physical I-Prim
activity I-Prim
level I-Prim
assessed I-Prim
with I-Prim
short-version I-Prim
IPAQ I-Prim
questionnaire I-Prim
37 I-Prim
. O

The O
collection O
of O
the O
same O
data O
items O
at O
multiple O
data O
points O
should O
facilitate O
imputation O
of O
values O
for O
data O
points O
missed O
by O
individual O
participants O
and O
minimise O
the O
impact O
of O
lower O
participation O
, O
however O
, O
this O
will O
remain O
a O
limitation O
for O
measures O
analysed O
cross-sectionally O
. O

We O
elected O
to O
include O
a O
small O
number O
of O
key O
competence O
measures O
as O
we O
felt O
that O
we O
could O
not O
interpret O
confidence O
entirely O
isolated O
from O
competence O
. O

The O
patient O
follow-up O
has O
three O
distinct O
phases--from O
randomization O
and O
baseline O
injection O
to O
the O
primary O
endpoint O
at O
six O
weeks O
, O
from O
optional O
crossover O
at O
six O
weeks O
until O
nine O
weeks O
, O
and O
the O
follow-up O
period O
from O
nine O
weeks O
to O
one O
year O
after O
randomization O
( O
see O
Figure O
1 O
) O
. O

In O
the O
all O
, O
mean O
total O
cholesterol O
, O
LDL O
, O
HDL O
, O
and O
triglyceride O
levels O
increased O
from O
baseline O
to O
the O
first O
assessment O
after O
tocilizumab O
infusion O
at O
week O
6 O
and O
remained O
at O
week O
6 O
levels O
with O
continued O
tocilizumab O
treatment O
( O
Table O
5 O
) O
. O

The O
primary O
outcome O
measure O
was O
the B-Prim
prevalence I-Prim
of I-Prim
arm I-Prim
, I-Prim
shoulder I-Prim
and I-Prim
neck I-Prim
symptoms I-Prim
. O

Sub-group O
analysis O
of O
those O
with O
a O
recorded O
hospitalisation O
within O
12 O
months O
prior O
to O
enrolment O
of O
the O
trial O
will O
be O
undertaken O
with O
respect O
to O
primary O
and O
secondary O
outcome O
measures O
. O

The O
structured O
adolescent O
questionnaire O
contained O
validated O
measures O
of O
the O
mental O
wellbeing O
and O
physical O
activity O
primary O
outcomes O
: O
negative O
mental O
health O
symptoms O
were O
measured O
using O
the O
Strengths O
and O
Difficulties O
Questionnaire O
( O
SDQ O
) O
64 O
; O
positive O
mental O
wellbeing O
was O
measured O
using O
the O
Positive O
and O
Negative O
Affect O
Scale O
( O
PANAS O
) O
65 O
; O
physical O
activity O
was O
measured O
using O
the O
Adolescent O
Physical O
Activity O
Questionnaire O
( O
PAQ-A O
) O
66 O
. O

This O
figure O
assumes O
that O
the O
annual O
incidence O
of O
the O
primary O
end-point O
on O
aspirin O
is O
9 O
% O
, O
6 O
16 O
the O
annual O
rate O
of O
primary O
end-points O
or O
death O
will O
be O
14 O
% O
and O
that O
loss O
to O
follow O
up O
will O
be O
1 O
% O
. O

Co-primary O
outcome O
measures O
are O
the B-Prim
duration I-Prim
of I-Prim
antibiotic I-Prim
therapy I-Prim
( I-Prim
superiority I-Prim
aspect I-Prim
of I-Prim
the I-Prim
trial I-Prim
) I-Prim
and O
the B-Prim
proportion I-Prim
of I-Prim
infants I-Prim
with I-Prim
a I-Prim
recurrence I-Prim
of I-Prim
infection I-Prim
requiring I-Prim
additional I-Prim
courses I-Prim
of I-Prim
antibiotic I-Prim
therapy I-Prim
and I-Prim
/ I-Prim
or I-Prim
death I-Prim
in I-Prim
the I-Prim
first I-Prim
month I-Prim
of I-Prim
life I-Prim
( I-Prim
safety I-Prim
of I-Prim
study I-Prim
intervention I-Prim
, I-Prim
non-inferiority I-Prim
aspect I-Prim
of I-Prim
the I-Prim
trial I-Prim
) I-Prim
. O

For O
intervention O
participants O
with O
an O
attrition O
of O
at O
least O
75 O
% O
a O
per-protocol O
analysis O
will O
be O
performed O
with O
data O
of O
the O
first O
measurement O
from O
baseline O
and O
, O
secondly O
. O

A O
per-protocol O
analysis O
will O
also O
be O
performed O
on O
the O
main O
outcomes O
using O
completers O
only O
, O
which O
we O
define O
as O
those O
patients O
who O
complete O
at O
least O
5 O
cCBT O
sessions O
. O

Instruments O
Primary O
outcome O
Depressive B-Prim
symptoms I-Prim
Symptoms O
of O
depression O
will O
be O
assessed O
with O
the O
Center O
for O
Epidemiological O
Studies O
Depression O
Scale O
( O
CES-D O
) O
31 O
38 O
. O

The O
primary O
outcome O
variable O
was O
the B-Prim
mean I-Prim
change I-Prim
in I-Prim
modified I-Prim
extrinsic I-Prim
tooth I-Prim
stain I-Prim
index I-Prim
( I-Prim
all I-Prim
sites I-Prim
) I-Prim
from I-Prim
baseline I-Prim
to I-Prim
week I-Prim
6 I-Prim
; O
this O
study O
duration O
was O
consistent O
with O
other O
tooth O
whitening O
studies O
in O
the O
literature O
3 O
10 O
11 O
12 O
13 O
and O
was O
also O
consistent O
with O
the O
FDA O
´ O
s O
definition O
of O
the O
primary O
time-point O
for O
smoking O
cessation O
efficacy O
( O
6 O
weeks O
with O
complete O
abstinence O
for O
the O
last O
four O
weeks O
) O
.The O
full O
study O
ran O
for O
12 O
weeks O
according O
to O
the O
design O
of O
traditional O
smoking O
cessation O
studies O
. O

Outcome O
measurements O
The O
primary O
endpoint O
shall O
be O
the B-Prim
change I-Prim
in I-Prim
the I-Prim
number I-Prim
of I-Prim
colorectal I-Prim
ACF I-Prim
after I-Prim
1-months’s I-Prim
intervention I-Prim
. O

Primary O
outcome O
measure O
Patient B-Prim
satisfaction I-Prim
As O
a O
surrogate O
of O
service O
quality O
, O
patient O
satisfaction O
will O
be O
assessed O
at O
baseline O
and O
at O
the O
end O
of O
12 O
months O
using O
the O
Short-Form O
Patient O
Satisfaction O
Questionnaire O
( O
PSQ-18 O
) O
14 O
. O

Discussion O
We O
have O
described O
the O
development O
of O
an O
outcome O
measure O
for O
quantifying O
patients' O
experiences O
of O
treatment O
for O
MS O
relapses O
, O
to O
be O
used O
as O
the O
primary O
outcome O
measure O
in O
a O
randomised O
controlled O
trial O
of O
service O
delivery O
20 O
. O

The O
primary O
outcome O
will O
be O
disability B-Prim
as I-Prim
measured I-Prim
by I-Prim
Roland-Morris I-Prim
Disability I-Prim
Questionnaire I-Prim
. O

This O
was O
the O
primary O
outcome O
measure O
. O

Primary O
end O
point O
" O
Optimized O
ventilation O
" O
when O
compared O
to O
" O
standard O
ventilation O
" O
was O
associated O
with O
a O
higher O
rate O
of O
pH O
normalization O
at O
two O
hours O
( O
51 O
% O
vs O
. O

Moreover O
, O
all O
statisticians O
and O
experts O
that O
were O
consulted O
about O
the O
primary O
outcome O
for O
this O
project O
advised O
us O
to O
move O
forward O
with O
the O
nonweighted O
score O
, O
as O
they O
agreed O
that O
weighted O
endpoints O
should O
be O
avoided O
when O
there O
is O
no O
clear O
evidence O
available O
to O
assign O
specific O
weights O
. O

The O
primary O
outcome O
will O
be O
sunbathing B-Prim
at I-Prim
1- I-Prim
, I-Prim
and I-Prim
12-months I-Prim
follow-up I-Prim
and O
a O
questionnaire-only O
control O
group O
will O
be O
employed O
for O
comparison O
. O

For O
the O
IMPALA O
study O
, O
an O
innovative O
nurse-led O
implementation O
strategy O
was O
developed O
, O
comprising O
key O
elements O
of O
risk O
assessment O
, O
risk O
communication O
, O
a O
decision O
aid O
, O
and O
adapted O
motivational O
interviewing O
. O

The O
primary O
endpoint O
of O
the O
study O
was O
the B-Prim
duration I-Prim
of I-Prim
the I-Prim
weaning I-Prim
process I-Prim
. O

The O
primary O
outcomes O
were O
day-28 B-Prim
failure I-Prim
rates I-Prim
( I-Prim
uncorrected I-Prim
and I-Prim
PCR I-Prim
corrected I-Prim
) I-Prim
. O

Ongoing O
RCTs O
using O
decline O
in O
GFR O
as O
the O
primary O
outcome O
measure O
include O
a O
European O
pediatric O
study O
and O
comparing O
ACEi O
vs. O
placebo O
18 O
, O
an O
Italian O
study O
comparing O
ACEi O
and O
prednisone O
to O
ACEi O
alone O
19 O
, O
and O
another O
Italian O
study O
examining O
intravenous O
and O
oral O
corticosteroids O
with O
and O
without O
azathioprine O
20 O
. O

The O
χ O
2 O
difference O
test O
indicated O
non O
– O
invariance O
for O
the O
first O
measure O
( O
p O
< O
.0001 O
) O
, O
and O
invariance O
for O
the O
second O
measure O
( O
p O
= O
.0889 O
) O
( O
Table O
6 O
) O
. O

Study O
researchers O
, O
screeners O
, O
research O
assistants O
and O
therapists O
are O
masked O
to O
treatment O
allocation O
during O
the O
screening O
period O
and O
the O
first O
assessment O
. O

The O
primary O
efficacy O
endpoint O
was O
PCR-adjusted B-Prim
42-day I-Prim
cure I-Prim
rates I-Prim
after I-Prim
starting I-Prim
treatment I-Prim
. O

Results O
Table O
3 O
presents O
the O
baseline O
, O
3-month O
follow-up O
, O
and O
6-month O
follow-up O
data O
for O
each O
of O
the O
primary O
study O
outcomes O
. O

In O
this O
trial O
the O
primary O
outcome O
measurement O
and O
most O
of O
the O
secondary O
outcome O
measurements O
will O
be O
scored O
by O
the O
patients O
. O

The O
two O
primary O
efficacy O
outcomes O
, O
FVC B-Prim
and O
mMRC B-Prim
, O
are O
combined O
in O
a O
responder O
analysis O
. O

We O
wished O
to O
reflect O
the O
population O
that O
present O
to O
primary O
care O
for O
assessment O
and O
treatment O
and O
who O
in O
many O
cases O
will O
not O
have O
these O
investigative O
procedures O
performed O
. O

However O
, O
the O
aforementioned O
studies O
used O
development O
of O
" O
clinical O
vasospasm O
" O
as O
primary O
endpoint O
whereas O
in O
the O
E O
ARLYDRAIN O
study O
the O
primary O
endpoint O
is O
degree O
of O
disability O
after O
6 O
months O
assessed O
in O
a O
prospective O
blinded O
manner O
using O
the O
mRS-score O
. O

The O
primary O
outcomes O
were O
comparison B-Prim
of I-Prim
the I-Prim
change I-Prim
from I-Prim
baseline I-Prim
to I-Prim
end I-Prim
of I-Prim
12 I-Prim
weeks I-Prim
between I-Prim
simvastatin I-Prim
and I-Prim
fenofibrate I-Prim
. O

The O
primary O
outcome O
measure O
of O
the O
study O
is O
cognitive B-Prim
decline I-Prim
as I-Prim
measured I-Prim
by I-Prim
the I-Prim
change I-Prim
from I-Prim
baseline I-Prim
in I-Prim
the I-Prim
total I-Prim
score I-Prim
on I-Prim
the I-Prim
Alzheimer's I-Prim
disease I-Prim
Assessment I-Prim
Scale-Cognitive I-Prim
section I-Prim
. O

The O
alternative O
hypothesis O
establishes O
a O
relationship O
between O
such O
consumption O
and O
the O
incidence O
of O
the O
primary O
variable O
. O

The O
extended O
AUDIT-C O
is O
used O
to O
derive O
the O
primary O
outcome O
measure O
for O
the O
study O
. O

The O
primary O
outcome O
measure O
is O
apathy B-Prim
after I-Prim
12 I-Prim
months I-Prim
using I-Prim
the I-Prim
German I-Prim
version I-Prim
of I-Prim
the I-Prim
Apathy I-Prim
Evaluation I-Prim
Scale I-Prim
- I-Prim
AES I-Prim
16 O
17 O
. O

Therefore O
, O
a O
minimum O
total O
of O
152 O
participants O
are O
required O
in O
this O
cross-over O
study O
to O
achieve O
the O
desired O
level O
of O
probability O
in O
detecting O
a O
statistically O
significant O
difference O
across O
the O
two O
primary O
outcome O
measures O
. O

Results O
of O
the O
effect O
of O
melatonin O
on O
primary O
and O
secondary O
sleep O
measurements O
are O
shown O
in O
Table O
2 O
. O

Outcome O
variables O
Our O
four O
main O
outcome O
variables O
were O
force B-Prim
platform I-Prim
variables I-Prim
PVF I-Prim
and O
impulse B-Prim
, O
the B-Prim
validated I-Prim
HCPI I-Prim
and O
the B-Prim
use I-Prim
of I-Prim
rescue I-Prim
NSAIDs I-Prim
. O

Outcome O
measures O
Primary O
outcome O
At O
present O
, O
the O
goal O
of O
asthma O
care O
is O
to O
achieve O
and O
maintain O
control O
of O
clinical O
manifestation O
of O
the O
disease O
27 O
28 O
. O

alpha O
= O
0.0095 O
instead O
of O
alpha O
= O
0.01 O
) O
Primary O
outcomes O
Assessment B-Prim
of I-Prim
group I-Prim
differences I-Prim
at I-Prim
6 I-Prim
months I-Prim
for I-Prim
: I-Prim
• I-Prim
Harris I-Prim
Hip I-Prim
Score I-Prim
( I-Prim
HHS I-Prim
) I-Prim
18 I-Prim
: O
this O
score O
will O
be O
used O
as O
a O
self-administered O
questionnaire O
in O
accordance O
with O
the O
developers' O
instructions O
. O

Salivary O
cotinine O
validation O
of O
smoking O
abstinence O
The O
primary O
endpoint O
of O
this O
study O
is O
biochemically B-Prim
verified I-Prim
7-day I-Prim
point I-Prim
prevalence I-Prim
smoking I-Prim
abstinence I-Prim
defined I-Prim
as I-Prim
no I-Prim
cigarettes I-Prim
( I-Prim
not I-Prim
even I-Prim
a I-Prim
puff I-Prim
) I-Prim
in I-Prim
the I-Prim
previous I-Prim
7 I-Prim
days I-Prim
at I-Prim
Week I-Prim
26 I-Prim
, I-Prim
validated I-Prim
using I-Prim
salivary I-Prim
cotinine I-Prim
collected I-Prim
at I-Prim
Week I-Prim
26. I-Prim

Only O
first O
consultations O
within O
the O
same O
episode O
will O
be O
evaluated O
for O
the O
primary O
outcome O
, O
using O
a O
10 O
day O
time O
window O
. O

Study O
results O
will O
be O
obtained O
for O
the O
main O
variable O
MNA B-Prim
test I-Prim
, O
a O
validated O
screening O
test O
with O
a O
sensitivity O
of O
80 O
% O
and O
a O
specificity O
of O
90 O
% O
14 O
, O
and O
also O
using O
other O
outcomes O
measures O
like O
anthropometric O
measurements O
( O
estimated O
according O
to O
standard O
recommendations O
) O
, O
a O
validated O
food O
frequency O
questionnaire O
, O
and O
biochemical O
markers O
. O

Although O
a O
strict O
Bonferroni O
adjustment O
for O
multiple O
testing O
would O
suggest O
use O
of O
somewhat O
more O
conservative O
significance O
levels O
( O
1 O
% O
for O
primary O
outcomes O
) O
, O
this O
adjustment O
is O
too O
conservative O
when O
outcomes O
are O
positively O
correlated O
, O
as O
they O
will O
be O
in O
this O
trial O
. O

The O
most O
efficacious O
combination O
of O
total O
daily O
dose O
and O
dosing O
interval O
for O
the O
primary O
endpoint O
was O
HU O
300 O
mg O
twice O
daily O
( O
P O
= O
0.017 O
) O
. O

For O
a O
primary O
outcome O
of O
CHD B-Prim
events I-Prim
( I-Prim
CHD I-Prim
death I-Prim
plus I-Prim
nonfatal I-Prim
MI I-Prim
) I-Prim
, O
it O
is O
projected O
that O
approximately O
500 O
CHD O
events O
will O
have O
occurred O
when O
5 O
years O
median O
follow-up O
has O
elapsed O
( O
during O
the O
first O
quarter O
of O
2005 O
) O
; O
by O
this O
time O
the O
trial O
will O
have O
80 O
% O
power O
to O
detect O
an O
observed O
22 O
% O
reduction O
in O
CHD O
events O
( O
based O
on O
the O
intention-to-treat O
method O
of O
analysis O
) O
. O

This O
primary O
endpoint O
is O
assessed O
using O
a B-Prim
validated I-Prim
8-item I-Prim
multiple I-Prim
choice I-Prim
type I-Prim
questionnaire I-Prim
on I-Prim
cosmesis I-Prim
and I-Prim
body I-Prim
image I-Prim
. O

This O
decision O
was O
made O
because O
the O
primary O
outcome O
of O
the O
trial O
is O
a B-Prim
dichotomous I-Prim
measure I-Prim
( I-Prim
occurrence I-Prim
of I-Prim
low I-Prim
back I-Prim
pain I-Prim
) I-Prim
and O
we O
wanted O
these O
analyses O
to O
be O
parallel O
. O

Outcome O
measurements O
Primary O
outcome O
measure O
Exacerbations B-Prim
Frequency O
, O
nature O
and O
severity O
of O
exacerbations O
of O
COPD O
will O
be O
evaluated O
in O
the O
first O
, O
the O
third O
and O
the O
sixth O
month O
during O
the O
follow-up O
period O
. O

End O
points O
The O
primary O
end O
point O
was O
the B-Prim
recovery I-Prim
rate I-Prim
, I-Prim
defined I-Prim
as I-Prim
the I-Prim
percentage I-Prim
of I-Prim
patients I-Prim
who I-Prim
had I-Prim
an I-Prim
adequate I-Prim
clinical I-Prim
and I-Prim
parasitological I-Prim
response I-Prim
( I-Prim
ACPR I-Prim
) I-Prim
after I-Prim
follow-up I-Prim
for I-Prim
28 I-Prim
days I-Prim
. O

The O
primary O
outcome O
will O
be O
a B-Prim
participant I-Prim
rating I-Prim
of I-Prim
global I-Prim
improvement I-Prim
, O
from O
which O
measures O
of O
success O
and O
recurrence O
will O
be O
derived O
. O

Endpoints O
The O
primary O
outcome O
criterion O
used O
is O
the B-Prim
number I-Prim
of I-Prim
days I-Prim
spent I-Prim
outside I-Prim
the I-Prim
hospital I-Prim
in I-Prim
the I-Prim
first I-Prim
year I-Prim
following I-Prim
the I-Prim
trauma I-Prim
. O

Students O
who O
did O
not O
complete O
the O
protocol O
including O
post-test O
could O
not O
be O
analyzed O
on O
the O
main O
dependent O
variable O
. O

After O
6 O
months O
the O
nonunion O
rates O
can O
be O
calculated O
and O
therefore O
6 O
months O
is O
the O
first O
possible O
endpoint O
to O
determine O
the O
success O
rate O
of O
the O
surgery O
. O

Data O
analyses O
Difference O
between O
the O
groups O
in O
the O
primary O
outcome O
will O
be O
analysed O
based O
on O
the O
basis O
of O
the O
" O
intention-to-treat O
" O
principle O
. O

Should O
baseline O
data O
differ O
between O
groups O
, O
regression O
will O
be O
used O
to O
check O
that O
the O
primary O
outcomes O
are O
not O
affected O
by O
this O
chance O
finding O
. O

Three O
methods O
of O
patient O
accrual O
were O
used O
to O
ensure O
consecutive O
patient O
accrual O
for O
primary O
outcomes O
– O
regular O
( O
weekly O
) O
phone O
calls O
to O
surgeons' O
offices O
, O
review O
of O
operating O
room O
booking O
logs O
, O
and O
hospital O
health O
records O
queries O
. O

The O
primary O
variable O
will O
be O
the B-Prim
incidence I-Prim
of I-Prim
spontaneous I-Prim
falls I-Prim
. O

The O
main O
outcomes O
are O
the B-Prim
number I-Prim
of I-Prim
days I-Prim
from I-Prim
the I-Prim
initial I-Prim
visit I-Prim
to I-Prim
return I-Prim
to I-Prim
regular I-Prim
work I-Prim
activities I-Prim
, O
and O
the B-Prim
total I-Prim
number I-Prim
of I-Prim
sick I-Prim
leave I-Prim
days I-Prim
during I-Prim
12 I-Prim
and I-Prim
24 I-Prim
months I-Prim
of I-Prim
follow-up I-Prim
. O

Primary O
and O
secondary O
outcomes O
The O
primary O
study O
endpoint O
of O
the O
EXCITE O
trial O
is O
the B-Prim
change I-Prim
in I-Prim
the I-Prim
coronary I-Prim
CBF I-Prim
index I-Prim
after I-Prim
4 I-Prim
weeks I-Prim
of I-Prim
therapy I-Prim
among I-Prim
the I-Prim
three I-Prim
treatment I-Prim
groups I-Prim
( O
Table O
1 O
) O
. O

The O
only O
variables O
assessed O
with O
the O
PP O
analysis O
set O
were O
the O
primary O
efficacy O
endpoint O
and O
TOTPAR O
. O

Success O
The O
primary O
outcome O
( O
' B-Prim
success I-Prim
' I-Prim
) O
, O
was O
detection B-Prim
of I-Prim
bilateral I-Prim
aerated I-Prim
middle I-Prim
ears I-Prim
( I-Prim
confirmed I-Prim
with I-Prim
tympanometry I-Prim
) I-Prim
at I-Prim
two I-Prim
consecutive I-Prim
monthly I-Prim
visits I-Prim
. O

Analysis O
Statistical O
analysis O
of O
clinical O
data O
We O
will O
analyse O
our O
primary O
outcome O
of O
severity B-Prim
of I-Prim
depression I-Prim
on O
the O
PHQ-9 O
at O
four O
months O
using O
between O
groups O
analysis O
of O
covariance O
on O
individual O
baseline O
depression O
score O
. O

Results O
Phase O
2 O
recruitment O
A O
total O
of O
58 O
eligible O
patients O
were O
recruited O
to O
the O
trial O
( O
46 O
% O
of O
those O
initially O
planned O
) O
and O
42 O
( O
72 O
% O
) O
provided O
data O
on O
the O
primary O
outcome O
at O
3 O
months O
. O

Figure O
1 O
Consort O
flowchart O
for O
primary O
and O
secondary O
outcome O
measures O
Consort O
flowchart O
for O
primary O
and O
secondary O
outcome O
measures O
. O

Primary O
outcome O
measures O
The B-Prim
Insomnia I-Prim
Severity I-Prim
Index I-Prim
( I-Prim
ISI I-Prim
) I-Prim
32 I-Prim
is O
a O
much O
used O
, O
7-item O
patient-reported O
outcome O
measure O
assessing O
the O
severity O
of O
initial O
, O
middle O
and O
late O
insomnia O
; O
sleep O
satisfaction O
; O
interference O
of O
insomnia O
with O
daytime O
functioning O
; O
noticeability O
of O
sleep O
problems O
by O
others O
; O
and O
distress O
about O
sleep O
difficulties O
. O

What O
should O
be O
the O
primary O
efficacy O
outcome O
? O

The O
trial O
will O
measure O
effect O
of O
injection O
on O
the O
primary O
outcome O
of O
pain B-Prim
, O
and O
secondary O
outcomes O
of O
function B-Sec
and O
quality B-Sec
of I-Sec
life I-Sec
. O

The O
primary O
outcomes O
are O
medial B-Prim
knee I-Prim
load I-Prim
during I-Prim
walking I-Prim
( I-Prim
the I-Prim
peak I-Prim
external I-Prim
knee I-Prim
adduction I-Prim
moment I-Prim
from I-Prim
3D I-Prim
gait I-Prim
analysis I-Prim
) I-Prim
, O
pain B-Prim
, O
and O
self-reported B-Prim
physical I-Prim
function I-Prim
measured I-Prim
at I-Prim
baseline I-Prim
and I-Prim
immediately I-Prim
following I-Prim
the I-Prim
program I-Prim
. O

The O
primary O
endpoint O
with O
respect O
to O
efficacy O
was O
change B-Prim
in I-Prim
BMD I-Prim
between I-Prim
pre-treatment I-Prim
and I-Prim
16 I-Prim
weeks I-Prim
. O

Anonymised O
and O
encrypted O
data O
pertaining O
to O
the O
computerised O
primary O
and O
secondary O
outcomes O
measures O
are O
sent O
via O
the O
Internet O
to O
a O
secure O
computer O
at O
the O
University O
of O
Nottingham O
. O

Outcomes O
Primary O
outcome O
The O
primary O
outcome O
is O
the B-Prim
proportion I-Prim
of I-Prim
patients I-Prim
attending I-Prim
facilities I-Prim
that I-Prim
report I-Prim
a I-Prim
fever I-Prim
or I-Prim
suspected I-Prim
malaria I-Prim
and I-Prim
receive I-Prim
treatment I-Prim
according I-Prim
to I-Prim
malaria I-Prim
guidelines I-Prim
. O

The O
primary O
endpoint O
of O
this O
study O
is O
the B-Prim
differences I-Prim
in I-Prim
birth I-Prim
weight I-Prim
between I-Prim
the I-Prim
2 I-Prim
groups I-Prim
. O

The O
study O
is O
therefore O
substantially O
overpowered O
to O
address O
the O
primary O
endpoint O
of O
hospitalisation B-Prim
. O

However O
, O
we O
do O
not O
include O
a O
proximal O
DVT O
in O
our O
primary O
outcome O
which O
only O
comes O
to O
attention O
because O
of O
symptoms O
starting O
more O
than O
30 O
days O
after O
enrollment O
because O
this O
might O
introduce O
bias O
. O

Analysis O
Primary O
outcome O
will O
be O
examined O
in O
an O
intention-to-treat O
framework O
as O
pregnancy B-Prim
rate I-Prim
at I-Prim
one I-Prim
year I-Prim
among O
women O
randomized O
to O
immediate O
insertion O
compared O
to O
women O
randomized O
to O
a O
planned O
insertion O
at O
4 O
weeks O
( O
" O
delayed O
insertion O
" O
) O
for O
each O
of O
the O
two O
IUC O
devices O
. O

The O
inclusion O
of O
women O
at O
a O
lower O
risk O
of O
the O
primary O
outcomes O
necessitated O
an O
increase O
in O
the O
sample O
size O
. O

Statistical O
analysis O
plan O
Analysis O
of O
efficacy O
PRP O
vs O
standard-of-care O
( O
parallel O
cannulated O
screws O
) O
The O
primary O
outcome O
measure O
, O
the B-Prim
proportion I-Prim
of I-Prim
patients I-Prim
requiring I-Prim
re-operation I-Prim
for I-Prim
failure I-Prim
of I-Prim
fixation I-Prim
within I-Prim
one I-Prim
year I-Prim
of I-Prim
sustaining I-Prim
the I-Prim
fracture I-Prim
, O
will O
be O
analysed O
using O
a O
chi-squared O
test O
for O
differences O
between O
internal O
fixation O
alone O
( O
control O
) O
and O
internal O
fixation O
and O
PRP O
( O
PRP O
) O
on O
an O
intention-to-treat O
basis O
. O

The O
study O
subjects O
number O
calculation O
assumed O
a O
two-tailed O
alpha O
= O
0.05 O
and O
1-β O
= O
90 O
% O
to O
detect O
a O
10 O
% O
difference O
with O
a O
standard O
error O
of O
0.28 O
in O
the O
comet B-Prim
assay I-Prim
which O
is O
primary O
outcome O
and O
an O
attrition O
rate O
( O
20 O
% O
) O
. O

Power O
calculation O
for O
the O
analysis O
of O
primary O
endpoints O
For O
the O
power O
calculation O
we O
assume O
that O
788 O
patients O
are O
available O
for O
analysis O
with O
24 O
patients O
per O
practice O
( O
i.e. O

Outcomes O
Given O
this O
degree O
of O
complexity O
identifying O
a O
single O
primary O
outcome O
measure O
to O
capture O
the O
impact O
of O
an O
OHC O
intervention O
is O
problematic O
6 O
. O

Our O
second O
primary O
outcome O
measure O
was O
the B-Prim
number I-Prim
of I-Prim
ECT I-Prim
treatments I-Prim
given I-Prim
. O

Primary O
treatment O
outcome O
is O
the B-Prim
patient's I-Prim
global I-Prim
perceived I-Prim
effect I-Prim
concerning I-Prim
recovery I-Prim
from I-Prim
the I-Prim
complaint I-Prim
. O

For O
this O
evaluation O
, O
the O
primary O
outcome O
measure O
, O
i.e. O

Accelerometry O
measures O
PA O
intensity O
over O
a O
period O
of O
six O
days O
, O
with O
the B-Prim
mean I-Prim
over I-Prim
six I-Prim
days I-Prim
used O
as O
the O
primary O
outcome O
measure O
. O

Between-treatment O
differences O
on O
quality O
of O
life O
scales O
( O
FACT-B O
, O
RSCL O
, O
HADS O
, O
and O
MRS O
) O
at O
the O
primary O
endpoint O
( O
3 O
weeks O
after O
completion O
of O
chemotherapy O
) O
were O
analysed O
using O
Analysis O
of O
Covariance O
( O
ANCOVA O
) O
( O
with O
pre-randomisation O
values O
as O
covariate O
) O
. O

The O
primary O
outcome O
was O
self-reported B-Prim
MUVD I-Prim
, O
upon O
ruling O
out O
reproductive O
tract O
infections O
( O
RTIs O
) O
, O
through O
lab O
analysis O
. O

Statistical O
analysis O
Regression O
models O
will O
be O
used O
to O
assess O
the O
effect O
of O
group O
allocation O
on O
the O
primary O
and O
secondary O
outcome O
measures O
after O
adjusting O
for O
baseline O
values O
. O

Table O
2 O
Comparison O
of O
primary O
and O
secondary O
outcomes O
in O
both O
treatment O
groups O
. O

The O
primary O
end O
points O
were O
defined O
as O
10-percentage B-Prim
point I-Prim
difference I-Prim
between I-Prim
arms I-Prim
in I-Prim
increase I-Prim
in I-Prim
the I-Prim
proportion I-Prim
of I-Prim
participants I-Prim
reaching I-Prim
the I-Prim
target I-Prim
level I-Prim
in I-Prim
five I-Prim
global I-Prim
and I-Prim
two I-Prim
patient-group I-Prim
specific I-Prim
clinical I-Prim
parameters I-Prim
at I-Prim
12 I-Prim
months I-Prim
( O
Table O
1 O
) O
. O

This O
trial O
attempts O
to O
enroll O
300 O
patients O
with O
lumbar O
disc O
herniations O
( O
150 O
patients O
in O
both O
treatment O
groups O
, O
including O
8 O
% O
loss O
to O
follow-up O
) O
which O
is O
regarded O
sufficient O
to O
detect O
a O
difference O
of O
20 O
% O
( O
α O
= O
0 O
, O
05 O
and O
a O
power O
of O
90 O
% O
) O
in O
the O
primary O
outcome O
. O

Analyses O
of O
the O
main O
outcomes O
will O
include O
as O
covariates O
any O
patient O
or O
physician O
factors O
that O
differed O
significantly O
between O
study O
arms O
. O

All O
study O
personnel O
directly O
or O
indirectly O
involved O
in O
assessments O
of O
primary O
or O
secondary O
outcomes O
were O
blinded O
to O
treatment O
assignment O
for O
the O
duration O
of O
the O
study O
. O

The O
final O
outcomes O
of O
this O
trial O
will O
assist O
clinicians O
in O
the O
development O
of O
effective O
and O
alternative O
treatment O
methods O
post O
proximal O
femoral O
fracture O
surgery O
which O
may O
ultimately O
result O
in O
a O
reduction O
in O
systemic O
inflammation O
, O
loss O
of O
weight O
and O
lean O
muscle O
and O
improvements O
in O
nutritional O
status O
, O
mobility O
, O
independence O
and O
quality O
of O
life O
among O
elderly O
patients O
. O

In O
order O
to O
allow O
for O
a O
90 O
% O
follow-up O
rate O
for O
the O
primary O
outcome O
measure O
of O
antibiotic B-Prim
prescribing I-Prim
we O
intend O
to O
recruit O
400 O
patients O
( O
20 O
per O
practice O
and O
100 O
in O
each O
cell O
) O
. O

Sample O
Size O
and O
Power O
Calculation O
The O
sample O
size O
calculation O
was O
approximated O
with O
a O
3x3-factorial O
ANOVA-approach O
based O
on O
the O
primary O
outcome O
and O
was O
done O
with O
the O
software O
" O
gpower O
3.1 O
" O
63 O
64 O
. O

Outcome O
measures O
The O
main O
outcome O
measure O
for O
self-perceived O
health O
was O
the B-Prim
generic I-Prim
instrument I-Prim
EuroQol-5D I-Prim
( I-Prim
EQ5D I-Prim
) I-Prim
17 O
18 O
. O

The O
primary O
outcome O
will O
be O
walking B-Prim
, I-Prim
measured I-Prim
by I-Prim
pedometer I-Prim
. O

Endpoints O
The O
primary O
trial O
endpoint O
will O
be O
tumor B-Prim
recurrence I-Prim
diagnosed I-Prim
by I-Prim
enhanced I-Prim
CT I-Prim
scan I-Prim
or I-Prim
serum I-Prim
alpha-fetoprotein I-Prim
level I-Prim
. O

Outcome O
Measures O
The O
two O
primary O
outcomes O
of O
this O
trial O
were O
neonatal B-Prim
mortality I-Prim
and O
omphalitis B-Prim
among I-Prim
live I-Prim
born I-Prim
enrolled I-Prim
infants I-Prim
. O

Primary O
outcome O
The O
primary O
outcome O
of O
the O
trial O
is O
represented O
by O
the B-Prim
clinical I-Prim
effectiveness I-Prim
of I-Prim
the I-Prim
SMATH I-Prim
® I-Prim
system I-Prim
versus I-Prim
sham I-Prim
therapy I-Prim
after I-Prim
4 I-Prim
weeks I-Prim
of I-Prim
treatment I-Prim
in I-Prim
patients I-Prim
with I-Prim
sub-acute I-Prim
and I-Prim
chronic I-Prim
non-specific I-Prim
LBP I-Prim
, I-Prim
determined I-Prim
by I-Prim
evaluating I-Prim
self I-Prim
perceived I-Prim
physical I-Prim
function I-Prim
with I-Prim
RMDQ I-Prim
scores I-Prim
. O

Outcomes O
The O
primary O
study O
outcomes O
will O
be O
changes B-Prim
, I-Prim
from I-Prim
baseline I-Prim
measures I-Prim
, I-Prim
in I-Prim
serum I-Prim
cholesterol I-Prim
and O
systolic B-Prim
blood I-Prim
pressure I-Prim
and O
self-reported B-Prim
current I-Prim
use I-Prim
of I-Prim
aspirin I-Prim
, I-Prim
a I-Prim
statin I-Prim
and I-Prim
at I-Prim
least I-Prim
two I-Prim
blood I-Prim
pressure I-Prim
lowering I-Prim
drugs I-Prim
. O

In O
summary O
, O
multi-level O
regression O
modelling O
was O
used O
to O
evaluate O
differences O
in O
our O
primary O
outcome O
, O
10-year B-Prim
CVD I-Prim
risk I-Prim
, O
between O
groups O
and O
over O
time O
, O
accounting O
for O
clustering O
at O
the O
practice O
level O
. O

The O
difference O
in O
recovery O
rates O
between O
groups O
in O
these O
trials O
ranged O
from O
27 O
% O
to O
55 O
% O
, O
with O
66 O
% O
to O
85 O
% O
of O
mothers O
in O
the O
intervention O
group O
classified O
as O
non-depressed O
at O
the O
primary O
outcome O
time O
period O
. O

Outcome O
measures O
The O
primary O
outcome O
is O
the B-Prim
child's I-Prim
psychosocial I-Prim
problems I-Prim
measured I-Prim
by I-Prim
the I-Prim
SDQ I-Prim
( I-Prim
parent I-Prim
and I-Prim
teacher I-Prim
versions I-Prim
) I-Prim
and I-Prim
the I-Prim
Eyberg I-Prim
Child I-Prim
Behaviour I-Prim
Inventory I-Prim
( I-Prim
ECBI I-Prim
) I-Prim
. O

Analysis O
The O
primary O
outcome O
of O
interest O
was O
a B-Prim
change I-Prim
in I-Prim
the I-Prim
serum I-Prim
ALT I-Prim
activity I-Prim
or O
the B-Prim
INR I-Prim
. O

Type O
of O
economic O
evaluation O
The O
first O
planned O
analysis O
is O
a O
cost O
effectiveness O
analysis O
( O
CEA O
) O
with O
increase B-Prim
in I-Prim
survival I-Prim
without I-Prim
severe I-Prim
disability I-Prim
at I-Prim
six I-Prim
months I-Prim
( I-Prim
the I-Prim
primary I-Prim
outcome I-Prim
in I-Prim
the I-Prim
CESAR I-Prim
trial I-Prim
) I-Prim
as O
the O
main O
outcome O
measure O
. O

Measurement O
Primary O
outcome O
for O
intervention O
trial O
The O
primary O
outcome O
for O
the O
intervention O
is O
the B-Prim
percentage I-Prim
of I-Prim
days I-Prim
on I-Prim
which I-Prim
the I-Prim
prescribed I-Prim
dose I-Prim
of I-Prim
main I-Prim
hypoglycaemic I-Prim
medication I-Prim
is I-Prim
taken I-Prim
as I-Prim
prescribed I-Prim
, O
measured B-Prim
with I-Prim
the I-Prim
TrackCap I-Prim
electronic I-Prim
medication I-Prim
monitor I-Prim
over I-Prim
a I-Prim
12-week I-Prim
period I-Prim
from I-Prim
eight I-Prim
to I-Prim
twenty I-Prim
weeks I-Prim
. O

Pre-specified O
primary O
outcomes O
included O
reduction B-Prim
in I-Prim
systolic I-Prim
blood I-Prim
pressure I-Prim
, O
total B-Prim
cholesterol I-Prim
and O
estimated B-Prim
10-year I-Prim
CVD I-Prim
risk I-Prim
. O

Data O
collection O
and O
outcome O
Data O
were O
collected O
both O
on O
cluster O
level O
as O
well O
as O
on O
individual O
level O
on O
three O
main O
domains O
; O
the O
intervention O
process O
( O
cluster O
level O
) O
, O
perinatal O
healthcare O
process O
indicators O
( O
cluster O
and O
individual O
level O
) O
, O
and O
the O
primary O
outcome O
of O
the O
intervention O
, O
being O
neonatal B-Prim
mortality I-Prim
( I-Prim
individual I-Prim
level I-Prim
) I-Prim
( O
Table O
1 O
) O
. O

Primary O
endpoint O
The O
primary O
endpoint O
is O
a B-Prim
composite I-Prim
of I-Prim
mortality I-Prim
or I-Prim
infections I-Prim
( O
i.e. O

Dexa-scan O
During O
the O
baseline O
and O
final O
assessment O
, O
a O
Dual O
Energy O
X-ray O
Absorptiometry O
( O
DEXA O
) O
scan O
will O
be O
used O
to O
make O
scans O
of O
the O
pelvis O
. O

During O
short-term O
assessment O
the O
following O
primary O
outcome O
measurements O
were O
recorded O
: O
1. O

C O
. O
The O
composite O
primary O
end O
point O
of O
death B-Prim
from I-Prim
any I-Prim
cause I-Prim
, I-Prim
recurrent I-Prim
infarction I-Prim
and I-Prim
unstable I-Prim
angina I-Prim
within I-Prim
one I-Prim
year I-Prim
( I-Prim
per I-Prim
protocol I-Prim
and I-Prim
adjusted I-Prim
for I-Prim
2 I-Prim
days I-Prim
PCI I-Prim
delay I-Prim
) I-Prim
. O

The O
primary O
outcomes O
of O
the O
interventions O
in O
the O
Well O
London O
project O
are O
: O
- B-Prim
For I-Prim
healthy I-Prim
eating I-Prim
a I-Prim
50 I-Prim
% I-Prim
increase I-Prim
in I-Prim
the I-Prim
proportion I-Prim
of I-Prim
adults I-Prim
( I-Prim
base I-Prim
estimate I-Prim
27 I-Prim
% I-Prim
) I-Prim
and O
a B-Prim
30 I-Prim
% I-Prim
increase I-Prim
in I-Prim
the I-Prim
proportion I-Prim
of I-Prim
children I-Prim
( I-Prim
base I-Prim
estimate I-Prim
47 I-Prim
% I-Prim
) I-Prim
who I-Prim
eat I-Prim
five I-Prim
or I-Prim
more I-Prim
pieces I-Prim
of I-Prim
fruit I-Prim
and I-Prim
vegetables I-Prim
a I-Prim
day I-Prim
. O

The O
primary O
outcome O
assessed O
at O
12 O
months O
is O
change B-Prim
in I-Prim
electrophysiological I-Prim
indices I-Prim
of I-Prim
peripheral I-Prim
and I-Prim
central I-Prim
neurosensory I-Prim
responses I-Prim
required I-Prim
for I-Prim
mobility I-Prim
and I-Prim
sensory I-Prim
function I-Prim
. O

Outcome O
Measures O
The O
goal O
of O
rehabilitation O
is O
to O
increase O
function O
and O
for O
this O
reason O
, O
we O
selected O
the B-Prim
shortened I-Prim
version I-Prim
of I-Prim
the I-Prim
Chedoke I-Prim
Arm I-Prim
& I-Prim
Hand I-Prim
Activity I-Prim
Inventory I-Prim
( I-Prim
CAHAI-7 I-Prim
) I-Prim
as O
the O
primary O
outcome O
measure O
. O

Sample O
size O
calculation O
Sample O
size O
calculations O
are O
based O
on O
the O
expected O
effect O
of O
the O
intervention O
on O
the O
primary O
outcome O
which O
is O
the B-Prim
adherence I-Prim
. O

However O
, O
as O
the O
number O
of O
patients O
injecting O
opioids O
at O
recruitment O
was O
low O
, O
the O
primary O
outcome O
was O
changed O
as O
‘the B-Prim
proportion I-Prim
of I-Prim
patients I-Prim
abstinent I-Prim
from I-Prim
of I-Prim
street I-Prim
opioids I-Prim
after I-Prim
1 I-Prim
year’ I-Prim
, O
and O
the O
dimension O
of O
the O
study O
was O
re-computed O
. O

Primary O
outcome O
measure O
The B-Prim
severity I-Prim
of I-Prim
anxiety I-Prim
symptoms I-Prim
is O
measured O
with O
the O
Beck O
Anxiety O
Inventory O
( O
BAI O
) O
60 O
. O

Freeman O
and O
colleagues O
recently O
conducted O
two O
clinical O
trials O
41 O
42 O
of O
omega-3 O
fatty O
acid O
supplementation O
and O
perinatal O
depression O
, O
using O
the O
EPDS O
as O
their O
primary O
measure O
of O
depressive O
symptomatology O
and O
reported O
a O
51 O
% O
and O
41 O
% O
reduction O
in O
EPDS O
score O
over O
an O
8 O
week O
study O
period O
. O

The O
prevalence O
of O
hyperglycaemia O
was O
based O
on O
initial O
PICU O
glucose O
measurement O
, O
highest O
value O
within O
24 O
hours O
, O
and O
highest O
value O
measured O
during O
PICU O
stay O
up O
to O
10 O
days O
after O
the O
first O
measurement O
. O

Sample O
size O
estimation O
The O
primary O
outcome O
is O
re-consultation B-Prim
for I-Prim
the I-Prim
same I-Prim
illness I-Prim
episode I-Prim
. O

Using O
self-selected B-Prim
gait I-Prim
speed I-Prim
as O
the O
primary O
outcome O
, O
this O
sample O
size O
has O
been O
estimated O
based O
on O
a O
range O
of O
change O
scores O
and O
standard O
deviation O
values O
reported O
in O
the O
literature O
. O

Outcome O
Measures O
The O
primary O
outcome O
measure O
will O
be O
time B-Prim
to I-Prim
the I-Prim
first I-Prim
episode I-Prim
of I-Prim
CRB I-Prim
. O

For O
the O
primary O
outcome O
only O
, O
the O
primary O
and O
secondary O
analyses O
will O
be O
conducted O
( O
i O
) O
for O
all O
participants O
completing O
the O
7-DAY O
PAR O
and O
( O
ii O
) O
with O
the O
addition O
of O
multiply O
imputed O
values O
of O
the O
primary O
outcome O
for O
those O
who O
did O
not O
complete O
the O
7-DAY O
PAR O
but O
who O
did O
complete O
either O
the O
Baecke O
or O
GPPAQ O
instruments O
at O
12-month O
follow-up O
. O

The O
intended O
primary O
outcome O
analysis O
, O
time B-Prim
to I-Prim
catheter I-Prim
association I-Prim
blood I-Prim
stream I-Prim
infection I-Prim
, O
definite O
or O
probable O
is O
shown O
in O
Figure O
1 O
. O

The O
primary O
end O
point O
was O
recurrence B-Prim
and O
the O
secondary O
end O
points O
were O
time B-Sec
off I-Sec
from I-Sec
work I-Sec
, O
postoperative B-Sec
pain I-Sec
, O
scrotal B-Sec
swelling I-Sec
and O
wound B-Sec
infections I-Sec
. O

The O
main O
outcomes O
will O
be O
sleep B-Prim
quality I-Prim
( I-Prim
self-report I-Prim
and I-Prim
objective I-Prim
measurement I-Prim
) I-Prim
, O
and O
self-reported B-Prim
functional I-Prim
disability I-Prim
, O
pain B-Prim
, O
quality B-Prim
of I-Prim
life I-Prim
, O
fear B-Prim
avoidance I-Prim
, O
anxiety B-Prim
and O
depression B-Prim
, O
physical B-Prim
activity I-Prim
, O
and O
patient B-Prim
satisfaction I-Prim
. O

In O
addition O
to O
practice O
level O
, O
patient O
level O
data O
will O
also O
be O
collected O
, O
and O
so O
the O
analysis O
is O
divided O
into O
practice O
level O
and O
patient O
level O
with O
the O
patient B-Prim
level I-Prim
analysis I-Prim
as O
the O
primary O
outcome O
. O

The O
main O
outcomes O
to O
assess O
the O
effectiveness O
would O
be O
point B-Prim
abstinence I-Prim
at I-Prim
4 I-Prim
weeks I-Prim
and O
continuous B-Prim
abstinence I-Prim
up I-Prim
to I-Prim
6 I-Prim
months I-Prim
. O

To O
explore O
any O
longer O
term O
effects O
, O
a O
repeated O
measures O
mixed O
model O
analysis O
of O
the O
primary O
and O
secondary O
outcomes O
will O
be O
undertaken O
, O
comparing O
groups O
across O
the O
6 O
and O
12 O
month O
time O
points O
. O

Primary O
outcome O
measure O
Body B-Prim
weight I-Prim
and O
body B-Prim
composition I-Prim
Patients O
will O
be O
weighed O
to O
the O
nearest O
0.05 O
kg O
and O
percentage O
body O
fat O
estimated O
using O
bio-electrical O
impedance O
( O
Bodystat O
1500 O
, O
Bodystat O
Ltd. O
, O
UK O
) O
. O

The O
primary O
outcome O
of O
the O
WEAN O
study O
is O
to B-Prim
evaluate I-Prim
compliance I-Prim
with I-Prim
the I-Prim
proposed I-Prim
weaning I-Prim
and I-Prim
sedation I-Prim
protocols I-Prim
. O

The O
primary O
outcome O
was O
self-rated B-Prim
overall I-Prim
effect I-Prim
of I-Prim
treatment I-Prim
, I-Prim
measured I-Prim
once I-Prim
; I-Prim
on I-Prim
the I-Prim
day I-Prim
treatment I-Prim
was I-Prim
completed I-Prim
. O

Data O
Collection O
The O
primary O
outcome O
was O
the B-Prim
disclosure I-Prim
rate I-Prim
of I-Prim
abuse I-Prim
by I-Prim
women I-Prim
who I-Prim
were I-Prim
identified I-Prim
by I-Prim
the I-Prim
VAWS I-Prim
tool I-Prim
during I-Prim
the I-Prim
three I-Prim
screening I-Prim
sessions I-Prim
compared I-Prim
to I-Prim
those I-Prim
in I-Prim
the I-Prim
interview I-Prim
group I-Prim
. O

These O
analyses O
will O
be O
repeated O
but O
using O
the O
occurrence O
of O
our O
primary O
outcome O
within O
14 O
days O
of O
randomisation O
( O
instead O
of O
30 O
days O
) O
. O

Post-intervention O
assessments O
are O
undertaken O
within O
two O
weeks O
of O
program O
completion O
and O
the O
final O
assessment O
is O
completed O
26 O
weeks O
after O
the O
baseline O
assessment O
( O
see O
Figure O
1 O
) O
. O

The O
primary O
effectiveness O
outcome O
will O
be O
quality B-Prim
adjusted I-Prim
life I-Prim
years I-Prim
( I-Prim
QALYs I-Prim
) I-Prim
measured I-Prim
over I-Prim
a I-Prim
time I-Prim
horizon I-Prim
of I-Prim
1 I-Prim
year I-Prim
based I-Prim
on I-Prim
EQ-5D I-Prim
scores I-Prim
collected I-Prim
during I-Prim
the I-Prim
trial I-Prim
; O
secondary O
analysis O
will O
examine O
the B-Sec
IWQoL I-Sec
to O
inform O
non O
preference-based O
cost-effectiveness O
analyses O
. O

Primary O
outcome O
measurements O
Physical B-Prim
activity I-Prim
The O
volume O
( O
frequency O
, O
intensity O
, O
duration O
) O
of O
leisure O
time O
and O
way O
to O
work O
physical O
activity O
are O
assessed O
by O
a O
self-administered O
questionnaire O
based O
on O
International O
Physical O
Activity O
Questionnaire O
( O
IPAQ O
) O
. O

Primary O
outcomes O
measures O
will O
be O
: O
1 B-Prim
) I-Prim
the I-Prim
percentage I-Prim
of I-Prim
participants I-Prim
who I-Prim
drink I-Prim
within I-Prim
the I-Prim
normative I-Prim
limits I-Prim
of I-Prim
the I-Prim
Dutch I-Prim
National I-Prim
Health I-Prim
Council I-Prim
for I-Prim
low-risk I-Prim
drinking I-Prim
, O
2 B-Prim
) I-Prim
reductions I-Prim
in I-Prim
mean I-Prim
weekly I-Prim
alcohol I-Prim
consumption I-Prim
, O
and O
3 B-Prim
) I-Prim
frequency I-Prim
of I-Prim
binge I-Prim
drinking I-Prim
. O

Modulation O
of O
key O
biochemical O
parameters O
of O
fat O
metabolism O
Reduction O
in O
serum O
glucose O
( O
17.0 O
% O
) O
, O
triglycerides O
( O
16.43 O
% O
) O
and O
LDL O
/ O
HDL O
ratio O
( O
12.6 O
% O
) O
was O
observed O
in O
LI85008F O
treated O
group O
compared O
to O
baseline O
( O
Table O
4 O
) O
. O

The O
primary O
end-point O
was O
disease-free B-Prim
survival I-Prim
( I-Prim
DFS I-Prim
) I-Prim
at I-Prim
three I-Prim
years I-Prim
. O

All O
primary O
and O
secondary O
outcomes O
of O
the O
effect O
evaluation O
were O
assessed O
at O
baseline O
, O
and O
at O
5 O
and O
17 O
week O
follow-up O
, O
except O
for O
the O
outcomes O
regarding O
the O
use O
of O
the O
identification O
cane O
. O

The O
primary O
end O
point O
was O
sustained B-Prim
remission I-Prim
, I-Prim
defined I-Prim
as I-Prim
freedom I-Prim
from I-Prim
relapse I-Prim
at I-Prim
the I-Prim
6 I-Prim
months I-Prim
follow-up I-Prim
visit I-Prim
. O

But O
the O
smaller O
than O
planned O
study O
sample O
could O
have O
influenced O
the O
results O
of O
the O
other O
outcomes O
who O
were O
in O
line O
with O
the O
primary O
outcome O
but O
failed O
to O
reach O
statistical O
significance O
. O

Study O
outcomes O
Primary O
outcomes O
Primary O
outcomes O
include O
emergency B-Prim
health I-Prim
service I-Prim
use I-Prim
( I-Prim
ie I-Prim
unplanned I-Prim
readmissions I-Prim
, I-Prim
time I-Prim
to I-Prim
first I-Prim
unplanned I-Prim
readmission I-Prim
, I-Prim
unplanned I-Prim
Emergency I-Prim
Department I-Prim
, I-Prim
General I-Prim
Practitioner I-Prim
and I-Prim
other I-Prim
health I-Prim
service I-Prim
use I-Prim
) I-Prim
, O
and O
functional B-Prim
ability I-Prim
( I-Prim
Instrumental I-Prim
Activities I-Prim
of I-Prim
Daily I-Prim
Living I-Prim
23 I-Prim
, I-Prim
Index I-Prim
of I-Prim
Activities I-Prim
of I-Prim
Daily I-Prim
Living I-Prim
24 I-Prim
, I-Prim
Walking I-Prim
Impairment I-Prim
Questionnaire I-Prim
25 I-Prim
) I-Prim
. O

Statistical O
analysis O
Baseline O
characteristics O
of O
the O
two O
intervention O
groups O
and O
control O
group O
with O
regard O
to O
the O
most O
important O
prognostic O
indicators O
and O
main O
outcome O
measures O
will O
be O
compared O
to O
assess O
the O
adequacy O
of O
the O
randomization O
. O

The O
primary O
endpoint O
of O
the O
study O
was O
the B-Prim
change I-Prim
from I-Prim
baseline I-Prim
to I-Prim
52 I-Prim
weeks I-Prim
of I-Prim
carotid I-Prim
arterial I-Prim
wall I-Prim
volume I-Prim
, I-Prim
reflecting I-Prim
plaque I-Prim
burden I-Prim
, I-Prim
as I-Prim
measured I-Prim
by I-Prim
carotid I-Prim
cardiovascular I-Prim
magnetic I-Prim
resonance I-Prim
. O

Primary O
and O
secondary O
endpoints O
Primary O
endpoint O
Binary B-Prim
functional I-Prim
outcome I-Prim
6 I-Prim
months I-Prim
( I-Prim
± I-Prim
14 I-Prim
days I-Prim
) I-Prim
after I-Prim
randomization I-Prim
( I-Prim
measured I-Prim
by I-Prim
the I-Prim
modified I-Prim
Rankin I-Prim
scale I-Prim
, I-Prim
a I-Prim
seven-point-scale I-Prim
from I-Prim
0 I-Prim
to I-Prim
6 I-Prim
points I-Prim
) I-Prim
. O

Study O
sample O
Sample O
size O
calculation O
in O
a O
cRCT O
was O
based O
on O
the O
expected O
improvement O
in O
the O
main O
outcome O
variables O
12 O
17 O
18 O
20 O
22 O
. O

We O
also O
discuss O
the O
advantages O
and O
disadvantages O
of O
testing O
the O
psychometric O
properties O
of O
the O
primary O
outcome O
measures O
concurrently O
with O
the O
trial O
. O

Analysis O
Primary O
Outcome O
Measures O
• O
Control O
and O
intervention O
arms O
: O
Cumulative B-Prim
incident I-Prim
≥ I-Prim
CIN3 I-Prim
detected I-Prim
up I-Prim
to I-Prim
and I-Prim
including I-Prim
four I-Prim
years I-Prim
in I-Prim
both I-Prim
the I-Prim
control I-Prim
arm I-Prim
and I-Prim
the I-Prim
intervention I-Prim
arm I-Prim
• O
Control O
and O
safety O
check O
arms O
: O
Incident B-Prim
≥ I-Prim
CIN2 I-Prim
detected I-Prim
at I-Prim
two I-Prim
years I-Prim
. O

The O
primary O
endpoint O
was O
the B-Prim
reduction I-Prim
in I-Prim
systolic I-Prim
blood I-Prim
pressure I-Prim
defined I-Prim
as I-Prim
the I-Prim
average I-Prim
of I-Prim
3 I-Prim
office I-Prim
readings I-Prim
with I-Prim
the I-Prim
patient I-Prim
in I-Prim
the I-Prim
sitting I-Prim
position I-Prim
. O

The O
following O
four O
main O
efficacy O
parameters O
were O
used O
: O
Early B-Prim
Treatment I-Prim
Failure I-Prim
( I-Prim
ETF I-Prim
) I-Prim
; O
Late B-Prim
Clinical I-Prim
Failure I-Prim
( I-Prim
LCF I-Prim
) I-Prim
; O
Late B-Prim
Parasitological I-Prim
Failure I-Prim
( I-Prim
LPF I-Prim
) I-Prim
; O
Adequate B-Prim
Clinical I-Prim
and I-Prim
Parasitological I-Prim
Response I-Prim
( I-Prim
ACPR I-Prim
) I-Prim
18 I-Prim
. O

Furthermore O
, O
the O
primary O
and O
secondary O
endpoints O
are O
to O
be O
analyzed O
in O
pre-specified O
subgroups O
, O
which O
are O
defined O
as O
: O
1. O

Primary O
outcomes O
The B-Prim
CORE-OM I-Prim
23 I-Prim
is O
a O
34-item O
scale O
covering O
four O
subscales O
of O
subjective O
well-being O
. O

The O
primary O
endpoint O
is O
the B-Prim
peak I-Prim
transaminase I-Prim
serum I-Prim
level I-Prim
( I-Prim
AST I-Prim
) I-Prim
during I-Prim
the I-Prim
first I-Prim
three I-Prim
days I-Prim
after I-Prim
transplantation I-Prim
as I-Prim
a I-Prim
surrogate I-Prim
readout I-Prim
for I-Prim
parenchymal I-Prim
liver I-Prim
injury I-Prim
. O

The O
two O
primary O
outcome O
measures O
are O
the B-Prim
difference I-Prim
in I-Prim
occurrence I-Prim
of I-Prim
DRPs I-Prim
between I-Prim
intervention I-Prim
and I-Prim
control I-Prim
group I-Prim
and O
adherence B-Prim
with I-Prim
drug I-Prim
use I-Prim
. O

Regarding O
the O
primary O
endpoint O
of O
neovessel O
formation O
at O
weeks O
10 O
and O
14 O
, O
all O
angiograms O
were O
reviewed O
in O
real O
time O
, O
with O
decision O
for O
further O
treatment O
based O
on O
real O
time O
assessments O
. O

: O
not O
significant O
; O
EASI-severity O
> O
= O
4 O
means O
that O
treatment O
is O
needed O
46 O
Adherence O
to O
treatment O
The O
primary O
outcome O
measure O
for O
this O
study O
was O
treatment B-Prim
adherence I-Prim
at I-Prim
and I-Prim
beyond I-Prim
eight I-Prim
sessions I-Prim
. O

The O
primary O
composite O
outcome O
of O
re-operation O
provides O
a O
patient-important O
estimate O
of O
effect O
superior O
to O
previously O
described O
measures O
such O
as O
radiographic O
fracture O
healing O
, O
delayed O
unions O
, O
and O
nonunions O
. O

The O
primary O
outcome O
( O
difference B-Prim
on I-Prim
endothelium-dependent I-Prim
brachial I-Prim
artery I-Prim
FMD I-Prim
at I-Prim
baseline I-Prim
and I-Prim
three I-Prim
months I-Prim
after I-Prim
randomization I-Prim
) O
and O
the O
secondary O
outcome O
( O
hs-CRP B-Sec
, O
glucose B-Sec
, O
blood B-Sec
lipid I-Sec
profile I-Sec
, O
and O
HOMA B-Sec
index I-Sec
) O
will O
be O
analyzed O
using O
repeated O
measures O
ANOVA O
for O
continuous O
variables O
. O

Sample O
size O
calculation O
and O
statistical O
analysis O
The O
primary O
endpoint O
for O
the O
study O
was O
the B-Prim
QTcF I-Prim
interval I-Prim
( I-Prim
QT I-Prim
interval I-Prim
corrected I-Prim
for I-Prim
heart I-Prim
rate I-Prim
using I-Prim
Fridericia's I-Prim
formula I-Prim
, I-Prim
QT I-Prim
/ I-Prim
RR I-Prim
0.33 I-Prim
) I-Prim
. O

The O
primary O
outcome O
was O
morning B-Prim
peak I-Prim
expiratory I-Prim
flow I-Prim
after I-Prim
4 I-Prim
weeks I-Prim
treatment I-Prim
. O

The O
main O
outcome O
measure O
of O
this O
study O
is O
long B-Prim
term I-Prim
adherence I-Prim
to I-Prim
physical I-Prim
activity I-Prim
. O

Self-rating O
measures O
were O
used O
as O
a O
primary O
outcome O
in O
many O
of O
the O
large O
collaborative O
care O
studies O
22 O
42 O
43 O
and O
have O
been O
shown O
to O
provide O
valid O
ratings O
in O
non-psychotic O
depressed O
outpatients O
44 O
. O

The O
primary O
outcomes O
were O
back-related B-Prim
functional I-Prim
status I-Prim
and O
symptom B-Prim
bothersomeness I-Prim
. O

Primary O
end O
point O
will O
be O
the B-Prim
conversion I-Prim
of I-Prim
AF I-Prim
to I-Prim
sinus I-Prim
rhythm I-Prim
confirmed I-Prim
in I-Prim
an I-Prim
electrocardiogram I-Prim
( I-Prim
ECG I-Prim
) I-Prim
during I-Prim
the I-Prim
observation I-Prim
period I-Prim
. O

We O
chose O
GHbA1c B-Prim
as O
the O
primary O
metabolic O
outcome O
measure O
because O
it O
is O
more O
reliable O
than O
the O
fasting O
glucose O
value O
, O
as O
it O
reflects O
the O
glycemic O
control O
during O
a O
8 O
– O
12 O
weeks O
time O
period O
. O

Figure O
3 O
POC O
Component O
: O
Key O
Efficacy O
Endpoints O
( O
A O
) O
Effect O
of O
maraviroc O
on O
ACR20 O
response O
rate O
over O
time O
POC O
Component O
: O
Key O
Efficacy O
Endpoints O
( O
A O
) O
Effect O
of O
maraviroc O
on O
ACR20 O
response O
rate O
over O
time O
. O

Outcome O
measures O
Primary O
outcome O
measure O
The O
primary O
outcome O
measure O
is O
an B-Prim
uneventful I-Prim
decline I-Prim
of I-Prim
serum I-Prim
hCG I-Prim
to I-Prim
an I-Prim
undetectable I-Prim
level I-Prim
( I-Prim
< I-Prim
2 I-Prim
IU I-Prim
/ I-Prim
l I-Prim
) I-Prim
by O
the O
initial O
intervention O
strategy O
, O
ie O
expectant O
management O
or O
a O
single O
dose O
systemic O
MTX O
. O

Primary O
outcome O
measures O
1. O

The O
secondary O
outcome O
measure O
of O
remission B-Sec
of I-Sec
major I-Sec
depressive I-Sec
disorder I-Sec
at I-Sec
each I-Sec
and I-Sec
all I-Sec
of I-Sec
24 I-Sec
, I-Sec
36 I-Sec
and I-Sec
48 I-Sec
weeks I-Sec
will O
be O
analysed O
in O
the O
same O
way O
as O
the O
primary O
outcome O
measure O
. O

The O
latter O
was O
our O
primary O
dependent O
variable O
. O

Data O
handlers O
were O
not O
blinded O
to O
the O
intervention O
status O
of O
responders O
, O
but O
this O
was O
not O
considered O
to O
be O
a O
source O
of O
bias O
as O
response B-Prim
rates I-Prim
were O
the O
primary O
outcome O
. O

Primary O
outcomes O
include O
objectively B-Prim
measured I-Prim
physical I-Prim
activity I-Prim
, O
fruit B-Prim
and I-Prim
vegetable I-Prim
intake I-Prim
, O
medication B-Prim
adherence I-Prim
, O
and O
smoking B-Prim
status I-Prim
. O

Results O
Postprandial O
metabolic O
parameters O
No O
significant O
differences O
were O
observed O
in O
any O
of O
the O
iAUCs O
of O
the O
main O
metabolic O
variables O
( O
glucose O
, O
insulin O
, O
non-sterified O
fatty O
acids O
, O
serum O
triglycerides O
and O
high O
density O
lipoprotein O
cholesterol O
) O
after O
intake O
of O
phenol-rich O
virgin O
olive O
oil O
compared O
with O
olive O
oil O
with O
lower O
content O
of O
these O
compounds O
( O
Table O
1 O
) O
. O

For O
the O
final O
analysis O
, O
the O
three O
hypotheses O
of O
the O
primary O
endpoint O
are O
tested O
at O
a O
nominal O
significance O
level O
of O
α2 O
= O
0.045 O
in O
the O
hierarchical O
manner O
described O
above O
. O

Primary O
outcome O
measures O
will O
be O
: O
1 B-Prim
) I-Prim
physical I-Prim
activity I-Prim
level I-Prim
, I-Prim
which I-Prim
will I-Prim
be I-Prim
measured I-Prim
objectively I-Prim
with I-Prim
an I-Prim
accelerometry-based I-Prim
activity I-Prim
monitor I-Prim
during I-Prim
72 I-Prim
h I-Prim
and I-Prim
subjectively I-Prim
with I-Prim
the I-Prim
Physical I-Prim
Activity I-Prim
Scale I-Prim
for I-Prim
Individuals I-Prim
with I-Prim
Physical I-Prim
Disabilities I-Prim
; O
2 B-Prim
) I-Prim
aerobic I-Prim
fitness I-Prim
, I-Prim
which I-Prim
will I-Prim
be I-Prim
measured I-Prim
with I-Prim
a I-Prim
maximal I-Prim
ramp I-Prim
test I-Prim
on I-Prim
a I-Prim
bicycle I-Prim
or I-Prim
armcrank I-Prim
ergometer I-Prim
and I-Prim
a I-Prim
6-minute I-Prim
walking I-Prim
or I-Prim
wheelchair I-Prim
test I-Prim
; O
3 B-Prim
) I-Prim
neuromuscular I-Prim
fitness I-Prim
, I-Prim
which I-Prim
will I-Prim
be I-Prim
measured I-Prim
with I-Prim
handheld I-Prim
dynamometry I-Prim
; O
and O
4 B-Prim
body I-Prim
composition I-Prim
, I-Prim
which I-Prim
will I-Prim
be I-Prim
determined I-Prim
by I-Prim
measuring I-Prim
body I-Prim
mass I-Prim
, I-Prim
height I-Prim
, I-Prim
waist I-Prim
circumference I-Prim
, I-Prim
fat I-Prim
mass I-Prim
and I-Prim
lipid I-Prim
profile I-Prim
. O

The B-Prim
safety I-Prim
and O
efficacy B-Prim
of I-Prim
this I-Prim
drug I-Prim
are O
analyzed O
as O
primary O
endpoints O
. O

Moreover O
the O
study O
seeks O
to O
identify O
individual O
and O
social O
factors O
that O
influence O
primary O
and O
secondary O
outcomes O
. O

The O
second O
primary O
outcome O
is O
pain B-Prim
from I-Prim
the I-Prim
donor I-Prim
site I-Prim
area I-Prim
. O

We O
used O
these O
findings O
as O
an O
estimate O
of O
the O
primary O
outcome O
for O
the O
power O
calculation O
, O
Women O
and O
clinicians O
did O
not O
consider O
the O
ultrasound O
assessment O
to O
be O
intrusive O
. O

Outcomes O
The O
primary O
outcomes O
were O
body B-Prim
weight I-Prim
( I-Prim
kg I-Prim
) I-Prim
and O
waist B-Prim
circumference I-Prim
( I-Prim
cm I-Prim
) I-Prim
. O

The O
primary O
outcome O
variable O
is O
defined O
as O
the B-Prim
length I-Prim
of I-Prim
time I-Prim
patients I-Prim
remain I-Prim
in I-Prim
the I-Prim
study I-Prim
. O

Primary O
outcome O
measure O
is O
the B-Prim
children’s I-Prim
body I-Prim
composition I-Prim
, I-Prim
operationalized I-Prim
as I-Prim
BMI I-Prim
z-score I-Prim
, O
waist B-Prim
circumference I-Prim
, O
and O
fat B-Prim
mass I-Prim
( I-Prim
biceps I-Prim
and I-Prim
triceps I-Prim
skinfolds I-Prim
) I-Prim
. O

Outcomes O
The O
primary O
outcome O
was O
the B-Prim
proportion I-Prim
of I-Prim
patients I-Prim
in I-Prim
each I-Prim
group I-Prim
with I-Prim
cardiovascular I-Prim
risk I-Prim
≥ I-Prim
10 I-Prim
% I-Prim
over I-Prim
five-years I-Prim
at I-Prim
12 I-Prim
months I-Prim
follow I-Prim
up I-Prim
. O

We O
conclude O
from O
our O
trial O
that O
overall O
, O
gabapentin O
did O
not O
relieve O
pain O
as O
compared O
to O
placebo O
on O
pain B-Prim
visual I-Prim
analogue I-Prim
scores I-Prim
, O
our O
primary O
outcome O
measure O
. O

The O
impact O
of O
the O
intensive O
implementation O
program O
on O
the O
implementation O
process O
and O
on O
the O
primary O
outcomes O
was O
examined O
in O
a O
random O
coefficient O
logistic O
regression O
model O
, O
which O
took O
into O
account O
that O
patients O
were O
grouped O
within O
pharmacy O
clusters O
. O

The O
subjective O
measurement O
of O
the O
primary O
outcome O
in O
our O
study O
( O
patient B-Prim
reported I-Prim
pain I-Prim
) O
was O
recognised O
to O
be O
prone O
to O
bias O
in O
an O
open O
trial O
design O
( O
ie O
, O
when O
people O
would O
know O
which O
intervention O
they O
had O
been O
randomised O
to O
) O
26 O
, O
and O
it O
was O
considered O
impossible O
to O
maintain O
an O
open O
trial O
sufficiently O
long O
for O
any O
placebo O
effect O
to O
have O
dissipated O
, O
and O
as O
such O
the O
inclusion O
of O
a O
placebo O
control O
was O
deemed O
to O
maximise O
scientific O
rigour O
. O

We O
will O
use O
cost-consequences O
analysis O
as O
a O
first O
step O
to O
compare O
any O
incremental O
costs O
of O
the O
intervention O
( O
costs O
accrued O
in O
the O
intervention O
arm O
, O
from O
intervention O
and O
resource O
use O
over O
the O
period O
of O
follow-up O
, O
compared O
to O
costs O
accrued O
in O
the O
control O
arm O
) O
to O
all O
primary O
and O
secondary O
outcomes O
, O
expressed O
in O
their O
natural O
units O
of O
measurement O
. O

Conclusions O
Fluticasone O
/ O
formoterol O
had O
a O
good O
safety O
and O
tolerability O
profile O
and O
showed O
statistically O
superior O
efficacy O
for O
the O
three O
co-primary O
endpoints O
compared O
to O
fluticasone O
, O
formoterol O
, O
and O
placebo O
, O
in O
adolescents O
and O
adults O
with O
mild-to-moderate O
asthma O
. O

Main O
variables O
Smoking B-Prim
cessation I-Prim
at I-Prim
12 I-Prim
months I-Prim
. O

Primary O
and O
secondary O
outcomes O
will O
be O
assessed O
by O
an O
external O
nurse O
who O
will O
be O
blinded O
to O
treatment O
assignment O
after O
12 O
months O
. O

Primary O
Study O
Endpoints O
Whole B-Prim
Body I-Prim
, I-Prim
Hip I-Prim
and I-Prim
Spine I-Prim
Bone I-Prim
Mineral I-Prim
Density I-Prim
, O
and O
Body B-Prim
Composition I-Prim
BMD O
( O
g O
/ O
cm O
2 O
) O
of O
the O
hip O
( O
total O
hip O
) O
and O
lumbar O
spine O
( O
L O
2 O
– O
4 O
) O
regions O
as O
well O
as O
whole O
body O
bone O
mineral O
content O
( O
BMC O
, O
g O
) O
will O
be O
assessed O
by O
dual-energy O
X-ray O
absorptiometry O
( O
DXA O
, O
Hologic O
Discovery O
A O
, O
Waltham O
, O
MA O
) O
. O

Conclusion O
These O
results O
provide O
assurance O
that O
dropout O
was O
not O
related O
to O
primary O
study O
outcomes O
. O

A B-Prim
composite' I-Prim
axial I-Prim
score' I-Prim
including I-Prim
the I-Prim
major I-Prim
clinical I-Prim
and I-Prim
anamnestic I-Prim
items I-Prim
on I-Prim
gait I-Prim
, I-Prim
posture I-Prim
and I-Prim
balance I-Prim
function I-Prim
from I-Prim
UPDRSII I-Prim
( I-Prim
items I-Prim
13-15 I-Prim
) I-Prim
and I-Prim
UPDRS I-Prim
III I-Prim
( I-Prim
items I-Prim
27-31 I-Prim
) I-Prim
constitutes O
the O
primary O
outcome O
measure O
. O

These O
surveys O
included O
measurement O
of O
primary O
outcome O
variables O
as O
described O
above O
( O
ie O
, O
screen B-Prim
time I-Prim
and I-Prim
fruit I-Prim
/ I-Prim
vegetable I-Prim
consumption I-Prim
) O
. O

Planned O
statistical O
analysis O
For O
the O
primary O
outcomes O
, O
we O
will O
use O
intention-to-treat O
analyses O
for O
all O
primary O
outcomes O
. O

The O
per O
protocol O
population O
, O
consisting O
of O
all O
patients O
of O
the O
ITT O
population O
who O
completed O
at O
least O
one O
chemotherapy O
cycle O
, O
have O
at O
least O
2 O
post-baseline O
assessments O
regarding O
the O
primary O
endpoint O
without O
pre-specified O
, O
selected O
major O
protocol O
deviations O
thought O
to O
impact O
on O
efficacy O
analysis O
. O

The O
primary O
outcome O
for O
this O
study O
is O
the B-Prim
proportion I-Prim
of I-Prim
patients I-Prim
who I-Prim
consume I-Prim
alcohol I-Prim
within I-Prim
recommended I-Prim
levels I-Prim
at I-Prim
6 I-Prim
month I-Prim
follow I-Prim
up I-Prim
. O

Power O
analysis O
The O
primary O
endpoint O
is O
the B-Prim
occurrence I-Prim
of I-Prim
delirium I-Prim
during I-Prim
the I-Prim
first I-Prim
eight I-Prim
days I-Prim
after I-Prim
the I-Prim
start I-Prim
of I-Prim
study I-Prim
medication I-Prim
. O

In O
addition O
to O
HIV B-Prim
incidence I-Prim
, O
all B-Prim
deaths I-Prim
and O
severe B-Prim
or I-Prim
life-threatening I-Prim
clinical I-Prim
and I-Prim
laboratory I-Prim
events I-Prim
confirmed I-Prim
on I-Prim
examination I-Prim
or I-Prim
repeat I-Prim
testing I-Prim
will O
be O
primary O
safety O
endpoints O
. O

Analysis O
Main O
outcome O
continuous O
variables O
were O
analyzed O
in O
SPSS O
19 O
using O
a O
linear O
mixed O
effects O
model O
fitted O
with O
full O
information O
maximum O
likelihood O
estimation O
( O
FIML O
) O
49 O
. O

Secondly O
, O
following O
publication O
of O
national O
guidance O
on O
the O
treatment O
of O
schizophrenia O
highlighting O
the O
importance O
of O
arts O
therapies O
in O
treating O
symptoms O
of O
schizophrenia O
19 O
, O
we O
promoted O
total B-Prim
symptom I-Prim
score I-Prim
as O
a O
co-primary O
outcome O
measure O
. O

The O
baseline O
comparison O
will O
be O
made O
between O
the O
main O
variables O
that O
we O
expected O
to O
be O
related O
to O
the O
primary O
outcome O
using O
the O
Chi-Square O
test O
or O
an O
analysis O
of O
variance O
( O
ANOVA O
) O
. O

Assessment O
of O
the O
primary O
outcome O
was O
blind O
to O
group O
allocation O
. O

The O
primary O
outcome O
is O
the B-Prim
last I-Prim
week's I-Prim
total I-Prim
alcohol I-Prim
consumption I-Prim
in I-Prim
units I-Prim
of I-Prim
alcohol I-Prim
. O

The O
effect O
size O
estimate O
of O
2000 B-Prim
steps I-Prim
per I-Prim
day I-Prim
change I-Prim
as O
the O
primary O
outcome O
is O
based O
on O
published O
research O
and O
clinically O
meaningful O
difference O
35 O
. O

Sample O
size O
calculations O
were O
performed O
post O
hoc O
as O
this O
was O
a O
sub-group O
analysis O
of O
a O
clinical O
trial O
with O
diarrhoea B-Prim
as O
the O
primary O
endpoint O
36 O
. O

Our O
primary O
outcomes O
are O
cardiorespiratory B-Prim
capacity I-Prim
, O
abdominal B-Prim
obesity I-Prim
, O
and O
lipid B-Prim
and I-Prim
glycemic I-Prim
control I-Prim
, O
while O
secondary O
outcomes O
include O
self-reported B-Sec
physical I-Sec
activity I-Sec
, O
quality B-Sec
of I-Sec
life I-Sec
and O
psychological B-Sec
distress I-Sec
. O

The O
primary O
outcome O
and O
some O
of O
the O
secondary O
outcomes O
, O
involve O
self-reported O
questionnaires O
being O
completed O
by O
participants O
thus O
precluding O
blinding O
of O
assessment O
. O

Sample O
size O
A O
power O
calculation O
was O
carried O
out O
for O
the O
main O
outcome O
variable O
ankle B-Prim
sprain I-Prim
recurrences I-Prim
. O

Our O
primary O
outcomes O
of O
maternal B-Prim
and I-Prim
perinatal I-Prim
mortality I-Prim
( I-Prim
within I-Prim
medical I-Prim
facilities I-Prim
) I-Prim
in O
a O
country O
like O
Malawi O
are O
influenced O
by O
many O
factors O
other O
than O
our O
intervention O
. O

The O
primary O
endpoint O
was O
analysed O
to O
determine O
whether O
the O
ID O
vaccine O
was O
non-inferior O
to O
IM O
vaccination O
. O

The O
primary O
composite O
outcome O
of O
re-operation B-Prim
provides O
a O
patient-important O
estimate O
of O
effect O
superior O
to O
previously O
described O
measures O
such O
as O
radiographic O
fracture O
healing O
, O
delayed O
unions O
, O
and O
nonunions O
. O

The O
main O
analysis O
will O
investigate O
differences O
in O
the O
primary O
outcome O
measure O
, O
the B-Prim
WOMAC I-Prim
score I-Prim
, O
between O
the O
two O
treatment O
groups O
on O
an O
intention-to-treat O
basis O
at O
12 O
months O
post-operation O
. O

The O
statistical O
power O
in O
the O
two O
trials O
is O
calculated O
with O
the O
prospect O
of O
using O
a O
log O
rank O
test-statistic O
to O
test O
the O
null-hypothesis O
of O
no O
difference O
in O
time O
from O
randomisation O
to O
the O
primary O
outcome O
. O

The O
primary O
outcome O
is O
the B-Prim
incidence I-Prim
of I-Prim
perioperative I-Prim
bleeding I-Prim
episodes I-Prim
and O
clinically B-Prim
apparent I-Prim
thromboembolic I-Prim
events I-Prim
within I-Prim
30 I-Prim
days I-Prim
after I-Prim
surgery I-Prim
. O

It O
was O
not O
deemed O
likely O
, O
however O
, O
that O
the O
non-blinded O
nature O
of O
this O
study O
had O
a O
detrimental O
effect O
on O
the O
results O
, O
because O
the O
primary O
efficacy O
measure O
was O
a O
physical O
rather O
than O
a O
subjective O
endpoint O
and O
analysis O
of O
the O
data O
was O
blinded O
until O
its O
completion O
. O

A O
decrease O
of O
the O
primary O
endpoint O
from O
28.3 O
% O
( O
PC O
group O
) O
to O
14.6 O
% O
( O
LC O
group O
) O
with O
power O
80 O
% O
, O
alpha O
two-sided O
5 O
% O
, O
Fisher O
exact O
, O
two O
proportions O
, O
1 O
: O
1 O
randomization O
can O
be O
demonstrated O
by O
randomizing O
2 O
× O
140 O
patients O
( O
PS O
Power O
and O
Sample O
Size O
Calculations O
, O
version O
2.1.30 O
, O
February O
2003 O
) O
. O

It O
is O
not O
powered O
to O
detect O
a O
clinically O
or O
economically O
meaningful O
difference O
in O
the O
primary O
outcome O
between O
the O
surgical O
and O
active O
monitoring O
groups O
. O

Lastly O
, O
the O
primary O
outcome O
is O
defined O
by O
absence B-Prim
of I-Prim
PD I-Prim
at I-Prim
3-yr I-Prim
follow-up I-Prim
, I-Prim
operationalized I-Prim
by I-Prim
not I-Prim
meeting I-Prim
criteria I-Prim
for I-Prim
a I-Prim
PD I-Prim
on I-Prim
the I-Prim
SCID-II I-Prim
. O

Only O
primary O
and O
secondary O
outcome O
measures O
will O
be O
analyzed O
. O

Primary O
and O
secondary O
endpoints O
The O
primary O
endpoints O
of O
the O
LIR O
! O
C O
trial O
are O
the B-Prim
disease-specific I-Prim
quality I-Prim
of I-Prim
life I-Prim
as I-Prim
measured I-Prim
by I-Prim
the I-Prim
IBDQ I-Prim
16 I-Prim
17 I-Prim
and O
the B-Prim
costs I-Prim
per I-Prim
QALY I-Prim
. O

Participants O
were O
seated O
for O
five O
minutes O
before O
the O
first O
blood O
pressure O
measurement O
and O
a O
rest O
period O
of O
two O
minutes O
between O
measures O
was O
used O
. O

The O
primary O
efficacy O
endpoint O
was O
the B-Prim
American I-Prim
College I-Prim
of I-Prim
Rheumatology I-Prim
20 I-Prim
% I-Prim
improvement I-Prim
criteria I-Prim
( I-Prim
ACR20 I-Prim
) I-Prim
response I-Prim
at I-Prim
week I-Prim
24 I-Prim
19 I-Prim
20 I-Prim
. O

Application O
of O
this O
testing O
strategy O
with O
local O
type O
I O
error O
rate O
α O
1 O
= O
0.0299 O
in O
the O
interim O
analysis O
guarantees O
control O
of O
the O
multiple O
type O
I O
error O
rate O
α O
= O
0.05 O
for O
the O
confirmatory O
test O
problem O
for O
the O
primary O
variable O
29 O
. O

We O
aim O
to O
show O
non-inferiority O
of O
the O
expectant O
management O
arm O
and O
therefore O
this O
primary O
assessment O
day O
was O
chosen O
: O
if O
there O
would O
be O
any O
difference O
between O
randomized O
groups O
, O
this O
difference O
is O
expected O
to O
be O
the O
largest O
three O
days O
postpartum O
5 O
. O

2 O
: O
Following O
the O
IYP O
, O
participants O
will O
show O
significant O
improvement O
on O
the O
primary O
outcomes O
of O
general B-Prim
functioning I-Prim
, O
arthritis B-Prim
functioning I-Prim
and O
HRQOL B-Prim
relative O
to O
controls O
. O

Statistical O
analysis O
Primary O
outcomes O
are O
psychological B-Prim
distress I-Prim
as I-Prim
measured I-Prim
with I-Prim
the I-Prim
HADS I-Prim
and O
physical B-Prim
role I-Prim
function I-Prim
as I-Prim
measured I-Prim
with I-Prim
the I-Prim
EORTC-QLQ-C30 I-Prim
. O

Loss O
to O
follow-up O
is O
expected O
to O
be O
marginal O
: O
during O
the O
period O
that O
the O
primary O
endpoint O
( O
POPF B-Prim
grade I-Prim
B I-Prim
or I-Prim
C I-Prim
) O
has O
to O
be O
assessed O
( O
until O
postoperative O
day O
30 O
) O
, O
all O
patients O
are O
under O
continuous O
in-hospital O
observation O
in O
the O
perioperative O
period O
, O
followed O
by O
in-hospital O
rehabilitation O
for O
the O
great O
majority O
and O
close O
ambulatory O
observation O
in O
every O
case O
. O

The O
primary O
endpoint O
for O
analysis O
will O
be O
data O
collected O
at O
week O
24. O

The O
primary O
outcome O
will O
be O
the B-Prim
ability I-Prim
of I-Prim
the I-Prim
intervention I-Prim
( I-Prim
Project I-Prim
Tomato I-Prim
) I-Prim
to I-Prim
maintain I-Prim
consumption I-Prim
of I-Prim
fruit I-Prim
and I-Prim
vegetable I-Prim
portions I-Prim
compared I-Prim
to I-Prim
the I-Prim
control I-Prim
group I-Prim
. O

Primary O
outcomes O
were O
analysed O
on O
an O
intention-to-treat O
basis O
: O
if O
the O
person O
did O
not O
finish O
the O
course O
of O
detoxification O
or O
did O
not O
give O
a O
urine O
sample O
then O
this O
was O
considered O
as O
a O
positive O
urine O
test O
for O
opiates O
. O

The O
primary O
outcome O
measure O
is O
change B-Prim
in I-Prim
body I-Prim
mass I-Prim
index I-Prim
and O
the O
secondary O
outcome O
measures O
are O
changes B-Sec
in I-Sec
body I-Sec
composition I-Sec
, O
risk B-Sec
factors I-Sec
for I-Sec
type I-Sec
2 I-Sec
diabetes I-Sec
and I-Sec
cardiovascular I-Sec
disease I-Sec
, O
changes B-Sec
in I-Sec
diet I-Sec
, O
physical B-Sec
activity I-Sec
, O
and O
psychosocial B-Sec
well-being I-Sec
( I-Sec
eg I-Sec
, I-Sec
quality I-Sec
of I-Sec
life I-Sec
) I-Sec
. O

Surprisingly O
, O
even O
though O
all O
these O
programs O
aimed O
at O
reducing O
the O
fragmentation O
of O
care O
, O
consolidating O
the O
range O
of O
services O
, O
and O
promoting O
a O
better O
match O
of O
resources O
to O
the O
older O
person's O
needs O
, O
only O
the O
Wisconsin O
Partnership O
Program O
( O
WPP O
) O
( O
a O
variation O
of O
the O
PACE O
Program O
) O
, O
12 O
, O
has O
investigated O
unmet O
needs O
for O
ADL O
/ O
IADL O
disabilities O
as O
a O
main O
outcome O
of O
an O
ISD O
network O
, O
but O
failed O
to O
achieve O
an O
impact O
. O

The O
expected O
primary O
endpoint O
was O
a B-Prim
decrease I-Prim
in I-Prim
carer I-Prim
burden I-Prim
in I-Prim
the I-Prim
intervention I-Prim
group I-Prim
three I-Prim
months I-Prim
after I-Prim
receiving I-Prim
the I-Prim
DA I-Prim
. O

The O
primary O
endpoint O
is O
the B-Prim
change I-Prim
from I-Prim
the I-Prim
baseline I-Prim
value I-Prim
of I-Prim
HbA1c I-Prim
at I-Prim
6 I-Prim
months I-Prim
. O

Only O
87 O
of O
the O
102 O
remaining O
patients O
( O
57 O
% O
of O
those O
randomised O
) O
reached O
the O
primary O
endpoint O
. O

Outcome O
Measures O
The O
first O
primary O
outcome O
measure O
, O
assessed O
at O
6 O
and O
26 O
weeks O
after O
randomisation O
, O
was O
patient-perceived B-Prim
recovery I-Prim
( I-Prim
PPR I-Prim
) I-Prim
10 I-Prim
. O

Sensitivity O
analysis O
A O
sensitivity O
analysis O
is O
an O
important O
feature O
in O
economic O
evaluations O
, O
since O
study O
results O
can O
be O
sensitive O
to O
the O
values O
assumed O
for O
by O
key O
parameters O
22 O
. O

Outcome O
measurements O
Primary O
outcomes O
Adequate B-Prim
relief I-Prim
( I-Prim
AR I-Prim
) I-Prim
will O
be O
used O
as O
a O
primary O
outcome O
to O
evaluate O
IBS O
symptom O
improvement O
. O

Primary O
endpoints O
are O
the B-Prim
local I-Prim
radiation I-Prim
dose I-Prim
leading I-Prim
to I-Prim
tumor I-Prim
infiltrating I-Prim
T4 I-Prim
cells I-Prim
as I-Prim
a I-Prim
surrogate I-Prim
parameter I-Prim
for I-Prim
antitumor I-Prim
activity I-Prim
. O

The O
primary O
study O
endpoint O
is O
progression-free B-Prim
survival I-Prim
. O

Primary O
outcome O
Overall O
, O
63 O
men O
( O
70 O
% O
) O
gave O
a O
urine O
sample O
at O
5 O
days O
post O
detoxification O
( O
Table O
4 O
) O
, O
between O
the O
two O
allocated O
regimens O
for O
provision O
of O
urine O
sample O
( O
RR O
1.18 O
, O
CI O
0.90 O
– O
1.54 O
, O
z O
= O
1.20 O
, O
p O
= O
0.43 O
) O
. O

Key O
messages O
• O
This O
study O
, O
the O
first O
to O
measure O
the O
response O
of O
individual O
delirium O
symptoms O
to O
antipsychotic O
therapy O
in O
the O
ICU O
, O
demonstrates O
that O
quetiapine O
use O
may O
be O
associated O
with O
more O
rapid O
resolution O
of O
many O
common O
ICU O
delirium O
symptoms O
compared O
to O
placebo O
, O
resulting O
in O
less O
time O
affected O
by O
hallucinations O
, O
inattention O
, O
symptom O
fluctuation O
and O
an O
undesirable O
level O
of O
consciousness O
. O

Analyses O
of O
covariance O
were O
used O
to O
examine O
the O
effects O
of O
the O
intervention O
( O
study O
arm O
allocation O
) O
on O
the O
primary O
outcomes O
( O
log B-Prim
HbA I-Prim
1c I-Prim
and O
HRQL B-Prim
) O
, O
with O
the O
inclusion O
of O
baseline O
values O
of O
the O
outcomes O
as O
covariates O
. O

The O
primary O
outcome O
will O
be O
the B-Prim
proportion I-Prim
of I-Prim
patients I-Prim
who I-Prim
are I-Prim
adherent I-Prim
to I-Prim
a I-Prim
complete I-Prim
, I-Prim
guideline-based I-Prim
medication I-Prim
regimen I-Prim
. O

Primary O
outcome O
measures O
are O
time B-Prim
to I-Prim
establish I-Prim
full I-Prim
enteral I-Prim
feeding I-Prim
and O
necrotising B-Prim
enterocolitis I-Prim
; O
secondary O
outcomes O
include O
sepsis B-Sec
and O
growth B-Sec
. O

Our O
primary O
endpoint O
is O
the B-Prim
reduction I-Prim
in I-Prim
the I-Prim
number I-Prim
of I-Prim
exacerbations I-Prim
of I-Prim
COPD I-Prim
in I-Prim
the I-Prim
year I-Prim
of I-Prim
treatment I-Prim
. O

The O
tests O
of O
the O
secondary O
hypotheses O
were O
performed O
in O
the O
following O
order O
if O
the O
primary O
endpoint O
was O
significant O
at O
level O
0.05 O
: O
( O
1 O
) O
percentage O
of O
subjects O
reaching O
LDL-C O
goal O
of O
< O
1.81 O
mmol O
/ O
L O
( O
70 O
mg O
/ O
dL O
) O
, O
( O
2 O
) O
percentage O
of O
subjects O
reaching O
LDL-C O
goal O
of O
< O
2.00 O
mmol O
/ O
L O
( O
77 O
mg O
/ O
dL O
) O
, O
( O
3 O
) O
percentage O
of O
subjects O
reaching O
LDL-C O
goal O
of O
< O
2.59 O
mmol O
/ O
L O
( O
100 O
mg O
/ O
dL O
) O
. O

Outcome O
measures O
Primary O
outcome O
• B-Prim
The I-Prim
incidence I-Prim
of I-Prim
AF I-Prim
according I-Prim
to I-Prim
a I-Prim
variety I-Prim
of I-Prim
screening I-Prim
strategies I-Prim
• I-Prim
The I-Prim
associated I-Prim
costs I-Prim
providing I-Prim
an I-Prim
incremental I-Prim
cost I-Prim
per I-Prim
case I-Prim
detected I-Prim
. O

Our O
hypothesis O
is O
that O
in O
uncomplicated O
( O
mild O
) O
acute O
diverticulitis O
, O
a O
liberal O
strategy O
treatment O
without O
antibiotics O
is O
a O
more O
cost-effective O
approach O
than O
conservative O
treatment O
strategy O
with O
hospital O
admission O
and O
antibiotics O
, O
outcome O
is O
measured O
by O
time-to-full B-Prim
recovery I-Prim
as O
primary O
outcome O
and O
diverticulitis-associated B-Sec
complication I-Sec
rates I-Sec
and O
patient B-Sec
well-being I-Sec
as O
secondary O
outcome O
. O

These O
effects O
are O
manifested O
at O
the O
main O
assessments O
( O
see O
Table O
2 O
: O
t4 O
, O
t6 O
, O
t8 O
) O
a O
cross O
the O
trial O
. O

Minimisation O
cut-offs O
were O
derived O
from O
an O
analysis O
of O
mean O
and O
median O
values O
in O
the O
first O
1000 O
Fenland O
participants O
measured O
. O

Primary O
outcome O
is O
severity B-Prim
of I-Prim
hip I-Prim
pain I-Prim
reported I-Prim
by I-Prim
the I-Prim
patients I-Prim
at I-Prim
2-week I-Prim
follow-up I-Prim
. O

To O
check O
the O
main O
hypothesis O
all O
variables O
will O
be O
compared O
( O
t0-tk O
) O
by O
means O
of O
the O
ANOVA O
test O
with O
adequate O
post-hoc O
contrasts O
for O
normally O
distributed O
variables O
or O
the O
Kruskal-Wallis O
H O
test O
. O

Separate O
mixed O
group O
( O
yoga O
vs. O
control O
) O
by O
time O
( O
baseline O
vs. O
post-treatment O
/ O
post-control O
) O
repeated O
measure O
analysis O
of O
variance O
( O
ANOVA O
) O
will O
be O
conducted O
on O
the O
primary O
outcomes O
, O
or O
the O
non-parametric O
equivalent O
( O
Friedman O
procedure O
) O
, O
in O
the O
event O
the O
assumptions O
for O
parametric O
analyses O
are O
not O
met O
. O

The O
primary O
outcome O
of O
interest O
is O
the B-Prim
proportion I-Prim
of I-Prim
subjects I-Prim
who I-Prim
self-report I-Prim
smoking I-Prim
cessation I-Prim
with I-Prim
urinary I-Prim
cotinine I-Prim
validation I-Prim
at I-Prim
12 I-Prim
months I-Prim
. O

The O
main O
outcome O
measure O
for O
residents O
in O
the O
model O
is O
quality B-Prim
of I-Prim
life I-Prim
. O

The O
primary O
outcome O
measure O
for O
this O
study O
is O
the B-Prim
sustained I-Prim
reversion I-Prim
to I-Prim
sinus I-Prim
rhythm I-Prim
with I-Prim
a I-Prim
heart I-Prim
rate I-Prim
greater I-Prim
than I-Prim
50 I-Prim
/ I-Prim
min I-Prim
within I-Prim
2 I-Prim
hours I-Prim
of I-Prim
completion I-Prim
of I-Prim
FDP I-Prim
/ I-Prim
placebo I-Prim
bolus I-Prim
. O

Subgroup O
analyses O
will O
be O
performed O
by O
assessing O
interactions O
of O
the O
primary O
outcome O
with O
a O
maximum O
of O
three O
pre-determined O
factors O
( O
education O
, O
gender O
, O
and O
baseline O
alcohol O
consumption O
) O
. O

Primary O
outcome O
measure O
is O
the B-Prim
change I-Prim
of I-Prim
tinnitus I-Prim
distress I-Prim
as I-Prim
quantified I-Prim
by I-Prim
the I-Prim
Tinnitus I-Prim
Questionnaire I-Prim
( I-Prim
TQ I-Prim
) I-Prim
. O

Results O
Among O
274 O
patients O
with O
evaluable O
efficacy O
data O
, O
the B-Prim
percentage I-Prim
of I-Prim
responders I-Prim
according I-Prim
to I-Prim
American I-Prim
College I-Prim
of I-Prim
Rheumatology I-Prim
50 I-Prim
criteria I-Prim
( O
the O
primary O
endpoint O
, O
based O
on O
a O
28-joint O
count O
) O
was O
significantly O
higher O
with O
canakinumab O
150 O
mg O
SC O
q4wk O
than O
with O
placebo O
( O
26.5 O
% O
vs. O
11.4 O
% O
, O
respectively O
; O
p O
= O
0.028 O
) O
. O

In O
this O
UK O
study O
of O
74 O
male O
prisoners O
with O
opiate O
addiction O
, O
lofexidine O
was O
compared O
with O
methadone O
with O
the O
primary O
outcome O
being O
self-reported B-Prim
withdrawal I-Prim
symptom I-Prim
severity I-Prim
during I-Prim
the I-Prim
detoxification I-Prim
period I-Prim
. O

The O
primary O
outcome O
measure O
was O
the B-Prim
intra-individual I-Prim
change I-Prim
in I-Prim
the I-Prim
total I-Prim
score I-Prim
of I-Prim
the I-Prim
Hamilton I-Prim
Rating I-Prim
Scale I-Prim
for I-Prim
Depression I-Prim
( I-Prim
HAM-D I-Prim
, I-Prim
17-item I-Prim
version I-Prim
) I-Prim
between I-Prim
baseline I-Prim
and I-Prim
the I-Prim
end I-Prim
of I-Prim
the I-Prim
6-week I-Prim
acute I-Prim
phase I-Prim
. O

The O
purpose O
of O
the O
additional O
combing O
immediately O
following O
the O
first O
treatment O
( O
ie O
a O
combing O
on O
days O
1 O
and O
2 O
rather O
than O
on O
day O
1 O
or O
day O
2 O
as O
have O
been O
used O
in O
other O
studies O
) O
was O
to O
enable O
the O
investigators O
a O
better O
opportunity O
to O
find O
any O
newly O
hatched O
nymphs O
in O
relation O
to O
evaluation O
of O
the O
first O
primary O
outcome O
measure O
, O
the B-Prim
ovicidal I-Prim
effect I-Prim
of I-Prim
the I-Prim
treatments I-Prim
, I-Prim
defined I-Prim
as I-Prim
no I-Prim
nymphal I-Prim
lice I-Prim
emerging I-Prim
from I-Prim
eggs I-Prim
between I-Prim
treatments I-Prim
. O

The O
primary O
outcome O
of O
interest O
will O
be O
biochemically B-Prim
verified I-Prim
continuous I-Prim
abstinence I-Prim
at I-Prim
1 I-Prim
year I-Prim
. O

The O
primary O
outcome O
is O
the B-Prim
proportion I-Prim
of I-Prim
risky I-Prim
sexual I-Prim
practices I-Prim
. O

Primary O
and O
secondary O
outcomes O
Our O
first O
objective O
is O
to O
compare O
the O
effectiveness O
of O
the O
two O
different O
strategies O
for O
changing O
lifestyle O
with O
each O
other O
as O
well O
as O
with O
a O
control O
group O
. O

The B-Prim
mean I-Prim
decrease I-Prim
in I-Prim
Young I-Prim
Mania I-Prim
Rating I-Prim
Scale I-Prim
score I-Prim
from I-Prim
baseline I-Prim
was O
used O
as O
the O
main O
outcome O
measure O
of O
response O
of O
mania O
to O
treatment O
. O

Mean O
differences O
Primary O
measures O
WOMAC B-Prim
Pain I-Prim
, O
Physical B-Prim
Function I-Prim
and O
Total B-Prim
scores I-Prim
improved O
more O
significantly O
in O
the O
OAK O
group O
than O
in O
the O
control O
group O
( O
Table O
4 O
) O
. O

The O
primary O
outcomes O
are O
physical B-Prim
activity I-Prim
, I-Prim
measured I-Prim
with I-Prim
the I-Prim
StepWatch I-Prim
activity I-Prim
monitor I-Prim
, O
and O
self-reported B-Prim
physical I-Prim
activity I-Prim
. O

The O
primary O
outcome O
of O
patient B-Prim
intention I-Prim
to I-Prim
visit I-Prim
a I-Prim
psychosocial I-Prim
counselor I-Prim
was O
measured O
by O
a O
single O
item O
( O
yes O
/ O
no O
) O
. O

Click O
here O
for O
file O
Sample O
size O
calculation O
( O
a O
) O
Sample O
size O
calculation O
for O
Theme O
1 O
The O
primary O
outcome O
measure O
was O
taken O
as O
the B-Prim
proportion I-Prim
admitted I-Prim
to I-Prim
hospital I-Prim
, O
with O
the O
secondary O
outcome O
measure O
being O
number B-Sec
of I-Sec
bed I-Sec
days I-Sec
. O

Outcomes O
The O
primary O
outcome O
was O
28-day B-Prim
all-cause I-Prim
mortality I-Prim
. O

An O
interim O
analysis O
on O
the O
primary O
end O
point O
( O
ie O
, O
efficacy B-Prim
) O
will O
be O
performed O
after O
50 O
% O
of O
patients O
have O
completed O
their O
follow-up O
. O

The O
primary O
outcome O
is O
adherence B-Prim
to I-Prim
medication I-Prim
. O

With O
16 O
clusters O
( O
8 O
pairs O
) O
this O
would O
give O
the O
study O
95 O
% O
power O
to O
detect O
a O
20 O
% O
reduction O
in O
primary O
outcome O
from O
75 O
% O
to O
55 O
% O
( O
as O
seen O
in O
the O
trial O
by O
Kettle O
et O
al O
2002 O
7 O
) O
or O
alternatively O
a O
small-to-moderate O
difference O
of O
one O
third O
of O
a O
standard O
deviation O
on O
continuous O
scales O
, O
such O
as O
VAS O
scores O
for O
pain O
) O
. O

Quantitative O
assessments O
For O
the O
primary O
outcome O
assessments O
, O
we O
will O
record O
the B-Prim
symptoms I-Prim
of I-Prim
schizophrenia I-Prim
at I-Prim
baseline I-Prim
and I-Prim
at I-Prim
12 I-Prim
months I-Prim
, I-Prim
with I-Prim
the I-Prim
Positive I-Prim
and I-Prim
Negative I-Prim
Syndrome I-Prim
Scale I-Prim
( I-Prim
PANSS I-Prim
) I-Prim
17 I-Prim
. O

At O
6 O
and O
12 O
months O
patients O
will O
be O
followed O
up O
by O
a O
research O
nurse O
( O
RN O
) O
where O
details O
of O
primary O
and O
secondary O
outcomes O
will O
be O
collected O
. O

The O
primary O
endpoint O
is O
to B-Prim
assess I-Prim
quality I-Prim
of I-Prim
life I-Prim
at I-Prim
6 I-Prim
months I-Prim
on I-Prim
the I-Prim
Minnesota I-Prim
questionnaire I-Prim
. O

End O
points O
The O
main O
end O
point O
was O
time B-Prim
to I-Prim
death I-Prim
from I-Prim
all I-Prim
causes I-Prim
, O
non-fatal B-Prim
myocardial I-Prim
infarction I-Prim
( I-Prim
MI I-Prim
) I-Prim
, O
non-fatal B-Prim
stroke I-Prim
, O
or O
heart B-Prim
failure I-Prim
requiring I-Prim
hospitalization I-Prim
or I-Prim
emergency I-Prim
service I-Prim
intervention I-Prim
. O

The O
primary O
outcome O
measure O
is O
sedentary B-Prim
time I-Prim
defined I-Prim
as I-Prim
time I-Prim
< I-Prim
100 I-Prim
counts I-Prim
per I-Prim
minute I-Prim
29 I-Prim
. O

Outcome O
measures O
To O
determine O
the O
effects O
of O
tadalafil O
on O
the O
microcirculation O
, O
the O
primary O
outcome O
measure O
was O
the B-Prim
temperature I-Prim
difference I-Prim
between I-Prim
the I-Prim
CRPS I-Prim
affected I-Prim
and I-Prim
the I-Prim
contralateral I-Prim
limbs I-Prim
. O

The O
primary O
outcome O
measures O
used O
to O
assess O
women's O
health O
and O
well-being O
at O
six O
months O
were O
the B-Prim
EPDS I-Prim
( I-Prim
a I-Prim
10-item I-Prim
scale I-Prim
developed I-Prim
for I-Prim
use I-Prim
in I-Prim
the I-Prim
postnatal I-Prim
period I-Prim
, I-Prim
in I-Prim
which I-Prim
a I-Prim
score I-Prim
≥ I-Prim
13 I-Prim
identifies I-Prim
probable I-Prim
depression I-Prim
33 I-Prim
, O
and O
the B-Prim
physical I-Prim
and I-Prim
mental I-Prim
component I-Prim
scores I-Prim
( I-Prim
PCS I-Prim
and I-Prim
MCS I-Prim
) I-Prim
of I-Prim
the I-Prim
Short I-Prim
Form I-Prim
36 I-Prim
( I-Prim
SF-36 I-Prim
) I-Prim
, I-Prim
a I-Prim
widely I-Prim
used I-Prim
general I-Prim
health I-Prim
status I-Prim
measure I-Prim
34 I-Prim
. O

Descriptive O
statistics O
The O
primary O
outcome O
parameter O
of O
time B-Prim
to I-Prim
functional I-Prim
recovery I-Prim
and O
the O
secondary O
parameter O
of O
LOS B-Sec
in I-Sec
hospital I-Sec
will O
be O
given O
in O
days O
, O
with O
a O
median O
and O
range O
. O

To O
analyze O
the O
primary O
outcome O
( O
ie O
, O
RRI B-Prim
) O
, O
the O
Kaplan-Meier O
method O
will O
be O
used O
. O

The O
primary O
and O
secondary O
endpoints O
will O
be O
analyzed O
on O
modified O
intention-to-treat O
analysis O
. O

The O
primary O
efficacy O
variable O
was O
trough B-Prim
forced I-Prim
expiratory I-Prim
volume I-Prim
in I-Prim
one I-Prim
second I-Prim
( I-Prim
FEV I-Prim
1 I-Prim
) I-Prim
at I-Prim
24 I-Prim
h I-Prim
post-dose I-Prim
after I-Prim
14 I-Prim
days I-Prim
. O

The O
primary O
outcome O
measure O
was O
the B-Prim
PHQ-9 I-Prim
. O

The O
aim O
of O
this O
randomised O
, O
controlled O
, O
single-blind O
, O
cross-over O
study O
in O
single-use O
dialyser O
bicarbonate O
haemodialysis O
was O
to O
detail O
the O
consequences O
on O
systemic B-Prim
haemodynamics I-Prim
( O
primary O
outcome O
) O
and O
on O
coagulation B-Sec
activation I-Sec
, O
acid-base B-Sec
status I-Sec
, O
calcium B-Sec
balance I-Sec
and O
dialysis B-Sec
efficiency I-Sec
( O
secondary O
outcomes O
) O
of O
using O
citric O
instead O
of O
acetic O
acid O
in O
haemodialysis O
fluids O
. O

The O
co-administration O
of O
formoterol O
and O
fluticasone O
shows O
superiority O
to O
the O
individual O
components O
administered O
separately O
and O
placebo O
for O
all O
three O
co-primary O
endpoints O
and O
confers O
significant O
benefits O
in O
terms O
of O
lung O
function O
, O
disease O
control O
, O
and O
asthma O
symptoms O
. O

The O
main O
outcome O
measures O
were O
SHBG B-Prim
and O
sex B-Prim
hormones I-Prim
[ I-Prim
ie I-Prim
, I-Prim
testosterone I-Prim
, I-Prim
estradiol I-Prim
, I-Prim
dehydroepiandrosterone I-Prim
sulfate I-Prim
] I-Prim
. O

Overall O
study O
design O
and O
participants O
Main O
outcomes O
and O
subjects O
The O
core O
portion O
of O
the O
study O
was O
a O
randomized O
post-test O
only O
control O
group O
design O
, O
for O
the O
main O
outcomes O
: O
attitudes B-Prim
, O
knowledge B-Prim
and O
skills B-Prim
in I-Prim
EBM I-Prim
. O

Assessing O
feasibility O
for O
a O
larger O
phase O
III O
trial O
According O
to O
the O
Medical O
Research O
Council's O
guidance O
for O
developing O
and O
evaluating O
complex O
interventions O
24 O
the O
piloting O
stage O
includes O
: O
testing O
procedures O
for O
delivering O
the O
intervention O
, O
estimating O
the O
likely O
rates O
of O
recruitment O
and O
retention O
of O
participants O
, O
and O
estimating O
the O
effect O
size O
of O
the O
primary O
outcome O
measure O
in O
preparation O
for O
a O
sample O
size O
calculation O
. O

The O
primary O
outcomes O
will O
be O
based O
on O
three O
validated O
QoL O
questionnaires O
, O
St O
Georges O
Respiratory O
Questionnaire O
( O
SGRQ O
) O
, O
Short O
Form O
Health O
Survey O
( O
SF-36 O
) O
and O
the O
COPD O
Assessment O
Test O
( O
CAT O
) O
. O

Statistical O
analyses O
Based O
on O
the O
primary O
outcome O
measures O
, O
a O
sample O
size O
of O
130 O
participants O
would O
provide O
80 O
% O
power O
to O
detect O
a O
difference O
of O
eight O
units O
on O
the O
LBPRS O
( O
SD O
= O
13 O
) O
between O
the O
primary O
and O
each O
of O
the O
comparator O
groups O
, O
assuming O
alpha O
of O
0.05 O
using O
a O
two-sided O
test O
. O

Sensitivity O
analyses O
will O
examine O
the O
impact O
of O
altering O
key O
assumptions O
and O
parameter O
values O
. O

Statistical O
analysis O
The O
primary O
endpoints O
of O
the O
study O
were O
clinical B-Prim
response I-Prim
at I-Prim
the I-Prim
test-of-cure I-Prim
visit I-Prim
( I-Prim
14 I-Prim
– I-Prim
35 I-Prim
days I-Prim
after I-Prim
therapy I-Prim
) I-Prim
for I-Prim
the I-Prim
m-mITT I-Prim
and I-Prim
ME I-Prim
populations I-Prim
. O

Primary O
endpoint O
is O
the B-Prim
incidence I-Prim
of I-Prim
clinically I-Prim
relevant I-Prim
VTE I-Prim
( I-Prim
symptomatic I-Prim
deep I-Prim
venous I-Prim
thrombosis I-Prim
( I-Prim
DVT I-Prim
) I-Prim
of I-Prim
the I-Prim
leg I-Prim
and I-Prim
/ I-Prim
or I-Prim
pelvic I-Prim
and I-Prim
/ I-Prim
or I-Prim
pulmonary I-Prim
embolism I-Prim
( I-Prim
PE I-Prim
) I-Prim
) I-Prim
within I-Prim
the I-Prim
first I-Prim
3 I-Prim
months I-Prim
. O

The O
primary O
outcome O
comparison O
will O
be O
of O
the B-Prim
proportion I-Prim
of I-Prim
infants I-Prim
with I-Prim
sleep I-Prim
and I-Prim
cry I-Prim
problems I-Prim
at I-Prim
4 I-Prim
months I-Prim
between O
the O
two O
trial O
arms O
. O

The O
main O
outcome O
measure O
of O
the O
trial O
will O
be O
the B-Prim
healing I-Prim
rate I-Prim
, I-Prim
defined I-Prim
as I-Prim
lesion I-Prim
disappearance I-Prim
in I-Prim
the I-Prim
affected I-Prim
zones I-Prim
after I-Prim
the I-Prim
topic I-Prim
application I-Prim
of I-Prim
the I-Prim
experimental I-Prim
treatment I-Prim
. O

For O
patients O
of O
the O
WLC O
group O
this O
is O
the O
final O
assessment O
. O

The O
primary O
outcome O
is O
patient-perceived B-Prim
recovery I-Prim
at I-Prim
52 I-Prim
weeks I-Prim
, I-Prim
using I-Prim
the I-Prim
Global I-Prim
Perceived I-Prim
Effect I-Prim
questionnaire I-Prim
. O

Neither O
the O
primary O
test O
variables O
nor O
the O
functional O
performance O
parameters O
showed O
that O
external O
focus O
instruction O
was O
beneficiary O
to O
internal O
focus O
instruction O
whilst O
learning O
to O
balance O
on O
a O
stable O
or O
unstable O
platform O
with O
concurrent O
feedback O
on O
a O
video O
screen O
. O

The O
primary O
outcomes O
will O
be O
the B-Prim
percentage I-Prim
reduction I-Prim
in I-Prim
binge I-Prim
drinking I-Prim
, O
weekly B-Prim
drinking I-Prim
and O
drinking-related B-Prim
problems I-Prim
after I-Prim
three I-Prim
specified I-Prim
time I-Prim
periods I-Prim
. O

ANOVA O
testing O
for O
primary O
outcome O
demonstrated O
a O
significant O
interaction O
effect O
time O
by O
group O
( O
F O
= O
7.4 O
; O
df O
= O
1 O
, O
33 O
; O
p O
= O
0.010 O
; O
η O
2 O
= O
0.183 O
) O
. O

The O
primary O
endpoint O
will O
be O
analysed O
using O
a O
time O
to O
event O
approach O
. O

The O
primary O
outcomes O
include O
the B-Prim
Extended I-Prim
Glasgow I-Prim
Outcome I-Prim
Scale I-Prim
and O
the B-Prim
Modified I-Prim
Rankin I-Prim
Scale I-Prim
. O

The O
reason O
for O
choosing O
pulmonary B-Prim
exacerbations I-Prim
as O
our O
primary O
outcome O
is O
two-fold O
. O

As O
reported O
in O
the O
GAIT O
clinical O
trial O
investigating O
glucosamine O
hydrochloride O
and O
chondroitin O
sulfate O
in O
osteoarthritis O
subjects O
11 O
, O
we O
used O
response B-Prim
rate I-Prim
to I-Prim
treatment I-Prim
as O
a O
primary O
efficacy O
variable O
based O
on O
the O
WOMAC O
A O
or O
pain O
criteria O
. O

Safety O
and O
efficacy O
monitoring O
The O
role O
of O
the O
DSMB O
is O
to O
perform O
an O
interim O
review O
of O
the O
trial's O
progress O
including O
updated O
figures O
on O
main O
outcomes O
and O
safety O
data O
. O

Study O
variables O
In O
addition O
to O
the O
inclusion O
and O
exclusion O
criteria O
, O
four O
types O
of O
variables O
will O
be O
collected O
: O
psychosocial O
, O
biomedical O
, O
treatment O
prescribed O
, O
and O
intermediate O
and O
final O
outcome O
variables O
( O
table O
2 O
) O
. O

Confidence O
intervals O
( O
95 O
% O
) O
will O
be O
computed O
for O
all O
primary O
and O
secondary O
outcomes O
. O

Outcome O
Measure O
Details O
The O
supplementary O
four O
items O
contributing O
to O
the O
21-item O
version O
of O
the O
HRSD O
17 O
will O
also O
be O
assessed O
, O
but O
not O
used O
as O
part O
of O
the O
primary O
outcome O
score O
. O

Primary O
outcome O
measure O
Participants O
are O
asked O
to O
rate O
their B-Prim
typical I-Prim
level I-Prim
of I-Prim
neck I-Prim
or I-Prim
back I-Prim
pain I-Prim
over I-Prim
the I-Prim
last I-Prim
week I-Prim
, I-Prim
using I-Prim
an I-Prim
ordinal I-Prim
11-box I-Prim
scale I-Prim
( I-Prim
0 I-Prim
= I-Prim
no I-Prim
pain I-Prim
, I-Prim
10 I-Prim
= I-Prim
the I-Prim
worst I-Prim
pain I-Prim
possible I-Prim
) I-Prim
31 I-Prim
. O

The O
primary O
effectiveness O
outcomes O
are O
pain B-Prim
and O
dysfunction B-Prim
assessed I-Prim
at I-Prim
the I-Prim
10-week I-Prim
telephone I-Prim
interview I-Prim
. O

Methods O
The O
VERTOS O
IV O
study O
is O
a O
prospective O
, O
multicenter O
RCT O
with O
pain B-Prim
relief I-Prim
as O
primary O
endpoint O
. O

Primary O
outcome O
measures O
are O
pulse B-Prim
wave I-Prim
velocity I-Prim
and O
carotid B-Prim
intima-media I-Prim
thickness I-Prim
. O

Analyses O
of O
covariance O
( O
with O
" O
other O
relevant O
variables O
" O
from O
above O
as O
covariates O
) O
will O
test O
the O
between O
group O
differences O
in O
the O
primary O
and O
secondary O
outcomes O
at O
each O
assessment O
time O
point O
and O
across O
time O
points O
for O
the O
parents O
and O
children O
. O

The O
primary O
outcome O
was O
trial B-Prim
feasibility I-Prim
, I-Prim
defined I-Prim
by I-Prim
randomization I-Prim
of I-Prim
> I-Prim
25 I-Prim
% I-Prim
of I-Prim
eligible I-Prim
patients I-Prim
, I-Prim
delivery I-Prim
of I-Prim
> I-Prim
75 I-Prim
% I-Prim
of I-Prim
the I-Prim
prescribed I-Prim
CRRT I-Prim
dose I-Prim
, I-Prim
and I-Prim
follow-up I-Prim
of I-Prim
> I-Prim
95 I-Prim
% I-Prim
of I-Prim
patients I-Prim
to I-Prim
60 I-Prim
days I-Prim
. O

Effect O
variables O
Main O
effect O
variables O
were O
u-AQP2 B-Prim
and O
u-ENaC B-Prim
. O

This O
was O
a O
24-week O
placebo-controlled O
and O
randomized O
intervention O
trial O
to O
investigate O
the O
effects O
of O
GTP O
and O
TC O
on O
relevant O
primary O
and O
secondary O
endpoints O
in O
postmenopausal O
women O
with O
osteopenia O
. O

Sample O
Size O
Considerations O
Gait B-Prim
speed I-Prim
at I-Prim
six I-Prim
months I-Prim
was O
chosen O
as O
the O
primary O
outcome O
because O
safe O
, O
independent O
walking O
is O
a O
high O
priority O
amongst O
patients O
participating O
in O
rehabilitation O
, O
and O
gait O
speed O
is O
often O
recommended O
as O
a O
measure O
of O
status O
and O
outcome O
46 O
47 O
. O

At O
6 O
and O
14 O
weeks O
after O
the O
start O
of O
treatment O
, O
the O
primary O
outcome O
and O
three O
potential O
mediators O
— O
self-efficacy O
, O
causal O
attributions O
and O
present-centred O
attention-awareness O
— O
will O
be O
measured O
. O

Primary O
outcome O
measures O
are O
measures B-Prim
of I-Prim
cognitive I-Prim
function I-Prim
. O

For O
our O
primary O
outcome O
, O
the O
slope O
of O
quality O
score O
change O
was O
also O
similar O
: O
-0.229 O
( O
95 O
% O
CI O
−0.644 O
to O
−0.185 O
) O
for O
controls O
and O
−0.549 O
( O
−0.831 O
to O
−0.267 O
) O
for O
mentees O
. O

The O
primary O
pharmacokinetic O
parameter O
was O
AUC O
τ O
. O

While O
the O
study's O
final O
assessment O
protocol O
was O
administered O
approximately O
eight O
months O
after O
baseline O
, O
one O
might O
still O
question O
whether O
the O
medical O
students' O
communication O
skills O
learning O
was O
maintained O
over O
a O
greater O
length O
of O
time O
. O

To O
circumvent O
this O
dilemma O
, O
we O
proposed O
that O
control O
participants O
should O
not O
receive O
a O
welfare O
rights O
assessment O
until O
the O
end O
of O
the O
trial O
period O
( O
ie O
following O
final O
outcome O
measurement O
) O
. O

The O
main O
outcomes O
are O
: O
serum B-Prim
levels I-Prim
of I-Prim
sTNFR-1 I-Prim
, I-Prim
sTNFR-2 I-Prim
, I-Prim
interleukin I-Prim
( I-Prim
IL I-Prim
) I-Prim
-6 I-Prim
, I-Prim
IL-10 I-Prim
, I-Prim
measured I-Prim
by I-Prim
the I-Prim
ELISA I-Prim
method I-Prim
; O
genotyping B-Prim
of I-Prim
tumor I-Prim
necrosis I-Prim
factor- I-Prim
( I-Prim
TNF I-Prim
) I-Prim
-alpha I-Prim
( I-Prim
rs1800629 I-Prim
) I-Prim
, I-Prim
IL6 I-Prim
( I-Prim
rs1800795 I-Prim
) I-Prim
, I-Prim
IL10 I-Prim
( I-Prim
rs1800896 I-Prim
) I-Prim
by I-Prim
the I-Prim
TaqMan I-Prim
Method I-Prim
( I-Prim
Applied I-Prim
Biosystems I-Prim
, I-Prim
Foster I-Prim
City I-Prim
, I-Prim
CA I-Prim
, I-Prim
USA I-Prim
) I-Prim
; O
and O
physical B-Prim
performance I-Prim
assessed I-Prim
by I-Prim
Timed I-Prim
Up I-Prim
and I-Prim
Go I-Prim
and I-Prim
10-Meter I-Prim
Walk I-Prim
Tests I-Prim
. O

Outcomes O
The O
primary O
outcome O
will O
be O
the B-Prim
ability I-Prim
of I-Prim
the I-Prim
Internet I-Prim
package I-Prim
to I-Prim
promote I-Prim
change I-Prim
in I-Prim
BMI I-Prim
over I-Prim
6 I-Prim
and I-Prim
12 I-Prim
months I-Prim
compared I-Prim
with I-Prim
traditional I-Prim
treatment I-Prim
. O

The O
primary O
outcome O
is O
pain-related B-Prim
disability I-Prim
and O
functional B-Prim
interference I-Prim
. O

Efficacy O
results O
In O
the O
double-blind O
part O
of O
the O
study O
, O
more O
patients O
on O
adalimumab O
achieved O
an B-Prim
ASAS40 I-Prim
, O
the O
primary O
outcome O
parameter O
, O
at O
week O
4 O
( O
41 O
% O
) O
, O
week O
8 O
( O
53 O
% O
) O
and O
week O
12 O
( O
53 O
% O
) O
than O
on O
placebo O
( O
20 O
% O
, O
33 O
% O
, O
33 O
% O
) O
, O
while O
differences O
at O
week O
8 O
only O
reached O
the O
border O
significance O
( O
P O
= O
0.05 O
) O
. O

The O
primary O
outcome O
measure O
is O
the B-Prim
patient-reported I-Prim
Disabilities I-Prim
of I-Prim
the I-Prim
Arm I-Prim
, I-Prim
Hand I-Prim
and I-Prim
Shoulder I-Prim
Questionnaire I-Prim
( I-Prim
DASH I-Prim
) I-Prim
. O

The O
primary O
outcome O
measures O
are O
the B-Prim
quality I-Prim
of I-Prim
life I-Prim
of I-Prim
people I-Prim
with I-Prim
dementia I-Prim
, I-Prim
as I-Prim
assessed I-Prim
by I-Prim
QoL-AD I-Prim
, O
and O
their B-Prim
care-givers' I-Prim
mental I-Prim
health I-Prim
as I-Prim
assessed I-Prim
by I-Prim
the I-Prim
GHQ-28 I-Prim
. O

Primary O
outcome O
measures O
will O
be O
the B-Prim
Nottingham I-Prim
Extended I-Prim
Activities I-Prim
of I-Prim
Daily I-Prim
Living I-Prim
Scale I-Prim
( I-Prim
NEADL I-Prim
) I-Prim
and O
the B-Prim
Late I-Prim
Life I-Prim
Disability I-Prim
Index I-Prim
( I-Prim
LLDI I-Prim
) I-Prim
which I-Prim
will I-Prim
measure I-Prim
functional I-Prim
independence I-Prim
, O
and O
participation B-Prim
and I-Prim
limitation I-Prim
in I-Prim
daily I-Prim
life I-Prim
activities I-Prim
. O

However O
, O
additional O
research O
is O
needed O
to O
assess O
the O
long-term O
efficacy O
of O
walnut O
consumption O
on O
PSA O
and O
other O
primary O
measures O
of O
prostate O
health O
. O

In O
order O
to O
adapt O
to O
the O
differences O
in O
populations O
, O
a O
pilot O
study O
comprising O
36 O
patients O
was O
conducted O
to O
determine O
the O
population O
size O
, O
inclusion O
and O
exclusion O
criteria O
, O
questionnaires O
, O
logistics O
and O
the O
primary O
outcome O
measures O
in O
the O
RCT O
. O

Our O
co-primary O
outcomes O
are O
the B-Prim
modified I-Prim
Roland I-Prim
score I-Prim
and O
pain B-Prim
numerical I-Prim
rating I-Prim
scale I-Prim
at I-Prim
1 I-Prim
month I-Prim
. O

We O
will O
also O
investigate O
the O
following O
areas O
: O
• O
differences O
in O
health O
care O
resources O
consumption O
• O
differences O
in O
comparing O
the O
costs O
of O
the O
study O
with O
the O
benefits O
resulting O
by O
the O
intervention O
( O
see O
Economic O
evaluation O
paragraph O
) O
A O
list O
of O
categories O
of O
the O
study O
outcomes O
, O
with O
the O
main O
outcome O
of O
each O
category O
, O
is O
reported O
in O
table O
1 O
. O

Primary O
endpoint O
is O
the B-Prim
comparison I-Prim
of I-Prim
the I-Prim
‘weaning I-Prim
time’ I-Prim
defined I-Prim
as I-Prim
the I-Prim
time I-Prim
required I-Prim
from I-Prim
discontinuation I-Prim
of I-Prim
the I-Prim
sedating I-Prim
agent I-Prim
until I-Prim
sufficient I-Prim
spontaneous I-Prim
breathing I-Prim
occurs I-Prim
. O

Sample O
size O
Our O
sample O
size O
calculation O
is O
based O
on O
the O
combined O
primary O
endpoints O
( B-Prim
a I-Prim
) I-Prim
number I-Prim
of I-Prim
patients I-Prim
that I-Prim
resume I-Prim
and I-Prim
maintain I-Prim
sports I-Prim
during I-Prim
12 I-Prim
months I-Prim
follow-up I-Prim
, O
and O
( B-Prim
b I-Prim
) I-Prim
the I-Prim
time I-Prim
to I-Prim
resumption I-Prim
of I-Prim
sport I-Prim
. O

The O
primary O
and O
secondary O
outcomes O
between O
the O
two O
intervention O
groups O
will O
be O
compared O
using O
the O
Chi-square O
test O
. O

Primary O
outcomes O
were O
changes B-Prim
between I-Prim
baseline I-Prim
and I-Prim
nine I-Prim
months I-Prim
of I-Prim
bone I-Prim
mineral I-Prim
density I-Prim
( I-Prim
BMD I-Prim
) I-Prim
of I-Prim
the I-Prim
proximal I-Prim
femur I-Prim
and I-Prim
lumbar I-Prim
spine I-Prim
( I-Prim
dual-energy I-Prim
X-ray I-Prim
absorptiometry I-Prim
) I-Prim
and O
serum B-Prim
markers I-Prim
of I-Prim
bone I-Prim
resorption I-Prim
and I-Prim
formation I-Prim
. O

The O
primary O
outcome O
was O
health-related B-Prim
quality I-Prim
of I-Prim
life I-Prim
( I-Prim
HRQoL I-Prim
) I-Prim
; O
secondary O
outcomes O
were O
mood B-Sec
state I-Sec
, O
dyspnea B-Sec
, O
gas B-Sec
exchange I-Sec
, O
functional B-Sec
status I-Sec
, O
pulmonary B-Sec
function I-Sec
, O
and O
exacerbation B-Sec
frequency I-Sec
. O

The B-Prim
LSAS-SR I-Prim
was O
the O
primary O
outcome O
measure O
. O

The O
primary O
outcome O
for O
the O
analyses O
in O
this O
manuscript O
was O
perinatal B-Prim
mortality I-Prim
( I-Prim
stillbirth I-Prim
or I-Prim
death I-Prim
during I-Prim
the I-Prim
first I-Prim
seven I-Prim
days I-Prim
after I-Prim
birth I-Prim
) I-Prim
. O

The O
patients O
were O
informed O
of O
the O
study O
before O
the O
first O
assessment O
and O
signed O
a O
written O
, O
informed O
consent O
statement O
. O

Two O
CEAs O
will O
be O
performed O
from O
the O
company O
perspective O
: O
1 O
) O
intervention O
costs O
together O
with O
savings O
as O
a O
result O
of O
reduced O
sick O
leave O
( O
absenteeism O
) O
and O
loss O
of O
productivity O
( O
presenteeism O
) O
will O
be O
compared O
to O
the O
obtained O
effects O
on O
the O
primary O
outcome O
measures O
lifestyle B-Prim
and O
vitality B-Prim
2 O
) O
intervention O
costs O
will O
be O
compared O
to O
the O
obtained O
benefits O
due O
to O
reduced O
sick O
leave O
and O
increased O
productivity O
. O

The O
primary O
endpoint O
was O
change B-Prim
in I-Prim
urinary I-Prim
HRQOL I-Prim
at I-Prim
3 I-Prim
months I-Prim
. O

Sample O
size O
and O
power O
The O
study O
will O
be O
powered O
on O
the O
main O
outcome O
measure O
, O
namely O
( B-Prim
change I-Prim
in I-Prim
) I-Prim
risk I-Prim
perception I-Prim
. O

The O
primary O
outcome O
of O
this O
study O
was O
the B-Prim
change I-Prim
in I-Prim
postbronchodilator I-Prim
FEV I-Prim
1 I-Prim
, O
which O
has O
been O
noted O
to O
improve O
in O
some O
, O
but O
not O
all O
, O
previous O
trials O
of O
ICS O
in O
COPD O
8 O
9 O
23 O
25 O
26 O
. O

In O
addition O
, O
participants O
with O
missing O
or O
inconsistent O
data O
on O
the O
main O
variables O
( O
n O
= O
1 O
, O
286 O
) O
or O
confounders O
( O
n O
= O
381 O
) O
were O
excluded O
, O
leaving O
19 O
, O
096 O
participants O
for O
statistical O
analyses O
. O

Analytic O
Methods O
The O
primary O
analysis O
will O
compare O
the O
primary O
outcome O
between O
the O
two O
treatments O
taking O
into O
account O
possible O
variability O
in O
the O
overall O
level O
of O
abstinence O
between O
sites O
. O

Study O
outcomes O
Primary O
outcome O
The O
primary O
outcome O
is O
the B-Prim
difference I-Prim
between I-Prim
the I-Prim
two I-Prim
groups I-Prim
in I-Prim
achieving I-Prim
a I-Prim
50 I-Prim
% I-Prim
increase I-Prim
in I-Prim
breast I-Prim
milk I-Prim
volume I-Prim
at I-Prim
the I-Prim
end I-Prim
of I-Prim
the I-Prim
first I-Prim
2-week I-Prim
period I-Prim
( I-Prim
mean I-Prim
day I-Prim
14 I-Prim
volume- I-Prim
mean I-Prim
day I-Prim
0 I-Prim
volume I-Prim
at I-Prim
entry I-Prim
) I-Prim
. O

Primary O
outcomes O
include O
obesity B-Prim
( I-Prim
BMI I-Prim
≥95 I-Prim
th I-Prim
percentile I-Prim
) I-Prim
and O
overweight B-Prim
( I-Prim
BMI I-Prim
≥85 I-Prim
th I-Prim
percentile I-Prim
) I-Prim
based I-Prim
on I-Prim
the I-Prim
1988 I-Prim
BMI I-Prim
tables I-Prim
of I-Prim
Hernandez I-Prim
19 I-Prim
. O

Nevertheless O
, O
multiple O
outcome O
measures O
can O
lead O
to O
false O
positive O
conclusions O
about O
the O
effectiveness O
of O
a O
treatment O
so O
a O
primary O
outcome O
variable O
( O
change B-Prim
in I-Prim
depressive I-Prim
symptoms I-Prim
) O
is O
specified O
. O

The O
primary O
endpoints O
of O
our O
study O
will O
be O
: O
A B-Prim
) I-Prim
To I-Prim
evaluate I-Prim
the I-Prim
conversion I-Prim
rate I-Prim
B B-Prim
) I-Prim
To I-Prim
evaluate I-Prim
morbidity I-Prim
, I-Prim
mortality I-Prim
, I-Prim
operation I-Prim
time I-Prim
C B-Prim
) I-Prim
To I-Prim
evaluate I-Prim
hospital I-Prim
stay I-Prim
, I-Prim
postoperative I-Prim
pain I-Prim
, I-Prim
return I-Prim
to I-Prim
normal I-Prim
activity I-Prim
The O
onset O
of O
any O
other O
complications O
will O
be O
recorded O
intraoperatively O
, O
postoperatively O
, O
at O
discharge O
, O
at O
7-days O
, O
1-month O
and O
6-months O
. O

The O
primary O
outcome O
was O
change B-Prim
in I-Prim
body I-Prim
weight I-Prim
and O
waist B-Prim
circumference I-Prim
. O

A O
post-hoc O
design O
that O
samples O
based O
on O
main O
trial O
outcomes O
would O
avoid O
this O
risk O
, O
but O
at O
the O
cost O
of O
being O
designed O
after O
trial O
effectiveness O
is O
known O
, O
and O
conducted O
long O
after O
the O
trial O
completes O
. O

Unless O
clinically O
necessary O
, O
there O
will O
be O
no O
angiographic O
follow-up O
until O
12 O
months O
post O
PCI O
, O
the O
timepoint O
for O
the O
primary O
endpoint O
of O
the O
stent O
comparison O
. O

Sample O
size O
To O
detect O
a O
true O
difference O
in O
the O
primary O
outcome O
measures O
of O
maximal B-Prim
exercise I-Prim
capacity I-Prim
and O
HRQoL B-Prim
, O
a O
total O
of O
36 O
subjects O
( O
18 O
per O
group O
) O
will O
be O
required O
. O

Study O
outcomes O
The O
primary O
outcomes O
in O
this O
trial O
are O
: O
( B-Prim
1 I-Prim
) I-Prim
immune I-Prim
reconstitution I-Prim
, I-Prim
defined I-Prim
as I-Prim
change I-Prim
in I-Prim
CD4 I-Prim
cell I-Prim
count I-Prim
; O
( B-Prim
2 I-Prim
) I-Prim
weight I-Prim
gain I-Prim
; O
and O
( B-Prim
3 I-Prim
) I-Prim
change I-Prim
in I-Prim
quality I-Prim
of I-Prim
life I-Prim
, I-Prim
defined I-Prim
as I-Prim
overall I-Prim
score I-Prim
on I-Prim
the I-Prim
Medical I-Prim
Outcomes I-Prim
Survey-HIV I-Prim
( I-Prim
MOS-HIV I-Prim
) I-Prim
14 I-Prim
, I-Prim
and I-Prim
individual I-Prim
scores I-Prim
for I-Prim
general I-Prim
health I-Prim
perceptions I-Prim
, I-Prim
physical I-Prim
functioning I-Prim
, I-Prim
pain I-Prim
, I-Prim
energy I-Prim
, I-Prim
role I-Prim
functioning I-Prim
, I-Prim
social I-Prim
functioning I-Prim
, I-Prim
and I-Prim
mental I-Prim
health I-Prim
. O

Finally O
, O
information O
on O
participant O
disposition O
was O
collected O
to O
document O
the O
recruitment O
of O
participants O
and O
their O
progression O
through O
the O
trial O
, O
numbers O
receiving O
intended O
treatment O
, O
those O
completing O
the O
study O
protocol O
and O
analysed O
for O
the O
primary O
outcome O
14 O
24 O
. O

The O
primary O
outcome O
measure O
is O
sick B-Prim
leave I-Prim
duration I-Prim
until I-Prim
full I-Prim
RTW I-Prim
. O

Primary O
outcome O
criterium O
Mobilization B-Prim
status I-Prim
as I-Prim
assessed I-Prim
by I-Prim
the I-Prim
4-item I-Prim
abbreviation I-Prim
of I-Prim
the I-Prim
Barthel I-Prim
index I-Prim
, I-Prim
focusing I-Prim
on I-Prim
lower I-Prim
extremity I-Prim
motoric I-Prim
function I-Prim
. O

Primary O
outcomes O
We O
are O
using O
the B-Prim
function I-Prim
component I-Prim
of I-Prim
the I-Prim
Late I-Prim
Life I-Prim
Function I-Prim
and I-Prim
Disability I-Prim
Instrument I-Prim
( I-Prim
LLFDI I-Prim
) I-Prim
to O
measure O
the O
functional O
ability O
constructs O
25 O
. O

Power O
analysis O
of O
project O
A1 O
Analysis O
is O
based O
on O
a O
statistical O
power O
of O
80 O
% O
with O
an O
alpha O
of O
5 O
% O
for O
detecting O
a B-Prim
meaningful I-Prim
difference I-Prim
of I-Prim
6 I-Prim
points I-Prim
ie I-Prim
10 I-Prim
% I-Prim
on I-Prim
the I-Prim
Action I-Prim
Research I-Prim
Arm I-Prim
Test I-Prim
, I-Prim
ARAT I-Prim
sum I-Prim
score I-Prim
as O
the O
primary O
outcome O
measure O
35 O
. O

Primary O
endpoint O
is O
number B-Prim
of I-Prim
scaphoid I-Prim
unions I-Prim
at I-Prim
six I-Prim
weeks I-Prim
, O
secondary O
endpoints O
are O
time B-Sec
interval I-Sec
to I-Sec
clinical I-Sec
and I-Sec
radiological I-Sec
consolidation I-Sec
, O
number B-Sec
of I-Sec
non-unions I-Sec
, O
functional B-Sec
status I-Sec
at I-Sec
52 I-Sec
weeks I-Sec
and O
non-adherence B-Sec
to I-Sec
the I-Sec
treatment I-Sec
protocol I-Sec
. O

Differences O
between O
treatment O
groups O
concerning O
the O
primary O
outcome O
measures O
will O
be O
expressed O
as O
relative O
risks O
and O
95 O
% O
confidence O
intervals O
or O
as O
central O
estimators O
and O
variance O
measures O
where O
appropriate O
. O

The O
time O
of O
recording O
for O
each O
participant O
was O
kept O
constant O
for O
the O
initial O
and O
final O
assessment O
. O

The O
primary O
outcome O
measure O
will O
be O
the B-Prim
rates I-Prim
of I-Prim
decline I-Prim
in I-Prim
eGFR I-Prim
( I-Prim
ml I-Prim
/ I-Prim
min I-Prim
/ I-Prim
1.73 I-Prim
m I-Prim
2 I-Prim
/ I-Prim
month I-Prim
) I-Prim
measured I-Prim
by I-Prim
MDRD I-Prim
and I-Prim
Cockcroft I-Prim
Gault I-Prim
equations I-Prim
. O

Table O
1 O
Subject O
characteristics O
and O
main O
outcome O
. O

The O
primary O
outcome O
for O
this O
trial O
was O
incidence B-Prim
of I-Prim
low I-Prim
back I-Prim
pain I-Prim
resulting I-Prim
in I-Prim
the I-Prim
seeking I-Prim
of I-Prim
health I-Prim
care I-Prim
. O

Outcome O
A O
primary O
outcome O
measure O
is O
change B-Prim
in I-Prim
AD I-Prim
patients’ I-Prim
weights I-Prim
. O

The O
primary O
endpoint O
of O
this O
study O
is O
26 O
weeks O
, O
whilst O
the O
52 O
week O
questionnaire O
will O
provide O
data O
on O
the O
longer O
term O
effectiveness O
of O
the O
interventions O
. O

The O
primary O
outcome O
was O
gingival B-Prim
bleeding I-Prim
with O
the O
hypothesis O
that O
6-monthly O
scale O
and O
polish O
would O
result O
in O
lower O
prevalence O
than O
12-month O
or O
24-month O
frequency O
. O

It O
also O
should O
be O
pointed O
out O
that O
an O
in O
vivo O
scenario O
is O
quite O
complex O
and O
the O
final O
outcome O
of O
an O
infectious O
process O
depends O
on O
the O
concerted O
action O
of O
several O
cells O
, O
including O
epithelial O
, O
endothelial O
, O
neutrophils O
, O
macrophages O
and O
lymphocytes O
, O
and O
therefore O
, O
we O
cannot O
rule O
out O
that O
glutamine O
may O
exert O
a O
positive O
effect O
on O
other O
cell O
types O
or O
even O
at O
the O
level O
of O
cross-talk O
between O
cells O
of O
the O
innate O
immune O
system O
. O

The O
principal O
outcome O
of O
this O
project O
will O
be O
the B-Prim
determination I-Prim
of I-Prim
the I-Prim
strength I-Prim
of I-Prim
effect I-Prim
of I-Prim
exercise I-Prim
on I-Prim
the I-Prim
well I-Prim
established I-Prim
musculoskeletal I-Prim
, I-Prim
cardiovascular I-Prim
and I-Prim
insulin I-Prim
metabolism I-Prim
side I-Prim
effects I-Prim
of I-Prim
ADT I-Prim
in I-Prim
prostate I-Prim
cancer I-Prim
patients I-Prim
. O

Outcomes O
Primary O
outcome O
The O
primary O
outcome O
was O
the B-Prim
duration I-Prim
of I-Prim
fluid I-Prim
fast I-Prim
prior I-Prim
to I-Prim
induction I-Prim
of I-Prim
anaesthesia I-Prim
. O

Figure O
2 O
illustrates O
the O
median O
and O
inter-quartile O
ranges O
for O
the O
primary O
outcome O
measure O
at O
the O
primary O
outcome O
point O
( O
9 O
months O
) O
. O

High-dose O
supplementation O
had O
no O
effect O
on O
several O
key O
measures O
that O
reveal O
HIV O
disease O
progression O
— O
CD4 O
count O
, O
plasma O
viral O
load O
, O
body O
mass O
index O
, O
or O
hemoglobin O
level O
concentration O
— O
and O
did O
not O
reduce O
death O
or O
disease O
progression O
risks O
for O
HIV-infected O
patients O
. O

The O
primary O
endpoint O
is O
the B-Prim
mortality I-Prim
rate I-Prim
within I-Prim
hospitalization I-Prim
. O

We O
assumed O
the O
ICC O
for O
primary O
care O
outcomes O
was O
0.02 O
50 O
. O

Participants O
reach O
the O
primary O
endpoint O
if O
at O
least O
one O
of O
the O
following O
occurs O
: O
( B-Prim
1 I-Prim
) I-Prim
death I-Prim
, O
( B-Prim
2 I-Prim
) I-Prim
acute I-Prim
myocardial I-Prim
infarction I-Prim
, O
( B-Prim
3 I-Prim
) I-Prim
cerebral I-Prim
thrombosis I-Prim
, O
( B-Prim
4 I-Prim
) I-Prim
cerebral I-Prim
hemorrhage I-Prim
, O
( B-Prim
5 I-Prim
) I-Prim
peripheral I-Prim
arterial I-Prim
occlusive I-Prim
disease I-Prim
. O

The O
primary O
outcomes O
are O
symptoms B-Prim
of I-Prim
depression I-Prim
and O
anxiety B-Prim
as I-Prim
measured I-Prim
by I-Prim
the I-Prim
PHQ-9 I-Prim
and I-Prim
GAD-7 I-Prim
31 I-Prim
32 I-Prim
. O

The O
overall O
acceptance O
of O
the O
tool O
and O
its O
ability O
to O
alter O
antibiotic O
prescribing O
for O
suspected O
strep O
or O
pneumonia O
will O
be O
determined O
by O
the O
final O
outcomes O
of O
the O
trial O
. O

The O
primary O
outcome O
measure O
, O
the B-Prim
Stanford I-Prim
Health I-Prim
Assessment I-Prim
Questionnaire I-Prim
Disability I-Prim
Index I-Prim
( I-Prim
HAQ-DI I-Prim
) I-Prim
which I-Prim
measures I-Prim
functional I-Prim
ability I-Prim
, O
and O
secondary O
measures O
of O
pain B-Sec
, O
fatigue B-Sec
and O
quality B-Sec
of I-Sec
life I-Sec
, O
will O
be O
assessed O
at O
baseline O
, O
eight O
and O
24 O
weeks O
by O
an O
independent O
assessor O
unaware O
of O
group O
allocation O
. O

Statistical O
issues O
Sample O
size O
calculations O
The O
study O
is O
designed O
as O
an O
equivalence O
study O
, O
whereby O
both O
treatments O
will O
have O
the O
same O
incidence O
of O
the O
primary O
outcome O
measure O
of O
combined B-Prim
bad I-Prim
neonatal I-Prim
outcome I-Prim
. O

The O
primary O
outcome O
will O
combine O
pain B-Prim
and O
function B-Prim
subscales I-Prim
of I-Prim
the I-Prim
AUSCAN I-Prim
31 I-Prim
40 I-Prim
and O
global B-Prim
assessment I-Prim
of I-Prim
improvement I-Prim
41 I-Prim
to I-Prim
determine I-Prim
a I-Prim
' I-Prim
responder' I-Prim
using I-Prim
the I-Prim
OARSI-OMERACT I-Prim
criteria I-Prim
42 I-Prim
at I-Prim
6 I-Prim
months I-Prim
post I-Prim
randomisation I-Prim
. O

Outcome O
measures O
Primary O
outcome O
measure O
The O
primary O
outcome O
measure O
is O
the B-Prim
time I-Prim
to I-Prim
the I-Prim
occurrence I-Prim
of I-Prim
a I-Prim
spontaneous I-Prim
viable I-Prim
IUP I-Prim
. O

Primary O
Outcome O
measure O
: O
Depression B-Prim
using I-Prim
the I-Prim
Children's I-Prim
Depression I-Prim
Inventory I-Prim
2 I-Prim
( I-Prim
CDI-2 I-Prim
) I-Prim
. O

The O
primary O
outcome O
measure O
( O
QPR B-Prim
) O
and O
the O
secondary O
outcome O
measures O
are O
listed O
in O
Section O
13. O

Authors' O
contributions O
DW O
is O
the O
principal O
investigator O
; O
she O
led O
the O
conception O
and O
design O
of O
the O
study O
, O
development O
of O
the O
intervention O
, O
selection O
of O
primary O
and O
secondary O
measures O
, O
and O
development O
of O
the O
manuscript O
. O

Primary O
outcome O
measures O
are O
symptoms B-Prim
of I-Prim
depression I-Prim
and O
anxiety B-Prim
. O

The O
main O
outcome O
will O
not O
simply O
be O
antibiotic O
prescribing O
in O
a O
single O
consultation O
as O
in O
individually O
randomized O
trials O
57 O
, O
but O
rather O
, O
antibiotic B-Prim
prescribing I-Prim
for I-Prim
a I-Prim
whole I-Prim
year I-Prim
. O

If O
they O
did O
not O
attend O
the O
day O
42 O
visit O
, O
the O
final O
outcome O
of O
the O
malaria O
episode O
was O
determined O
where O
possible O
. O

We O
recommend O
that O
randomised O
controlled O
trials O
of O
sufficient O
power O
are O
carried O
out O
using O
primary O
outcomes O
of O
reduction O
in O
outward O
directed O
aggression O
, O
improvement O
in O
quality O
of O
life O
and O
cost O
efficacy O
as O
measured O
by O
standardised O
scales O
" O
27 O
. O

Study O
parameters O
Primary O
study O
outcome O
The O
primary O
outcome O
of O
the O
study O
will O
be O
the B-Prim
capability I-Prim
of I-Prim
functional I-Prim
skills I-Prim
in I-Prim
mobility I-Prim
and I-Prim
self-care I-Prim
using I-Prim
the I-Prim
Functional I-Prim
Skills I-Prim
Scale I-Prim
of I-Prim
the I-Prim
PEDI I-Prim
( I-Prim
PEDI-FSS I-Prim
; I-Prim
37 I-Prim
) I-Prim
. O

Outcomes O
The O
primary O
outcome O
measure O
is O
‘recurrence’ B-Prim
, I-Prim
defined I-Prim
as I-Prim
the I-Prim
proportion I-Prim
of I-Prim
patients I-Prim
with I-Prim
recurrent I-Prim
haemorrhoids I-Prim
at I-Prim
12 I-Prim
months I-Prim
, I-Prim
as I-Prim
derived I-Prim
from I-Prim
a I-Prim
telephone I-Prim
assessment I-Prim
in I-Prim
combination I-Prim
with I-Prim
GP I-Prim
and I-Prim
hospital I-Prim
records I-Prim
. O

The O
main O
outcome O
measures O
assessed O
in O
the O
pilot O
were O
success B-Prim
at I-Prim
quitting I-Prim
( I-Prim
expired I-Prim
CO I-Prim
≤ I-Prim
9 I-Prim
ppm I-Prim
) I-Prim
, O
the B-Prim
dose I-Prim
of I-Prim
NRT I-Prim
used I-Prim
, O
and O
the B-Prim
rating I-Prim
of I-Prim
withdrawal I-Prim
symptoms I-Prim
using I-Prim
the I-Prim
Mood I-Prim
and I-Prim
Symptoms I-Prim
Scale I-Prim
. O

Measurement O
of O
cardiac O
output O
Monitoring O
of O
the O
key O
cardiovascular O
variables O
of O
blood O
pressure O
and O
cardiac O
output O
( O
volume O
of O
blood O
pumped O
by O
the O
heart O
per O
minute O
) O
is O
common O
in O
patients O
at O
high O
risk O
of O
intra-operative O
and O
postoperative O
complications O
. O

The B-Prim
Shoulder I-Prim
Pain I-Prim
and I-Prim
Disability I-Prim
Index I-Prim
( I-Prim
SPADI I-Prim
) I-Prim
at I-Prim
1 I-Prim
year I-Prim
follow-up I-Prim
was O
used O
as O
the O
primary O
outcome O
25 O
26 O
. O

Discussion O
In O
this O
paper O
, O
we O
have O
reported O
the O
background O
, O
the O
rationale O
, O
and O
the O
study O
protocol O
for O
a O
unique O
multi-center O
randomized O
controlled O
trial O
whose O
main O
outcome O
is O
a B-Prim
biochemical I-Prim
measurement I-Prim
( I-Prim
ie I-Prim
CRP I-Prim
) I-Prim
. O

The O
primary O
endpoint O
will O
be O
assessed O
in O
Q3 O
2016. O

Primary O
end-points O
of O
the O
study O
were O
peak B-Prim
systolic I-Prim
and I-Prim
end-diastolic I-Prim
blood I-Prim
flow I-Prim
velocities I-Prim
in I-Prim
the I-Prim
short I-Prim
posterior I-Prim
ciliary I-Prim
artery I-Prim
( I-Prim
SPCA I-Prim
) I-Prim
under I-Prim
the I-Prim
new I-Prim
therapy I-Prim
. O

b O
Primary O
efficacy O
outcome O
. O

The O
primary O
outcome O
for O
the O
initial O
trial O
was O
the B-Prim
time I-Prim
until I-Prim
shock I-Prim
reversal I-Prim
with O
a O
secondary O
outcome O
of O
attenuation B-Sec
of I-Sec
the I-Sec
inflammatory I-Sec
cascade I-Sec
following I-Sec
intervention I-Sec
. O

Intra O
class O
correlations O
will O
be O
assessed O
for O
all O
the O
main O
outcome O
measures O
and O
multilevel O
modelling O
used O
to O
take O
into O
account O
any O
design O
effects O
as O
well O
as O
the O
non O
independence O
of O
data O
from O
multiple O
children O
in O
one O
family O
. O

For O
the O
primary O
endpoint O
( O
HAQ-DI B-Prim
at I-Prim
8 I-Prim
and I-Prim
24 I-Prim
weeks I-Prim
) O
an O
analysis O
of O
covariance O
( O
ANCOVA O
) O
will O
be O
used O
to O
explore O
between O
group O
differences O
in O
terms O
of O
the O
continuous O
variables O
thereby O
accounting O
for O
baseline O
scores O
. O

Sample O
size O
calculation O
As O
our O
primary O
outcome O
measure O
is O
gene B-Prim
expression I-Prim
in I-Prim
whole I-Prim
blood I-Prim
, O
a O
priori O
sample O
size O
calculations O
are O
not O
possible O
. O

Sample O
size O
consideration O
The O
sample O
size O
and O
power O
calculations O
have O
been O
estimated O
for O
the O
primary O
outcome O
of O
this O
study O
, O
ie O
, O
the B-Prim
rate I-Prim
of I-Prim
falls I-Prim
. O

There O
was O
no O
effect O
on O
length B-Prim
of I-Prim
stay I-Prim
( O
the O
primary O
endpoint O
) O
, O
but O
a O
pronounced O
effect O
upon O
postoperative O
complications O
, O
mainly O
delirium O
( O
34 O
% O
versus O
44 O
% O
) O
and O
pressure O
sores O
( O
5 O
% O
versus O
17 O
% O
) O
21 O
. O

The O
primary O
outcome O
is O
the B-Prim
proportion I-Prim
of I-Prim
participants I-Prim
who I-Prim
self-report I-Prim
seven-day I-Prim
point I-Prim
prevalence I-Prim
abstinence I-Prim
at I-Prim
six I-Prim
months I-Prim
since I-Prim
Quit I-Prim
date I-Prim
. O

We O
hope O
to O
assess O
long O
term O
maintenance O
of O
exercise O
participation O
in O
a O
full O
trial O
and O
to O
obtain O
information O
about O
the O
influence O
specific O
elements O
of O
the O
program O
have O
on O
the O
primary O
outcome O
. O

The O
analysis O
will O
determine O
the O
size O
of O
the O
effect O
, O
if O
any O
, O
of O
physical O
activity O
on O
primary O
and O
secondary O
outcome O
variables O
. O

Primary O
Outcome O
The O
primary O
outcome O
is O
mean B-Prim
change I-Prim
difference I-Prim
in I-Prim
child I-Prim
percent I-Prim
body I-Prim
fat I-Prim
between I-Prim
baseline I-Prim
and I-Prim
post-intervention I-Prim
. O

Prognostic O
outcome O
measure O
Psychosocial O
workload O
is O
considered O
to O
be O
a O
potentially O
prognostic O
factor O
for O
the O
primary O
outcome O
measure O
, O
' B-Prim
need I-Prim
for I-Prim
recovery I-Prim
after I-Prim
work' I-Prim
. O

Primary O
outcome O
variable O
will O
be O
the B-Prim
Action I-Prim
Research I-Prim
Arm I-Prim
Test I-Prim
( I-Prim
ARAT I-Prim
) I-Prim
, I-Prim
assessed I-Prim
at I-Prim
1 I-Prim
, I-Prim
2 I-Prim
, I-Prim
3 I-Prim
, I-Prim
4 I-Prim
, I-Prim
5 I-Prim
, I-Prim
8 I-Prim
, I-Prim
12 I-Prim
and I-Prim
26 I-Prim
weeks I-Prim
post I-Prim
stroke I-Prim
. O

Endpoints O
The O
primary O
outcome O
was O
the B-Prim
mean I-Prim
time I-Prim
to I-Prim
onset I-Prim
of I-Prim
the I-Prim
first I-Prim
24-h I-Prim
heartburn-free I-Prim
period I-Prim
after I-Prim
initial I-Prim
dosing I-Prim
. O

Both O
budesonide O
/ O
formoterol O
( O
160 O
/ O
4.5 O
μg O
one O
inhalation O
) O
and O
salbutamol O
( O
100 O
μg O
two O
inhalations O
) O
were O
superior O
to O
placebo O
for O
the O
primary O
efficacy O
variable O
– O
the B-Prim
onset I-Prim
of I-Prim
relief I-Prim
of I-Prim
dyspnoea I-Prim
, I-Prim
expressed I-Prim
as I-Prim
the I-Prim
change I-Prim
in I-Prim
Borg I-Prim
score I-Prim
1 I-Prim
minute I-Prim
after I-Prim
study I-Prim
drug I-Prim
administration I-Prim
. O

The O
primary O
outcome O
measure O
is O
' B-Prim
distress I-Prim
due I-Prim
to I-Prim
breathlessness' I-Prim
measured I-Prim
using I-Prim
a I-Prim
Numerical I-Prim
Rating I-Prim
Scale I-Prim
( I-Prim
NRS I-Prim
; I-Prim
0-10 I-Prim
) I-Prim
. O

By O
day O
8 O
( O
the O
first O
assessment O
) O
, O
physicians O
assessed O
disease O
activity O
as O
absent O
or O
minimal O
in O
31 O
( O
88.6 O
% O
) O
patients O
, O
and O
this O
response O
was O
maintained O
at O
the O
end O
of O
part O
1 O
( O
Figure O
1a O
) O
. O

Methods O
/ O
Design O
The O
PROUD O
trial O
is O
designed O
as O
a O
randomised O
, O
controlled O
, O
observer O
, O
surgeon O
and O
patient O
blinded O
multicenter O
superiority O
trial O
with O
two O
parallel O
groups O
and O
a O
primary O
endpoint O
of O
wound B-Prim
infection I-Prim
during I-Prim
30 I-Prim
days I-Prim
after I-Prim
surgery I-Prim
. O

Thus O
, O
the O
only O
effect O
on O
the O
primary O
endpoint O
was O
the O
drugs O
used O
and O
not O
the O
variation O
in O
sedation O
/ O
analgesic O
levels O
. O

Primary O
outcome O
measures O
The B-Prim
objectively I-Prim
and I-Prim
subjectively I-Prim
measured I-Prim
difference I-Prim
in I-Prim
nocturnal I-Prim
restlessness I-Prim
between I-Prim
T0-T1-T2 I-Prim
. O

There O
will O
be O
two O
primary O
outcome O
measures O
obtained O
at O
one O
, O
six O
, O
and O
12 O
month O
follow-up O
: O
1 B-Prim
) I-Prim
24-hour I-Prim
expired I-Prim
air I-Prim
CO I-Prim
validated I-Prim
self-reported I-Prim
smoking I-Prim
cessation I-Prim
and O
2 B-Prim
) I-Prim
7-day I-Prim
self-reported I-Prim
smoking I-Prim
cessation I-Prim
. O

Statistical O
analysis O
On O
the O
basis O
of O
the O
nature O
of O
the O
primary O
outcome O
measure O
, O
patients O
with O
protocol O
violations O
and O
/ O
or O
missing O
data O
were O
excluded O
from O
the O
primary O
analysis O
. O

This O
score O
is O
also O
primary O
endpoint O
in O
the O
similar O
RCT O
going O
on O
in O
Trondheim O
, O
Norway O
53 O
. O

Involuntary B-Prim
termination I-Prim
of I-Prim
a I-Prim
woman's I-Prim
pregnancy I-Prim
( I-Prim
miscarriage I-Prim
) I-Prim
and O
other B-Prim
fetal I-Prim
loss I-Prim
( I-Prim
eg I-Prim
stillbirth I-Prim
) I-Prim
, I-Prim
( O
primary O
outcomes O
of O
importance O
to O
the O
main O
study O
) O
were O
reported O
as O
adverse O
events O
, O
although O
participation O
in O
the O
intervention O
study O
was O
never O
considered O
to O
be O
a O
causal O
factor O
by O
the O
Data O
Safety O
Monitoring O
Board O
. O

In O
case O
of O
potential O
unilateral O
treatment O
, O
the O
primary O
outcome O
measure O
will O
only O
be O
measured O
for O
the O
participant's O
potentially O
treated O
leg O
. O

With O
the O
proposed O
sample O
size O
of O
247 O
and O
247 O
for O
the O
two O
groups O
( O
ie O
assuming O
a O
1 O
: O
1 O
allocation O
ratio O
) O
, O
the O
study O
will O
have O
power O
of O
80 O
% O
to O
yield O
a O
statistically O
significant O
result O
using O
a O
chi-squared O
test O
( O
assuming O
an O
intention-to-treat O
principle O
for O
the O
analysis O
) O
at O
alpha O
= O
0.05 O
/ O
2 O
( O
ie O
using O
the O
Bonferroni O
correction O
factor O
for O
the O
two O
primary O
outcomes O
) O
. O

Statistical O
and O
Health O
Economic O
analyses O
Differences O
in O
the O
primary O
outcome O
, O
recurrence B-Prim
of I-Prim
haemorrhoids I-Prim
between I-Prim
the I-Prim
two I-Prim
treatment I-Prim
groups I-Prim
, O
will O
be O
analysed O
using O
logistic O
regression O
adjusting O
for O
sex O
, O
age O
at O
surgery O
and O
history O
of O
previous O
intervention O
as O
fixed O
effect O
covariates O
and O
surgeon O
as O
a O
random O
effect O
. O

The O
primary O
endpoints O
were O
the B-Prim
proportion I-Prim
of I-Prim
children I-Prim
achieving I-Prim
a I-Prim
well I-Prim
clinical I-Prim
response I-Prim
and O
time B-Prim
to I-Prim
a I-Prim
well I-Prim
clinical I-Prim
response I-Prim
. O

Statistical O
design O
The O
primary O
endpoint O
was O
change B-Prim
in I-Prim
EPIC I-Prim
urinary I-Prim
HRQOL I-Prim
domain I-Prim
summary I-Prim
score I-Prim
at I-Prim
3 I-Prim
months I-Prim
after I-Prim
the I-Prim
completion I-Prim
of I-Prim
RT I-Prim
( I-Prim
ΔEPIC-U I-Prim
3mo I-Prim
) I-Prim
. O

We O
want O
to O
be O
able O
to O
demonstrate O
moderate O
effects O
( O
d O
= O
0.5 O
) O
on O
the O
primary O
outcome O
measure O
, O
while O
using O
a O
power O
0.80 O
, O
with O
alpha O
set O
at O
.05 O
( O
two-tailed O
) O
. O

It O
was O
calculated O
that O
a O
sample O
size O
of O
90 O
evaluable O
subjects O
per O
group O
would O
provide O
an O
overall O
power O
of O
92 O
% O
to O
meet O
the O
non-inferiority O
criteria O
for O
both O
the O
primary O
endpoints O
assuming O
the O
groups O
elicited O
identical O
immune O
responses O
. O

Although O
the O
magnitude O
of O
the O
improvement O
was O
small O
, O
significance O
in O
the O
primary O
outcome O
and O
many O
secondary O
outcomes O
was O
achieved O
. O

Primary O
end-points O
( O
baseline O
T0 O
and O
post-intervention O
T1 O
) O
and O
all O
follow-up O
measures O
( O
T2-T3 O
) O
are O
expected O
to O
be O
completed O
in O
January O
2013. O

Statistical O
analysis O
The O
primary O
aim O
of O
the O
statistical O
analysis O
is O
to O
compare O
the O
two O
arms O
, O
with O
respect O
to O
the O
primary O
and O
secondary O
outcomes O
, O
ie O
the O
time O
to O
virological O
treatment O
failure O
and O
adherence O
. O

Primary O
analysis O
used O
repeated O
measures O
analysis O
of O
variance O
( O
ANOVA O
) O
with O
the O
3 O
, O
6 O
and O
12 O
month O
data O
as O
outcomes O
and O
the O
appropriate O
baseline O
measurement O
as O
a O
covariate O
to O
test O
for O
the O
main O
effect O
of O
group O
( O
LI O
versus O
UC O
, O
intention-to-treat O
analyses O
) O
on O
QOL O
outcome O
measures O
( O
FACT-G O
; O
physical O
, O
functional O
, O
social O
, O
emotional O
well-being O
, O
fatigue O
and O
endometrial O
subscales O
) O
and O
self-efficacy O
( O
WEL O
; O
negative O
emotions O
, O
food O
availability O
, O
social O
pressure O
, O
positive O
activities O
, O
physical O
discomfort O
) O
. O

Minimum O
data O
collection O
at O
each O
follow-up O
data O
collection O
stage O
will O
attempt O
to O
capture O
the O
primary O
outcomes O
, O
AUSCAN B-Prim
and O
global B-Prim
change I-Prim
scores I-Prim
, O
in O
the O
event O
of O
non-response O
to O
the O
mailed O
follow-up O
questionnaire O
. O

The O
primary O
outcome O
of O
this O
study O
is O
be O
the B-Prim
number I-Prim
of I-Prim
new I-Prim
falls I-Prim
and I-Prim
fallers I-Prim
. O

Outcomes O
Primary O
endpoints O
are O
the B-Prim
number I-Prim
and I-Prim
stage I-Prim
of I-Prim
detected I-Prim
breast I-Prim
cancers I-Prim
, I-Prim
both I-Prim
DCIS I-Prim
and I-Prim
invasive I-Prim
, I-Prim
in I-Prim
each I-Prim
arm I-Prim
. O

Clinical O
efficacy O
measures O
As O
the O
primary O
aim O
of O
this O
pedalling O
intervention O
is O
to O
enhance O
ability O
to O
voluntarily O
contract O
paretic O
muscle O
, O
the O
primary O
measure O
enables O
assessment O
of O
impairment O
level O
change O
. O

The O
main O
outcome O
measures O
were O
time B-Prim
from I-Prim
induction I-Prim
to I-Prim
delivery I-Prim
and O
incidence B-Prim
of I-Prim
vaginal I-Prim
delivery I-Prim
within I-Prim
12 I-Prim
and I-Prim
24 I-Prim
hours I-Prim
. O

Parents O
receive O
€ O
15 O
, O
- O
after O
completing O
the O
first O
assessment O
, O
€ O
25 O
, O
- O
after O
participating O
in O
the O
program O
and O
completing O
the O
second O
assessment O
and O
€ O
40 O
, O
- O
after O
completing O
the O
follow O
up O
assessment O
. O

Outcome O
measures O
The O
primary O
outcome O
measure O
was O
the B-Prim
incidence I-Prim
of I-Prim
AEs I-Prim
( I-Prim
sum I-Prim
of I-Prim
the I-Prim
incidence I-Prim
of I-Prim
pressure I-Prim
ulcers I-Prim
, I-Prim
urinary I-Prim
tract I-Prim
infections I-Prim
and I-Prim
falls I-Prim
) I-Prim
. O

Conclusions O
Formoterol O
4.5 O
μg O
and O
9 O
μg O
bid O
was O
effective O
and O
well O
tolerated O
in O
patients O
with O
COPD O
; O
there O
was O
no O
difference O
between O
formoterol O
doses O
for O
the O
primary O
endpoint O
; O
however O
, O
an O
added O
value O
of O
formoterol O
9 O
μg O
over O
4.5 O
μg O
bid O
was O
observed O
for O
some O
secondary O
endpoints O
. O

On O
the O
basis O
of O
this O
trial O
, O
it O
was O
initially O
hypothesised O
a B-Prim
withdrawal I-Prim
proportion I-Prim
from I-Prim
allocated I-Prim
treatment I-Prim
within I-Prim
3 I-Prim
months I-Prim
( O
primary O
study O
endpoint O
) O
of O
25 O
% O
in O
the O
group O
treated O
with O
clozapine O
plus O
haloperidol O
( O
control O
group O
) O
. O

Primary O
efficacy O
parameter O
The O
primary O
efficacy O
instrument O
was O
the B-Prim
11-point I-Prim
NRS I-Prim
in I-Prim
patients' I-Prim
daily I-Prim
pain I-Prim
diaries I-Prim
. O

The O
primary O
end-point O
variable O
was O
to B-Prim
decrease I-Prim
reintubation I-Prim
rates I-Prim
, I-Prim
defined I-Prim
by I-Prim
the I-Prim
necessity I-Prim
of I-Prim
mechanical I-Prim
positive-pressure I-Prim
ventilation I-Prim
through I-Prim
orotracheal I-Prim
intubation I-Prim
in I-Prim
the I-Prim
first I-Prim
48 I-Prim
hours I-Prim
after I-Prim
extubation I-Prim
, I-Prim
in I-Prim
the I-Prim
treatment I-Prim
group I-Prim
. O

The O
primary O
outcomes O
in O
this O
trial O
will O
include O
differences B-Prim
in I-Prim
Nepean I-Prim
Dyspepsia I-Prim
Index I-Prim
scores I-Prim
and O
differences B-Prim
in I-Prim
the I-Prim
Symptom I-Prim
Index I-Prim
of I-Prim
Dyspepsia I-Prim
before I-Prim
randomization I-Prim
, I-Prim
2 I-Prim
weeks I-Prim
and I-Prim
4 I-Prim
weeks I-Prim
after I-Prim
randomization I-Prim
, I-Prim
and I-Prim
1 I-Prim
month I-Prim
and I-Prim
3 I-Prim
months I-Prim
after I-Prim
completing I-Prim
treatment I-Prim
. O

The O
primary O
endpoint O
is O
a B-Prim
composite I-Prim
endpoint I-Prim
of I-Prim
mortality I-Prim
and I-Prim
re-admissions I-Prim
for I-Prim
biliary I-Prim
events I-Prim
. O

The O
former O
leads O
to O
, O
where O
t O
1 O
> O
0 O
is O
the O
time O
at O
which O
the O
first O
set O
of O
measurements O
are O
taken O
. O

Outcome O
measures O
include O
: O
weight B-Prim
( O
primary O
outcome O
) O
, O
% O
body O
fat O
, O
waist O
circumference O
, O
blood O
pressure O
, O
resting O
heart O
rate O
, O
objectively O
measured O
physical O
activity O
, O
self-reported O
dietary O
intake O
, O
sedentary O
behaviour O
, O
physical O
activity O
and O
dietary O
cognitions O
, O
sleepiness O
, O
quality O
of O
life O
, O
and O
perceived O
sexual O
health O
. O

Final O
analysis O
of O
the O
data O
is O
not O
yet O
available O
for O
comparing O
the O
two O
intervention O
groups O
in O
terms O
of O
protocol O
credibility O
, O
satisfaction O
, O
or O
the O
primary O
and O
secondary O
outcomes O
. O

Four O
main O
assessments O
encompass O
the O
treatment O
phase O
and O
follow-up O
. O

The O
primary O
outcome O
measure O
is O
ADHD B-Prim
symptoms I-Prim
. O

The O
primary O
outcome O
will O
be O
uptake B-Prim
of I-Prim
the I-Prim
1 I-Prim
st I-Prim
and I-Prim
3 I-Prim
rd I-Prim
vaccinations I-Prim
. O

The O
data O
analysis O
of O
the O
primary O
and O
secondary O
outcomes O
is O
mainly O
based O
on O
the O
ITT O
population O
. O

The O
main O
secondary O
set O
of O
outcome O
measures O
describes O
patient B-Sec
adherence I-Sec
. O

Study O
endpoints O
The O
primary O
endpoint O
is O
6-month B-Prim
in-stent I-Prim
neointimal I-Prim
hyperplasia I-Prim
area I-Prim
assessed I-Prim
by I-Prim
OCT. I-Prim

Statistical O
analysis O
Primary O
efficacy O
variable O
The O
primary O
efficacy O
variable O
was O
the B-Prim
p27 I-Prim
antigen I-Prim
analysis I-Prim
of I-Prim
serum I-Prim
samples I-Prim
. O

Primary O
outcome O
: O
Timed B-Prim
" I-Prim
up I-Prim
and I-Prim
go I-Prim
" I-Prim
test I-Prim
, O
secondary O
outcomes O
: O
peak B-Sec
surface I-Sec
EMG I-Sec
of I-Sec
gluteus I-Sec
maximus I-Sec
and I-Sec
gluteus I-Sec
medius I-Sec
, O
activation B-Sec
patterns I-Sec
of I-Sec
hemiplegic I-Sec
leg I-Sec
musculature I-Sec
, O
temporo-spatial B-Sec
gait I-Sec
parameters I-Sec
, O
hemiplegic B-Sec
hip I-Sec
kinematics I-Sec
in I-Sec
the I-Sec
frontal I-Sec
and I-Sec
sagittal I-Sec
planes I-Sec
, O
dynamic B-Sec
balance I-Sec
, O
daily B-Sec
activity I-Sec
measured I-Sec
by I-Sec
accelerometry I-Sec
, O
Stroke B-Sec
Impact I-Sec
Scale I-Sec
. O

This O
sample O
size O
would O
yield O
95 O
% O
statistical O
power O
with O
a O
true O
difference O
in O
the O
primary O
endpoint O
of O
2. O

Sample O
size O
Main O
study O
The O
primary O
outcome O
is O
the B-Prim
Process I-Prim
of I-Prim
Recovery I-Prim
Questionnaire I-Prim
( I-Prim
QPR I-Prim
) I-Prim
26 I-Prim
. O

Protocol O
outcome O
measures O
The O
primary O
outcome O
was O
the B-Prim
change I-Prim
in I-Prim
morning I-Prim
peak I-Prim
expiratory I-Prim
flow I-Prim
( I-Prim
PEF I-Prim
) I-Prim
rate I-Prim
from I-Prim
baseline I-Prim
to I-Prim
the I-Prim
end I-Prim
of I-Prim
the I-Prim
treatment I-Prim
period I-Prim
( I-Prim
mean I-Prim
of I-Prim
weeks I-Prim
23 I-Prim
– I-Prim
24 I-Prim
) I-Prim
. O

Calculations O
performed O
at O
80 O
% O
power O
with O
an O
alpha O
level O
of O
0.05 O
suggested O
that O
35 O
participants O
per O
group O
were O
needed O
to O
detect O
a O
difference O
in O
the O
primary O
outcome O
measure O
of O
violent B-Prim
attitudes I-Prim
using I-Prim
the I-Prim
Total I-Prim
MVQ I-Prim
score I-Prim
with O
an O
effect O
size O
of O
.42 O
[ O
pre-treatment O
mean O
15.95 O
( O
S.D. O

The O
principal O
outcome O
variable O
( O
POV O
) O
will O
be O
taken O
as O
the B-Prim
change I-Prim
in I-Prim
the I-Prim
global I-Prim
score I-Prim
on I-Prim
the I-Prim
Yale I-Prim
Scale I-Prim
, O
adjusted O
for O
the O
baseline O
values O
. O

While O
the O
study O
was O
open-label O
after O
concealed O
allocation O
, O
the O
primary O
end O
point O
was O
measured O
by O
staff O
blinded O
to O
treatment O
group O
. O

The O
secondary O
objective O
is O
to O
estimate O
the O
precise O
sample O
size O
and O
primary O
endpoint O
required O
for O
the O
large O
scale O
RCT O
. O

In O
order O
to O
test O
the O
hypothesis O
that O
the O
change O
in O
head O
circumference O
differs O
between O
the O
two O
groups O
while O
taking O
account O
of O
the O
clustering O
arising O
from O
multiple O
pregnancies O
, O
the O
primary O
outcome O
will O
be O
assessed O
using O
a O
general O
linear O
model O
. O

Sample O
size O
and O
power O
We O
will O
randomize O
n O
= O
32 O
participants O
to O
each O
treatment O
group O
and O
assume O
6 O
% O
of O
participants O
will O
drop O
out O
by O
the O
end O
of O
the O
study O
so O
that O
there O
will O
be O
n O
= O
30 O
participants O
in O
each O
group O
at O
the O
final O
endpoint O
. O

Specifically O
, O
we O
aim O
to O
investigate O
the O
effects O
of O
a O
12-month O
exercise O
program O
designed O
to O
load O
the O
musculoskeletal O
system O
and O
reduce O
cardiovascular O
and O
diabetes O
disease O
progression O
on O
the O
following O
primary O
endpoints O
: O
1 B-Prim
) I-Prim
bone I-Prim
mineral I-Prim
density I-Prim
; O
2 B-Prim
) I-Prim
cardiorespiratory I-Prim
function I-Prim
and I-Prim
maximal I-Prim
oxygen I-Prim
capacity I-Prim
; O
3 B-Prim
) I-Prim
body I-Prim
composition I-Prim
( I-Prim
lean I-Prim
mass I-Prim
and I-Prim
fat I-Prim
mass I-Prim
) I-Prim
; O
4 B-Prim
) I-Prim
blood I-Prim
pressure I-Prim
and I-Prim
cardiovascular I-Prim
function I-Prim
; O
5 B-Prim
) I-Prim
lipids I-Prim
and I-Prim
glycemic I-Prim
control I-Prim
; O
and O
6 B-Prim
) I-Prim
quality I-Prim
of I-Prim
life I-Prim
and I-Prim
psychological I-Prim
distress I-Prim
. O

We O
have O
chosen O
this O
primary O
outcome O
because O
delirium O
is O
extremely O
common O
in O
hip O
fracture O
patients O
7 O
, O
there O
is O
increasing O
evidence O
that O
delirium O
may O
have O
long-term O
negative O
consequences O
upon O
cognition O
9 O
10 O
, O
and O
such O
consequences O
are O
devastating O
. O

The O
primary O
end-point O
of O
MR-IMPACT O
II O
was O
the B-Prim
comparison I-Prim
of I-Prim
sensitivity I-Prim
and O
specificity B-Prim
of I-Prim
perfusion-CMR I-Prim
to I-Prim
detect I-Prim
CAD I-Prim
on I-Prim
CXA I-Prim
vs I-Prim
SPECT I-Prim
based I-Prim
on I-Prim
a I-Prim
single-point I-Prim
threshold I-Prim
reading I-Prim
. O

Main O
outcome O
measurement O
for O
patients' B-Prim
QoL I-Prim
is O
the B-Prim
scale I-Prim
physical I-Prim
functioning I-Prim
of I-Prim
the I-Prim
SF-36 I-Prim
health I-Prim
questionnaire I-Prim
in I-Prim
a I-Prim
12-month I-Prim
follow-up I-Prim
. O

Our O
power O
calculation O
is O
based O
on O
our O
primary O
outcome O
of O
weight B-Prim
, O
under O
the O
null O
hypothesis O
that O
there O
will O
be O
no O
between-group O
difference O
in O
weight O
at O
the O
3-month O
time O
point O
. O

Secondary O
analyses O
A O
sensitivity O
analysis O
will O
be O
performed O
on O
the O
primary O
variable O
to O
assess O
the O
impact O
of O
protocol O
deviations O
using O
the O
per O
protocol O
analysis O
set O
. O

The O
primary O
endpoint O
is O
overall B-Prim
survival I-Prim
that I-Prim
is I-Prim
assessed I-Prim
with I-Prim
a I-Prim
minimum I-Prim
follow-up I-Prim
of I-Prim
36 I-Prim
months I-Prim
. O

In O
the O
cost-effectiveness O
study O
, O
the O
primary O
outcome O
is O
the B-Prim
level I-Prim
of I-Prim
functional I-Prim
abilities I-Prim
as I-Prim
measured I-Prim
with I-Prim
the I-Prim
Katz-15 I-Prim
index I-Prim
. O

This O
simple O
size O
gives O
a O
statistical O
power O
of O
higher O
than O
80 O
% O
, O
to O
enable O
any O
difference O
between O
the O
control O
and O
the O
intervention O
group O
greater O
than O
3 O
with O
respect O
to O
the O
primary O
outcome O
scale O
from O
the O
physical O
functioning O
SF-36 O
and O
MLHQ O
to O
be O
found O
to O
be O
significant O
, O
with O
a O
significance O
level O
of O
5 O
% O
using O
the O
two-tailed O
Student's O
t O
test O
( O
standard O
deviations O
obtained O
from O
prior O
studies O
with O
similar O
population O
to O
that O
of O
our O
project O
: O
SD O
= O
10 O
points O
of O
the O
quality O
of O
life O
questionnaires O
SF-36 O
and O
MLHQ O
) O
12 O
25 O
26 O
. O

The B-Prim
total I-Prim
score I-Prim
will O
represent O
the O
primary O
outcome O
. O

Loss O
to O
follow O
up O
for O
the O
primary O
outcome O
of O
HbA1c B-Prim
should O
be O
small O
, O
as O
all O
of O
these O
patients O
will O
be O
attending O
clinic O
on O
a O
regular O
basis O
where O
HbA1c O
is O
monitored O
for O
clinical O
purposes O
. O

The O
primary O
outcome O
measure O
for O
both O
of O
these O
trials O
is O
the B-Prim
number I-Prim
of I-Prim
CST I-Prim
sessions I-Prim
run I-Prim
for I-Prim
people I-Prim
with I-Prim
dementia I-Prim
. O

The O
data O
will O
be O
analysed O
at O
3 O
, O
6 O
and O
12 O
month O
follow-up O
, O
however O
, O
6 O
months O
is O
the O
primary O
end O
point O
for O
the O
study O
. O

The O
primary O
end O
point O
will O
be O
average B-Prim
pain I-Prim
at I-Prim
rest I-Prim
over I-Prim
the I-Prim
first I-Prim
12-hour I-Prim
post-operative I-Prim
period I-Prim
on I-Prim
a I-Prim
verbal I-Prim
analogue I-Prim
pain I-Prim
score I-Prim
. O

All O
randomized O
patients O
will O
be O
included O
in O
the O
intention-to-treat O
analysis O
of O
the O
primary O
outcome O
. O

The O
primary O
outcome O
was O
a B-Prim
reduction I-Prim
in I-Prim
depression I-Prim
. O

Using O
t-tests O
for O
continuous O
variables O
and O
chi-square O
tests O
of O
association O
for O
categorical O
variables O
, O
baseline O
differences O
were O
examined O
in O
key O
study O
outcomes O
by O
intervention O
condition O
to O
assess O
the O
equivalence O
of O
the O
study O
intervention O
conditions O
. O

The O
main O
outcome O
measured O
was O
time B-Prim
to I-Prim
achieve I-Prim
haemostasis I-Prim
at I-Prim
the I-Prim
suture I-Prim
line I-Prim
. O

Primary O
outcome O
The O
primary O
outcome O
measure O
will O
be O
self-assessed B-Prim
health I-Prim
related I-Prim
quality I-Prim
of I-Prim
life I-Prim
assessed I-Prim
using I-Prim
the I-Prim
York I-Prim
SF-12 I-Prim
23 I-Prim
. O

Where O
primary O
outcomes O
reach O
statistical O
significance O
, O
any O
noted O
difference O
in O
the O
baseline O
group O
comparison O
will O
be O
tested O
by O
univariate O
comparison O
with O
stepwise O
addition O
into O
a O
multivariate O
model O
for O
those O
with O
univariate O
significance O
of O
P O
< O
0.1 O
. O

The O
primary O
outcome O
will O
be O
the B-Prim
proportion I-Prim
of I-Prim
patients I-Prim
who I-Prim
are I-Prim
adherent I-Prim
to I-Prim
a I-Prim
complete I-Prim
, I-Prim
guideline-based I-Prim
ACS I-Prim
medication I-Prim
regimen I-Prim
at I-Prim
six I-Prim
and I-Prim
twelve I-Prim
months I-Prim
post-discharge I-Prim
. O

The O
trial O
used O
a O
simple O
, O
relevant O
and O
pragmatic O
primary O
clinical O
endpoint O
rather O
than O
a O
composite O
score O
such O
as O
symptom O
frequency O
plus O
intensity O
. O

The O
final O
NOAAH O
report O
will O
include O
an O
economic O
analysis O
, O
but O
cannot O
address O
cost-benefit O
in O
terms O
of O
hard O
cardiovascular O
outcomes O
, O
because O
blood B-Prim
pressure I-Prim
control I-Prim
is O
the O
main O
outcome O
in O
this O
trial O
with O
limited O
sample O
size O
and O
short O
follow-up O
. O

The O
design O
protects O
the O
primary O
end O
point O
by O
measuring O
attendance O
before O
providing O
further O
information O
about O
the O
trial O
or O
collecting O
questionnaire O
data O
that O
may O
have O
intervention O
effects O
. O

Definition O
of O
end O
points O
Primary O
outcomes O
were O
changes B-Prim
in I-Prim
lifestyle I-Prim
according I-Prim
to I-Prim
established I-Prim
goals I-Prim
that O
have O
been O
shown O
to O
reduce O
incidence O
of O
type O
2 O
diabetes O
, O
improve O
health O
and O
to O
improve O
cardiovascular O
risk O
profile O
. O

The O
primary O
outcome O
measure O
of O
the O
clinical O
evaluation O
is O
depression B-Prim
severity I-Prim
measured I-Prim
by I-Prim
the I-Prim
Beck I-Prim
Depression I-Prim
Intenvory-II I-Prim
( I-Prim
BDI-II I-Prim
) I-Prim
. O

The O
primary O
outcome O
at O
10 O
weeks O
post-partum O
was O
parental B-Prim
participation I-Prim
in I-Prim
each I-Prim
arm I-Prim
, I-Prim
as I-Prim
indicated I-Prim
by I-Prim
the I-Prim
respective I-Prim
return I-Prim
or I-Prim
non-return I-Prim
of I-Prim
a I-Prim
reply I-Prim
form I-Prim
( I-Prim
or I-Prim
via I-Prim
telephone I-Prim
or I-Prim
email I-Prim
response I-Prim
) I-Prim
. O

12 O
, O
were O
performed O
for O
the O
3 O
main O
outcomes O
( O
for O
all O
: O
power O
0.9 O
; O
alpha O
0.05 O
) O
. O

Diary O
All O
participants O
randomised O
to O
the O
trial O
will O
be O
given O
a O
diary O
to O
complete O
at O
baseline O
( O
nurse O
clinical O
assessment O
) O
and O
at O
6 O
months O
( O
the O
primary O
end O
point O
) O
. O

Frequency O
domain O
variables O
, O
including O
total O
, O
HF O
and O
low O
frequency O
( O
LF O
) O
power O
and O
LF O
: O
HF O
ratio O
will O
be O
derived O
from O
spectral O
analysis O
of O
successive O
R-R O
intervals O
. O

Primary O
outcome O
, O
troponin B-Prim
T I-Prim
on I-Prim
POD1 I-Prim
, O
reached O
statistical O
significance O
in O
the O
unadjusted O
as O
well O
as O
the O
linear O
regression O
model O
, O
adjusted O
for O
age O
of O
the O
patient O
, O
ECC O
, O
blood O
products O
, O
as O
well O
as O
the O
baseline O
troponin O
level O
. O

Patient O
Assessment O
and O
Measurements O
Primary O
outcome O
measure O
of O
the O
randomized O
trial O
will O
be O
the B-Prim
change I-Prim
in I-Prim
the I-Prim
Global I-Prim
Index I-Prim
of I-Prim
the I-Prim
Outcome I-Prim
Questionnaire I-Prim
( I-Prim
OQ I-Prim
45.2 I-Prim
) I-Prim
. O

The O
primary O
analysis O
was O
a O
comparison O
between O
the O
pregabalin O
and O
placebo O
groups O
at O
final O
assessment O
and O
was O
based O
on O
an O
analysis O
of O
covariance O
model O
, O
including O
dose O
groups O
and O
baseline O
mean O
pain O
score O
as O
factors O
. O

Sample O
size O
The O
main O
end-points O
are O
six O
and O
24 O
months O
12 O
. O

Data O
on O
the O
primary O
outcome O
as O
well O
as O
on O
intensity O
of O
pain O
, O
sick O
leave O
, O
work O
productivity O
, O
and O
health O
care O
costs O
are O
collected O
every O
3 O
months O
. O

We O
calculate O
the O
mean O
from O
the O
first O
two O
measurements O
with O
less O
than O
5 O
mm O
Hg O
difference O
in O
both O
systolic O
and O
diastolic O
blood O
pressure O
49 O
. O

Primary O
endpoint O
Primary O
endpoint O
is O
3-year B-Prim
DFS I-Prim
in I-Prim
study I-Prim
groups I-Prim
( I-Prim
proportion I-Prim
of I-Prim
patients I-Prim
without I-Prim
local I-Prim
or I-Prim
distant I-Prim
recurrence I-Prim
, I-Prim
or I-Prim
second I-Prim
primary I-Prim
of I-Prim
same I-Prim
of I-Prim
other I-Prim
cancer I-Prim
, I-Prim
death I-Prim
from I-Prim
same I-Prim
cancer I-Prim
of I-Prim
any I-Prim
other I-Prim
cause I-Prim
during I-Prim
the I-Prim
defined I-Prim
period I-Prim
of I-Prim
time I-Prim
) I-Prim
. O

Sample O
size O
Power O
is O
assessed O
for O
the O
primary O
endpoint O
, O
ie O
increased B-Prim
compliance I-Prim
with I-Prim
cervical I-Prim
cancer I-Prim
screening I-Prim
. O

Primary O
outcomes O
include O
unplanned B-Prim
use I-Prim
of I-Prim
heath I-Prim
services I-Prim
for I-Prim
negative I-Prim
event I-Prim
( I-Prim
frequency I-Prim
calendar I-Prim
) I-Prim
and O
quality B-Prim
of I-Prim
life I-Prim
( I-Prim
EQ-5D I-Prim
and I-Prim
Quality I-Prim
of I-Prim
Life I-Prim
Index I-Prim
) I-Prim
. O

For O
the O
primary O
outcome O
measure O
of O
this O
substudy O
, O
work B-Prim
functioning I-Prim
, O
no O
information O
on O
probable O
difference O
on O
ward-level O
exists O
. O

Statistical O
analysis O
A O
linear O
regression O
model O
will O
be O
used O
to O
compare O
collaborative O
care O
with O
usual O
care O
on O
the O
primary O
outcome O
adjusted O
for O
baseline O
depression O
severity O
( O
as O
measured O
by O
the B-Prim
PHQ-9 I-Prim
) O
and O
physical O
/ O
functional O
limitations O
( O
as O
measured O
by O
the O
SF-12 O
physical O
functioning O
scale O
) O
. O

The O
majority O
of O
patients O
would O
reach O
the O
primary O
endpoint O
after O
extubation O
and O
then O
once O
weaned O
down O
to O
a O
single O
inotrope O
. O

Statistical O
analyses O
and O
data O
management O
The O
primary O
endpoint O
is O
the B-Prim
maximum I-Prim
absolute I-Prim
AST I-Prim
value I-Prim
( I-Prim
U I-Prim
/ I-Prim
l I-Prim
) I-Prim
on I-Prim
one I-Prim
of I-Prim
the I-Prim
first I-Prim
three I-Prim
post-operative I-Prim
days I-Prim
. O

Primary O
outcome O
variable O
was O
retention B-Prim
in I-Prim
treatment I-Prim
, I-Prim
which I-Prim
was I-Prim
defined I-Prim
as I-Prim
the I-Prim
number I-Prim
of I-Prim
weeks I-Prim
that I-Prim
patients I-Prim
remained I-Prim
in I-Prim
the I-Prim
study I-Prim
before I-Prim
being I-Prim
discharged I-Prim
. O

The O
primary O
endpoint O
was O
the B-Prim
overall I-Prim
discomfort I-Prim
reported I-Prim
during I-Prim
WC I-Prim
versus I-Prim
SC I-Prim
pH-metry I-Prim
. O

Regarding O
the O
primary O
outcome O
measure O
, O
Short O
treatment O
is O
definite O
inferior O
to O
Standard O
treatment O
with O
statistical O
significance O
of O
≥ O
95 O
% O
certainty O
and O
2 O
) O
. O

The O
primary O
outcome O
measure O
is O
the B-Prim
proportion I-Prim
of I-Prim
women I-Prim
continuously I-Prim
enrolled I-Prim
for I-Prim
24 I-Prim
months I-Prim
with I-Prim
≥1 I-Prim
mammogram I-Prim
in I-Prim
the I-Prim
past I-Prim
24 I-Prim
months I-Prim
. O

The O
primary O
endpoint O
of O
this O
study O
ACR B-Prim
50 I-Prim
improvement I-Prim
compared O
to O
placebo O
was O
reached O
with O
the O
150 O
mg O
sc O
q4wk O
dose O
. O

The O
main O
outcomes O
will O
be O
the B-Prim
Cobb I-Prim
angle I-Prim
two I-Prim
years I-Prim
after I-Prim
inclusion I-Prim
and O
health-related B-Prim
quality I-Prim
of I-Prim
life I-Prim
. O

Major B-Prim
bleeding I-Prim
was O
the O
main O
safety O
outcome O
. O

In O
order O
to O
provide O
sufficient O
power O
to O
detect O
a O
difference O
in O
primary O
outcomes O
( O
Body B-Prim
Mass I-Prim
Index-BMI I-Prim
& I-Prim
ESE I-Prim
at I-Prim
12 I-Prim
month I-Prim
follow-up I-Prim
) O
between O
children O
in O
the O
intervention O
schools O
and O
control O
schools O
, O
the O
target O
sample O
size O
is O
396. O

Primary O
outcome O
: O
length B-Prim
of I-Prim
acute I-Prim
hospital I-Prim
stay I-Prim
is O
determined O
by O
a O
blinded O
team O
of O
clinicians O
. O

Outcome O
measures O
The O
primary O
outcome O
measure O
is O
children's B-Prim
physical I-Prim
activity I-Prim
, I-Prim
as I-Prim
measured I-Prim
by I-Prim
accelerometers I-Prim
. O

Primary O
and O
Secondary O
Outcomes O
There O
will O
be O
a O
composite O
endpoint O
in O
which O
a O
patient O
will O
be O
classified O
as O
having O
a O
positive O
response O
if O
both O
of O
the O
following O
criteria O
are O
satisfied O
: O
• O
Reduction O
in O
proteinuria O
( O
expressed O
as O
the O
protein O
: O
creatinine O
ratio O
in O
a O
first O
morning O
urine O
specimen O
) O
at O
6 O
months O
by O
≥ O
50 O
% O
of O
the O
value O
at O
the O
time O
of O
screening O
, O
AND O
• O
Estimated O
GFR O
( O
eGFR O
) O
at O
6 O
months O
≥ O
75 O
% O
of O
the O
value O
at O
the O
time O
of O
randomization O
in O
those O
with O
an O
initial O
eGFR O
< O
75 O
mL O
/ O
min O
/ O
1.73 O
m O
2 O
OR O
eGFR O
persistently O
≥75 O
mL O
/ O
min O
/ O
1.73 O
m O
2 O
in O
those O
whose O
renal O
function O
was O
≥75 O
mL O
/ O
min O
/ O
1.73 O
m O
2 O
at O
the O
time O
of O
randomization O
. O

Discussion O
This O
randomized O
phase O
2 O
study O
met O
its O
primary O
endpoint O
of O
improved B-Prim
PFS I-Prim
for I-Prim
the I-Prim
maintenance I-Prim
phase I-Prim
, O
based O
on O
the O
Cox O
regression O
model O
stratified O
by O
the O
best O
overall O
response O
to O
induction O
therapy O
( O
HR O
= O
0.76 O
, O
one-sided O
p-value O
< O
0.2 O
) O
, O
indicating O
that O
continuation O
maintenance O
therapy O
with O
pemetrexed O
following O
first-line O
treatment O
with O
pemetrexed O
and O
cisplatin O
was O
sufficiently O
beneficial O
to O
warrant O
further O
investigation O
. O

Key O
secondary O
outcome O
measures O
were O
breathlessness B-Sec
on I-Sec
the I-Sec
transition I-Sec
dyspnoea I-Sec
index I-Sec
( I-Sec
TDI I-Sec
) I-Sec
and O
health-related B-Sec
quality I-Sec
of I-Sec
life I-Sec
( I-Sec
HRQoL I-Sec
) I-Sec
according I-Sec
to I-Sec
the I-Sec
St. I-Sec
George's I-Sec
Respiratory I-Sec
Questionnaire I-Sec
( I-Sec
SGRQ I-Sec
) I-Sec
at I-Sec
Week I-Sec
26 I-Sec
, O
while O
important O
secondary O
outcomes O
were O
time B-Sec
to I-Sec
first I-Sec
moderate I-Sec
or I-Sec
severe I-Sec
COPD I-Sec
exacerbation I-Sec
and O
mean B-Sec
daily I-Sec
rescue I-Sec
medication I-Sec
use I-Sec
over I-Sec
26 I-Sec
weeks I-Sec
. O

The O
analysis O
of O
the O
primary O
outcomes O
was O
by O
a O
simple O
2 O
× O
2 O
table O
. O

As O
one O
of O
the O
main O
outcomes O
of O
these O
interventions O
is O
their O
impact O
on O
quality O
of O
life O
, O
a O
cost-utility O
analysis O
represents O
the O
preferred O
type O
of O
economic O
evaluation O
. O

To O
correct O
this O
possible O
bias O
, O
self-applied B-Prim
instruments I-Prim
will O
be O
preferred O
as O
main O
outcome O
variables O
. O

Assessments O
and O
Analyses O
Primary O
end O
points O
were O
PK B-Prim
parameters I-Prim
and O
safety B-Prim
and O
tolerability B-Prim
. O

Our O
primary O
outcomes O
were O
improvement B-Prim
of I-Prim
GHbA I-Prim
1c I-Prim
and O
the B-Prim
SF-36 I-Prim
quality I-Prim
of I-Prim
life I-Prim
score I-Prim
. O

The O
main O
primary O
outcome O
measure O
is O
the B-Prim
disease I-Prim
specific I-Prim
disability I-Prim
of I-Prim
daily I-Prim
functioning I-Prim
. O

Our O
post O
hoc O
analysis O
of O
the O
primary O
outcome O
, O
stratified O
for O
gestational O
age O
, O
demonstrated O
higher O
PIPP O
scores O
in O
infants O
less O
than O
28 O
weeks O
( O
up O
to O
1 O
to O
2 O
points O
) O
than O
in O
those O
28 O
weeks O
or O
greater O
. O

Outcomes O
The O
primary O
endpoint O
for O
the O
IMOAP O
is O
to B-Prim
assess I-Prim
whether I-Prim
the I-Prim
efficacy I-Prim
of I-Prim
the I-Prim
healthcare I-Prim
professionals' I-Prim
usual I-Prim
practices I-Prim
, I-Prim
together I-Prim
with I-Prim
a I-Prim
motivational I-Prim
group I-Prim
intervention I-Prim
( I-Prim
delivered I-Prim
by I-Prim
a I-Prim
nurse I-Prim
trained I-Prim
by I-Prim
an I-Prim
expert I-Prim
psychologist I-Prim
) I-Prim
, I-Prim
is I-Prim
more I-Prim
effective I-Prim
than I-Prim
an I-Prim
isolated I-Prim
traditional I-Prim
intervention I-Prim
on I-Prim
weight I-Prim
loss I-Prim
and I-Prim
its I-Prim
maintenance I-Prim
in I-Prim
overweight I-Prim
and I-Prim
obese I-Prim
patients I-Prim
. O

Statistical O
analysis O
In O
order O
to O
establish O
the O
noninferiority O
margin O
for O
the O
primary O
endpoint O
, O
the O
results O
of O
two O
large O
, O
phase O
3 O
, O
placebo-controlled O
trials O
of O
12 O
weeks O
duration O
were O
examined O
: O
one O
in O
patients O
with O
lung O
cancer O
( O
n O
= O
314 O
) O
5 O
, O
and O
one O
in O
patients O
with O
lymphoproliferative O
disease O
( O
n O
= O
344 O
) O
3 O
. O

Measures O
The O
primary O
outcome O
will O
be O
the B-Prim
level I-Prim
of I-Prim
depressive I-Prim
symptoms I-Prim
at I-Prim
6 I-Prim
, I-Prim
12 I-Prim
, I-Prim
18 I-Prim
and I-Prim
24 I-Prim
months I-Prim
follow I-Prim
up I-Prim
measured I-Prim
with I-Prim
the I-Prim
Child I-Prim
Depression I-Prim
Inventory I-Prim
( I-Prim
CDI I-Prim
) I-Prim
42 I-Prim
, O
which O
is O
reliable O
and O
valid O
43 O
44 O
. O

The O
target O
sample O
size O
is O
273 O
enrolled O
, O
which O
assuming O
a O
20 O
% O
attrition O
rate O
at O
12 O
months O
, O
will O
provide O
us O
with O
84 O
% O
power O
to O
detect O
a O
moderate O
effect O
size O
of O
.50 O
for O
the O
primary O
outcome O
. O

Primary O
Study O
Endpoints O
The O
primary O
study O
outcome O
is O
: O
• B-Prim
Neonatal I-Prim
Respiratory I-Prim
Distress I-Prim
Syndrome I-Prim
( I-Prim
defined I-Prim
by I-Prim
the I-Prim
incidence I-Prim
( I-Prim
increasing I-Prim
respiratory I-Prim
distress I-Prim
or I-Prim
oxygen I-Prim
requirement I-Prim
or I-Prim
the I-Prim
need I-Prim
for I-Prim
respiratory I-Prim
support I-Prim
from I-Prim
the I-Prim
first I-Prim
six I-Prim
hours I-Prim
of I-Prim
life I-Prim
, I-Prim
in I-Prim
a I-Prim
term I-Prim
or I-Prim
preterm I-Prim
infant I-Prim
) I-Prim
and I-Prim
severity I-Prim
of I-Prim
neonatal I-Prim
respiratory I-Prim
disease I-Prim
( I-Prim
mild I-Prim
= I-Prim
mean I-Prim
airway I-Prim
pressure I-Prim
( I-Prim
MAP I-Prim
) I-Prim
< I-Prim
7 I-Prim
cm I-Prim
H I-Prim
2 I-Prim
O I-Prim
, I-Prim
and I-Prim
/ I-Prim
or I-Prim
fractional I-Prim
inspired I-Prim
oxygen I-Prim
( I-Prim
FiO I-Prim
2 I-Prim
) I-Prim
< I-Prim
0.4 I-Prim
; I-Prim
moderate I-Prim
= I-Prim
MAP I-Prim
7 I-Prim
– I-Prim
9.9 I-Prim
cm I-Prim
H I-Prim
2 I-Prim
O I-Prim
, I-Prim
and I-Prim
/ I-Prim
or I-Prim
FiO I-Prim
2 I-Prim
0.40 I-Prim
– I-Prim
0.79 I-Prim
; I-Prim
severe I-Prim
= I-Prim
MAP I-Prim
≥ I-Prim
10 I-Prim
cm I-Prim
H I-Prim
2 I-Prim
O I-Prim
, I-Prim
and I-Prim
/ I-Prim
or I-Prim
FiO I-Prim
2 I-Prim
≥ I-Prim
0.80 I-Prim
with I-Prim
need I-Prim
for I-Prim
ventilation I-Prim
) I-Prim
2 I-Prim
. O

The O
background O
and O
final O
fluorescent O
intensities O
were O
measured O
5 O
minutes O
after O
treatment O
with O
or O
without O
SIN-1 O
( O
f.c. O

Supplemental O
analyses O
of O
the O
primary O
efficacy O
parameter O
included O
weekly O
mean O
pain O
scores O
and O
proportion O
of O
responders O
. O

Effect O
sizes O
for O
primary O
outcome O
measures O
were O
informed O
by O
the O
literature O
and O
agreed O
by O
study O
site O
clinicians O
. O

The O
primary O
outcome O
measure O
is O
resident B-Prim
agitation I-Prim
, I-Prim
to I-Prim
be I-Prim
assessed I-Prim
with I-Prim
the I-Prim
Cohen-Mansfield I-Prim
Agitation I-Prim
Inventory I-Prim
. O

Primary O
measures O
are O
: O
infant B-Prim
gaze I-Prim
aversion I-Prim
, O
mother-infant B-Prim
gaze I-Prim
coordination I-Prim
, O
infant B-Prim
distress I-Prim
, O
maternal B-Prim
interaction I-Prim
style I-Prim
( I-Prim
affectionate I-Prim
vs. I-Prim
intrusive I-Prim
) I-Prim
, O
and O
responses B-Prim
of I-Prim
mothers I-Prim
and I-Prim
infants I-Prim
to I-Prim
gaze I-Prim
aversion I-Prim
. O

As O
the O
primary O
outcome O
is O
self-report B-Prim
, O
bias O
is O
minimized O
. O

The O
primary O
outcome O
will O
be O
an B-Prim
improvement I-Prim
in I-Prim
insulin I-Prim
sensitivity I-Prim
, I-Prim
measured I-Prim
by I-Prim
hyperinsulinaemic I-Prim
euglycaemic I-Prim
clamp I-Prim
. O

We O
recorded O
the O
mean O
of O
three O
serial O
efforts O
of O
the O
key O
pinch O
measurement O
( O
thumb O
pad O
to O
lateral O
aspect O
of O
middle O
phalanx O
of O
the O
index O
finger O
) O
using O
a O
B O
& O
L O
Engineered O
( O
B O
& O
L O
Engineering O
3002 O
Dow O
Ave O
, O
Suite O
416 O
, O
Tuscin O
CA O
92780 O
) O
30 O
lbs. O

Seven O
primary O
outcomes O
showed O
no O
statistically O
significant O
difference O
between O
MLU O
and O
CLU O
: O
caesarean B-Prim
birth I-Prim
( O
163 O
[ O
14.8 O
% O
] O
vs O
84 O
[ O
15.2 O
% O
] O
; O
relative O
risk O
( O
RR O
) O
0.97 O
, O
95 O
% O
CI O
0.76 O
, O
1.24 O
) O
, O
induction B-Prim
of I-Prim
labour I-Prim
( O
248 O
[ O
22.5 O
% O
] O
vs O
138 O
[ O
25.0 O
% O
] O
; O
RR O
0.90 O
, O
95 O
% O
CI O
0.75 O
, O
1.08 O
) O
, O
episiotomy O
( O
126 O
[ O
11.4 O
% O
] O
vs O
68 O
[ O
12.3 O
% O
] O
; O
RR O
0.93 O
, O
95 O
% O
CI O
0.70 O
, O
1.23 O
) O
, O
instrumental B-Prim
birth I-Prim
( O
139 O
[ O
12.6 O
% O
] O
vs O
79 O
[ O
14.3 O
% O
] O
; O
RR O
0.88 O
, O
95 O
% O
CI O
0.68 O
, O
1.14 O
) O
, O
Apgar B-Prim
scores I-Prim
less I-Prim
than I-Prim
8 I-Prim
( O
10 O
[ O
0.9 O
% O
] O
vs O
9 O
[ O
1.6 O
% O
] O
; O
RR O
0.56 O
, O
95 O
% O
CI O
0.23 O
, O
1.36 O
) O
, O
postpartum B-Prim
haemorrhage I-Prim
( O
PPH O
) O
( O
144 O
[ O
13.1 O
% O
] O
vs O
75 O
[ O
13.6 O
% O
] O
; O
RR O
0.96 O
, O
95 O
% O
CI O
0.74 O
, O
1.25 O
) O
and O
initiation B-Prim
of I-Prim
breastfeeding I-Prim
( O
616 O
[ O
55.9 O
% O
] O
vs O
317 O
[ O
57.4 O
% O
] O
; O
RR O
0.97 O
, O
95 O
% O
CI O
0.89 O
, O
1.06 O
) O
( O
Table O
6 O
) O
. O

The O
three O
co-primary O
endpoints O
all O
demonstrated O
that O
the O
fluticasone O
/ O
formoterol O
combination O
product O
was O
superior O
in O
efficacy O
compared O
to O
each O
of O
the O
comparators O
. O

Main O
outcomes O
will O
be O
objectively-measured B-Prim
physical I-Prim
activity I-Prim
, O
sedentary B-Prim
behaviour I-Prim
and O
activity B-Prim
behaviours I-Prim
; O
food B-Prim
intake I-Prim
( I-Prim
measured I-Prim
by I-Prim
3 I-Prim
day I-Prim
diary I-Prim
) I-Prim
and O
food B-Prim
behaviours I-Prim
; O
body B-Prim
composition I-Prim
, O
fitness B-Prim
and O
physical B-Prim
function I-Prim
; I-Prim
mental I-Prim
and I-Prim
social I-Prim
well-being I-Prim
( I-Prim
quality I-Prim
of I-Prim
life I-Prim
, I-Prim
mood I-Prim
and I-Prim
attitudes I-Prim
) I-Prim
, O
and O
family B-Prim
functioning I-Prim
. O

Subgroup O
analysis O
of O
the O
primary O
clinical O
outcome O
( O
IOP B-Prim
) O
will O
be O
done O
according O
to O
ethnicity O
( O
Chinese O
or O
non-Chinese O
) O
, O
and O
diagnosis O
( O
PAC O
or O
PACG O
) O
. O

S-GGT B-Prim
was O
chosen O
to O
be O
the O
primary O
outcome O
of O
the O
trial O
because O
it O
is O
widely O
used O
in O
screening O
for O
alcohol O
problems O
and O
correlates O
with O
alcohol O
consumption O
. O

Table O
1 O
demonstrates O
the O
differences O
detectable O
between O
any O
two O
intervention O
groups O
for O
the O
listed O
primary O
measure O
( O
eg O
erythromycin O
vs. O
erythromycin-placebo O
) O
in O
each O
of O
the O
specified O
sub-groups O
( O
SPL O
and O
PROM O
) O
. O

Table O
2 O
displays O
the O
degree O
of O
correlation O
between O
the O
first O
and O
second O
measurements O
as O
well O
as O
the O
95 O
% O
confidence O
intervals O
. O

The O
main O
efficacy O
parameter O
was O
change B-Prim
of I-Prim
lower I-Prim
leg I-Prim
volume I-Prim
, I-Prim
determined I-Prim
by I-Prim
water I-Prim
replacement I-Prim
plethysmometry I-Prim
. O

Analytic O
Strategy O
Sample O
size O
and O
power O
calculations O
are O
based O
on O
the O
assumptions O
regarding O
the O
changes O
under O
treatment O
in O
two O
key O
measures O
of O
interest O
, O
namely O
, O
quality B-Prim
of I-Prim
life I-Prim
as I-Prim
measured I-Prim
by I-Prim
the I-Prim
Headache I-Prim
Impact I-Prim
Test I-Prim
( I-Prim
HIT I-Prim
) I-Prim
and O
headache B-Prim
frequency I-Prim
based I-Prim
on I-Prim
headache I-Prim
diary I-Prim
. O

In O
the O
control O
group O
, O
one O
withdrew O
and O
two O
did O
not O
attend O
the O
final O
assessment O
. O

Our O
screening O
procedure O
, O
using O
the B-Prim
PRIME-MD I-Prim
as O
the O
primary O
measure O
to O
diagnose O
major O
depression O
, O
yielded O
many O
patients O
with O
only O
mild O
symptoms O
( O
57 O
% O
) O
. O

The O
primary O
safety O
variables O
were O
unexpected B-Prim
ocular I-Prim
or I-Prim
systemic I-Prim
findings I-Prim
, O
adverse B-Prim
event I-Prim
rate I-Prim
, O
and O
temporary B-Prim
and I-Prim
permanent I-Prim
discontinuation I-Prim
. O

An O
intention O
to O
treat O
analysis O
will O
be O
carried O
out O
on O
the O
primary O
and O
secondary O
outcomes O
. O

Main O
outcome O
is O
tested O
according O
to O
the O
intention O
to O
treat O
principle O
. O

Table O
2 O
Outcome O
measures O
of O
the O
effect O
evaluation O
Primary O
outcome O
measures O
Instrument O
No. O

The O
primary O
outcome O
variable O
was O
child B-Prim
body I-Prim
mass I-Prim
index I-Prim
( I-Prim
BMI I-Prim
) I-Prim
z-score I-Prim
. O

The O
primary O
outcome O
was O
the B-Prim
percentage I-Prim
of I-Prim
days I-Prim
on I-Prim
which I-Prim
the I-Prim
prescribed I-Prim
dose I-Prim
of I-Prim
medication I-Prim
was I-Prim
taken I-Prim
, I-Prim
measured I-Prim
objectively I-Prim
over I-Prim
12 I-Prim
weeks I-Prim
with I-Prim
an I-Prim
electronic I-Prim
medication-monitoring I-Prim
device I-Prim
( I-Prim
TrackCap I-Prim
, I-Prim
Aardex I-Prim
, I-Prim
Switzerland I-Prim
) I-Prim
. O

However O
, O
as O
we O
do O
not O
quite O
know O
how O
marked O
the O
effect O
of O
the O
scrotal O
patches O
will O
be O
, O
we O
decided O
to O
make O
the B-Prim
change I-Prim
in I-Prim
sperm I-Prim
count I-Prim
after I-Prim
90 I-Prim
days I-Prim
of I-Prim
wearing I-Prim
the I-Prim
scrotal I-Prim
cooling I-Prim
patches I-Prim
compared I-Prim
with I-Prim
the I-Prim
control I-Prim
group I-Prim
the O
primary O
outcome O
measure O
, O
because O
if O
statistically O
significant O
differences O
between O
groups O
are O
identified O
, O
a O
post O
hoc O
sample O
size O
calculation O
could O
show O
that O
the O
current O
sample O
size O
( O
20 O
in O
each O
arm O
) O
was O
of O
sufficient O
power O
. O

The O
primary O
efficacy O
measure O
of O
combined B-Prim
renal I-Prim
parameters I-Prim
was O
calculated O
according O
to O
the O
method O
of O
Hartung O
22 O
; O
eCrCl O
was O
analyzed O
by O
repeated O
measures O
ANOVA O
, O
RRT O
requirement O
by O
Fisher's O
exact O
test O
, O
and O
RRT O
duration O
by O
t-test O
. O

As O
seen O
in O
Additional O
file O
1 O
the O
between O
group O
effect O
size O
for O
the O
main O
outcome O
measure O
PDSS B-Prim
was O
d O
= O
0.00 O
( O
CI95 O
% O
= O
-0.41 O
to O
0.41 O
) O
at O
post-treatment O
. O

This O
study's O
primary O
outcome O
will O
be O
the B-Prim
ADOS I-Prim
social I-Prim
communication I-Prim
algorithm I-Prim
score I-Prim
which O
has O
been O
used O
as O
an O
outcome O
measure O
in O
previous O
RCTs O
investigating O
effects O
of O
interventions O
for O
autism O
6 O
38 O
39 O
. O

Primary O
feasibility O
outcomes O
are O
: O
incidence B-Prim
of I-Prim
the I-Prim
index I-Prim
condition I-Prim
, O
the B-Prim
proportion I-Prim
of I-Prim
eligible I-Prim
patients I-Prim
within I-Prim
the I-Prim
screening I-Prim
cohort I-Prim
, O
recruitment B-Prim
rate I-Prim
for I-Prim
those I-Prim
deemed I-Prim
eligible I-Prim
, O
allocation B-Prim
crossover I-Prim
and O
short-term B-Prim
compliance I-Prim
with I-Prim
the I-Prim
study I-Prim
protocol I-Prim
. O

Primary O
outcome O
measures O
were O
global B-Prim
perceived I-Prim
effect I-Prim
( I-Prim
GPE I-Prim
) I-Prim
and O
the B-Prim
impact I-Prim
of I-Prim
the I-Prim
headache I-Prim
using I-Prim
the I-Prim
Headache I-Prim
Impact I-Prim
Test I-Prim
( I-Prim
HIT-6 I-Prim
) I-Prim
. O

There O
was O
one O
randomization O
error O
and O
primary O
outcome O
was O
unavailable O
for O
3 O
infants O
owing O
to O
technical O
difficulties O
with O
the O
video O
recordings O
. O

The O
main O
outcome O
indicators O
were O
cure B-Prim
and O
severity B-Prim
of I-Prim
IAD I-Prim
. O

Iota-Carrageenan O
nasal O
spray O
was O
superior O
to O
placebo O
( O
p O
< O
0.046 O
) O
with O
respect O
to O
the O
primary O
endpoint O
mean O
of O
TSS O
over O
days O
2-4 O
( O
Table O
1 O
) O
. O

The O
difference O
between O
the O
groups O
in O
the O
primary O
end-point O
will O
be O
tested O
by O
means O
of O
the O
two-sided O
log-rank O
test O
. O

Results O
will O
be O
compared O
using O
the O
Generalized O
Linear O
Mixed O
Model O
( O
GLMM O
) O
approach O
to O
focus O
on O
variation O
in O
the O
primary O
outcome O
: O
early B-Prim
childhood I-Prim
caries I-Prim
levels I-Prim
. O

Primary O
outcome O
The O
primary O
outcome O
measure O
of O
the O
study O
was O
the B-Prim
Gastrointestinal I-Prim
Symptom I-Prim
Rating I-Prim
Scale-IBS I-Prim
version I-Prim
( I-Prim
GSRS-IBS I-Prim
) I-Prim
42 I-Prim
. O

Sample O
size O
The O
primary O
outcome O
was O
the B-Prim
EQ-5D I-Prim
utility I-Prim
. O

This O
paper O
presents O
the O
main O
outcomes O
of O
Switch™ O
, O
a O
family- O
, O
school- O
, O
and O
community-based O
intervention O
aimed O
at O
changing O
key O
behaviors O
( O
PA O
, O
television O
viewing O
/ O
screen O
time O
, O
and O
nutrition O
) O
related O
to O
childhood O
obesity O
. O

Cure O
will O
be O
defined O
as O
: O
• O
a O
control O
score O
( O
NCS O
) O
of O
0 O
( O
misalignment O
never O
noticed O
by O
parents O
, O
no O
observable O
deviation O
on O
cover O
test O
) O
• O
demonstrable O
near O
stereoacuity O
in O
children O
over O
3 O
years O
of O
age O
Secondary O
outcomes O
include O
age-specific B-Sec
QOL I-Sec
assessments I-Sec
, O
median B-Sec
scores I-Sec
of I-Sec
control I-Sec
of I-Sec
exotropia I-Sec
assessed I-Sec
by I-Sec
parental I-Sec
report I-Sec
and O
clinical B-Sec
components I-Sec
of I-Sec
the I-Sec
NCS I-Sec
and I-Sec
the I-Sec
Mayo I-Sec
Score I-Sec
, O
rates B-Sec
of I-Sec
amblyopia I-Sec
, O
use B-Sec
of I-Sec
health-care I-Sec
resources I-Sec
, O
NHS B-Sec
costs I-Sec
, O
costs B-Sec
to I-Sec
families I-Sec
accessing I-Sec
the I-Sec
treatments I-Sec
being I-Sec
evaluated I-Sec
and O
incremental B-Sec
cost I-Sec
per I-Sec
cured I-Sec
patient I-Sec
( I-Sec
with I-Sec
cure I-Sec
as I-Sec
defined I-Sec
by I-Sec
the I-Sec
primary I-Sec
outcome I-Sec
) I-Sec
, O
and O
a I-Sec
cost-consequences I-Sec
analysis I-Sec
based I-Sec
on I-Sec
the I-Sec
incremental I-Sec
cost I-Sec
with I-Sec
respect I-Sec
to I-Sec
changes I-Sec
in I-Sec
all I-Sec
relevant I-Sec
outcomes I-Sec
where O
possible O
. O

Endpoints O
The O
primary O
endpoint O
was O
the B-Prim
proportion I-Prim
of I-Prim
children I-Prim
aged I-Prim
9-23 I-Prim
months I-Prim
completely I-Prim
vaccinated I-Prim
. O

Conclusions O
The O
IN O
TOUCH O
study O
is O
the O
first O
to O
investigate O
the O
effect O
of O
telemonitoring O
on O
top O
of O
ICT O
guided O
DM O
on O
the O
quality O
and O
efficiency O
of O
care O
in O
patients O
with O
worsening O
HF O
and O
will O
use O
a B-Prim
composite I-Prim
score I-Prim
as O
its O
primary O
endpoint O
. O

Primary O
endpoint O
: O
level B-Prim
of I-Prim
physical I-Prim
activity I-Prim
Primary O
endpoint O
is O
the B-Prim
level I-Prim
of I-Prim
physical I-Prim
activity I-Prim
, I-Prim
as I-Prim
measured I-Prim
with I-Prim
a I-Prim
7-day I-Prim
recall I-Prim
, I-Prim
based I-Prim
on I-Prim
an I-Prim
interview-based I-Prim
physical I-Prim
activity I-Prim
questionnaire I-Prim
, I-Prim
the I-Prim
LAPAQ I-Prim
35 I-Prim
. O

Outcome O
measures O
The O
primary O
outcome O
measure O
was O
HR B-Prim
and O
lnHF B-Prim
( I-Prim
to I-Prim
determine I-Prim
adaptations I-Prim
in I-Prim
autonomic I-Prim
control I-Prim
specifically I-Prim
vagal I-Prim
autonomic I-Prim
control I-Prim
) I-Prim
. O

In O
light O
of O
these O
considerations O
, O
the O
DSMB O
recommended O
: O
( O
a O
) O
to O
reduce O
the O
number O
of O
cohorts O
to O
4 O
( O
to O
conserve O
budget O
) O
; O
( O
b O
) O
to O
focus O
recruitment O
in O
Cohort O
4 O
on O
patients O
who O
were O
not O
in O
BP O
control O
at O
baseline O
( O
to O
ensure O
that O
the O
study O
population O
approximated O
the O
original O
target O
population O
as O
much O
as O
possible O
) O
; O
and O
( O
c O
) O
to O
change O
the O
primary O
outcome O
to O
change O
in O
SBP O
, O
measured O
as O
a O
continuous O
variable O
, O
while O
maintaining O
the O
dichotomous O
measure O
of O
BP B-Sec
control I-Sec
as O
a O
secondary O
outcome O
( O
to O
increase O
statistical O
power O
by O
, O
for O
example O
, O
being O
able O
to O
differentiate O
between O
greater O
decreases O
in O
SBP O
among O
patients O
who O
were O
in O
BP O
control O
at O
baseline O
) O
. O

From O
this O
, O
we O
estimated O
that O
with O
a O
sample O
size O
of O
60 O
we O
would O
have O
a O
finding O
of O
clinical O
and O
statistical O
significance O
for O
differences O
in O
the O
primary O
outcome O
. O

Outcomes O
When O
the O
data O
analysis O
takes O
place O
, O
the O
primary O
outcomes O
will O
be O
percentage B-Prim
reductions I-Prim
in I-Prim
binge I-Prim
drinking I-Prim
, O
weekly B-Prim
and I-Prim
weekend I-Prim
drinking I-Prim
, O
and O
drinking-related B-Prim
problems I-Prim
. O

Consumption O
of O
acetaminophen O
( O
up O
to O
four O
325-mg O
tablets O
per O
day O
) O
was O
permitted O
for O
residual O
knee O
or O
other O
body O
pain O
throughout O
the O
treatment O
period O
, O
but O
not O
during O
the O
washout O
period O
prior O
to O
baseline O
assessment O
or O
during O
the O
week O
prior O
to O
final O
assessment O
at O
week O
6. O

Outcome O
measures O
The O
primary O
outcome O
measure O
will O
be O
the B-Prim
incidence I-Prim
of I-Prim
new I-Prim
falls I-Prim
, I-Prim
fallers I-Prim
, I-Prim
based I-Prim
on I-Prim
the I-Prim
Falls I-Prim
Calendar I-Prim
. O

The O
primary O
efficacy O
measure O
was O
the B-Prim
serum I-Prim
phosphorus I-Prim
at I-Prim
12 I-Prim
weeks I-Prim
. O

Clinical O
outcomes O
Primary O
clinical O
endpoint O
will O
be O
the B-Prim
improvement I-Prim
in I-Prim
health-related I-Prim
quality I-Prim
of I-Prim
life I-Prim
( I-Prim
HRQoL I-Prim
) I-Prim
at I-Prim
one I-Prim
year I-Prim
follow-up I-Prim
after I-Prim
the I-Prim
12 I-Prim
weeks I-Prim
of I-Prim
therapy I-Prim
as I-Prim
measured I-Prim
by I-Prim
the I-Prim
Mental I-Prim
Component I-Prim
Summary I-Prim
Score I-Prim
of I-Prim
the I-Prim
SF-36 I-Prim
. O

Primary O
outcome O
is O
to B-Prim
recruit I-Prim
at I-Prim
least I-Prim
four I-Prim
patients I-Prim
every I-Prim
month I-Prim
with I-Prim
80 I-Prim
% I-Prim
of I-Prim
eligible I-Prim
patients I-Prim
being I-Prim
recruited I-Prim
. O

Table O
1 O
Baseline O
characteristics O
of O
study O
participants O
described O
for O
primary O
and O
secondary O
outcome O
measures O
. O

Statistical O
Analyses O
/ O
Sample O
Size O
and O
Power O
Calculations O
Sample O
Size O
and O
Power O
The O
primary O
endpoint O
is O
cotinine B-Prim
verified I-Prim
continuous I-Prim
abstinence I-Prim
at I-Prim
12 I-Prim
months I-Prim
. O

The O
primary O
outcome O
variables O
of O
heart B-Prim
rate I-Prim
and O
heart B-Prim
rate I-Prim
variability I-Prim
were O
measured O
to O
assess O
autonomic O
function O
associated O
with O
cardiovascular O
disease O
. O

Trial O
phase O
The O
primary O
outcomes O
( O
Table O
1 O
) O
include O
quality B-Prim
of I-Prim
life I-Prim
, I-Prim
measured I-Prim
across I-Prim
four I-Prim
dimensions I-Prim
( I-Prim
physical I-Prim
, I-Prim
psychological I-Prim
, I-Prim
environmental I-Prim
, I-Prim
social I-Prim
) I-Prim
using I-Prim
the I-Prim
WHOQoL-Bref I-Prim
58 I-Prim
, O
and O
mental B-Prim
health I-Prim
status I-Prim
, I-Prim
using I-Prim
the I-Prim
mental I-Prim
component I-Prim
of I-Prim
the I-Prim
SF-12 I-Prim
59 I-Prim
. O

For O
both O
primary O
and O
secondary O
outcomes O
, O
the O
change O
from O
study O
baseline O
for O
a O
given O
parameter O
was O
calculated O
( O
ie O
, O
Day O
28 O
value O
minus O
baseline O
value O
) O
. O

Primary O
outcomes O
will O
undergo O
a O
two-way O
analysis O
of O
variance O
controlling O
for O
covariants O
such O
as O
operating O
room O
ambient O
temperature O
and O
volume O
of O
intraoperative O
irrigation O
solution O
. O

The B-Prim
duration I-Prim
and O
severity B-Prim
of I-Prim
diarrhea I-Prim
were O
the O
main O
endpoint O
variables O
of O
the O
study O
performed O
in O
a O
metabolic O
unit O
. O

For O
stratified O
analyses O
of O
the O
primary O
outcome O
we O
will O
use O
formal O
tests O
of O
interaction O
between O
allocated O
interventions O
and O
subgroup O
in O
multivariable O
logistic O
regression O
models O
40 O
. O

The O
primary O
outcome O
of O
the O
study O
was O
lung B-Prim
function I-Prim
. O

All O
pre-planned O
sensitivity O
analyses O
of O
the O
primary O
endpoint O
confirmed O
non-inferiority O
. O

Figure O
6 O
Medical O
Outcome O
Study O
Short O
Form O
36 O
( O
SF-36 O
) O
domain O
scores O
at O
end O
point O
( O
last O
observation O
carried O
forward O
) O
for O
pooled O
intent-to O
with O
≥ O
50 O
% O
or O
< O
50 O
% O
reductions O
in O
monthly O
migraine O
frequency O
Medical O
Outcome O
Study O
Short O
Form O
36 O
( O
SF-36 O
) O
domain O
scores O
at O
end O
point O
( O
last O
observation O
carried O
forward O
) O
for O
pooled O
intent-to O
with O
* O
#8805 O
; O
50 O
% O
or O
< O
50 O
% O
reductions O
in O
monthly O
migraine O
frequency O
. O

At O
3 O
months O
, O
primary O
outcome O
( O
psychosocial B-Prim
functions I-Prim
) O
and O
secondary O
outcome O
variables O
( O
HRQOL B-Sec
) O
will O
be O
re-assessed O
. O

Separate O
calculations O
were O
performed O
using O
two O
of O
the O
primary O
outcome O
measures O
, O
so O
as O
to O
determine O
the O
sample-size O
requirements O
based O
on O
stepping O
reactions O
( O
average O
number O
of O
' O
extra O
' O
steps O
taken O
to O
recover O
balance O
) O
and O
grasping O
reactions O
( O
handrail-contact O
time O
) O
. O

Difference B-Prim
in I-Prim
plasma I-Prim
bone I-Prim
marker I-Prim
concentration I-Prim
between I-Prim
treatment I-Prim
groups I-Prim
was O
the O
primary O
outcome O
. O

Primary O
efficacy O
endpoint O
analysis O
consisted O
of O
all O
randomized O
and O
dispensed O
subjects O
with O
baseline O
and O
at O
least O
1 O
post-treatment O
VA O
recorded O
. O

In O
the O
present O
study O
, O
efficacy O
of O
sodium O
hyaluronate O
, O
as O
measured O
by O
the O
primary O
outcome O
variable O
, O
did O
not O
show O
signs O
of O
waning O
at O
the O
25-week O
timepoint O
. O

Primary O
outcomes O
are O
distress B-Prim
and O
MS-related B-Prim
social I-Prim
and I-Prim
role I-Prim
impairment I-Prim
at I-Prim
twelve I-Prim
month I-Prim
follow-up I-Prim
. O

The O
primary O
endpoint O
was O
the B-Prim
percent I-Prim
of I-Prim
subjects I-Prim
meeting I-Prim
TR I-Prim
during I-Prim
the I-Prim
initial I-Prim
30 I-Prim
minutes I-Prim
of I-Prim
treatment I-Prim
. O

The O
primary O
measure O
is O
the B-Prim
total I-Prim
score I-Prim
of I-Prim
this I-Prim
task I-Prim
( I-Prim
max I-Prim
= I-Prim
18 I-Prim
) I-Prim
. O

The O
primary O
end-point O
of O
this O
trial O
is O
the B-Prim
overall I-Prim
quality I-Prim
of I-Prim
end-of-life I-Prim
care I-Prim
provided I-Prim
on I-Prim
the I-Prim
ward I-Prim
to I-Prim
dying I-Prim
cancer I-Prim
patients I-Prim
and I-Prim
their I-Prim
families I-Prim
. O

It O
is O
anticipated O
that O
the O
primary O
economic O
endpoint O
will O
involve O
a O
clinically O
significant O
improvement O
in O
fatigue O
( O
eg O
cost O
per O
unit O
change O
in O
the O
fatigue O
outcome O
measure O
) O
. O

Primary O
efficacy O
variable O
was O
response B-Prim
rate I-Prim
based I-Prim
on I-Prim
a I-Prim
20 I-Prim
% I-Prim
improvement I-Prim
in I-Prim
WOMAC I-Prim
pain I-Prim
scores I-Prim
. O

We O
will O
use O
evidence O
on O
the O
association O
between O
walking O
capacity O
( O
distance O
and O
speed O
) O
and O
mortality O
risk O
to O
extrapolate O
our O
intermediate O
endpoints O
( O
distance O
walked O
in O
6 O
minutes O
and O
timed O
up-and-go O
assessment O
) O
to O
final O
outcomes O
. O

A O
result O
was O
considered O
statistically O
significant O
when O
the O
P O
value O
was O
< O
0.05 O
for O
primary O
outcomes O
( O
BMD B-Prim
) O
and O
< O
0.01 O
for O
secondary O
outcomes O
. O

The O
primary O
endpoint O
was O
the B-Prim
proportion I-Prim
of I-Prim
patients I-Prim
relapse-free I-Prim
at I-Prim
Week I-Prim
26. I-Prim

The O
primary O
outcome O
measure O
is O
the B-Prim
patient's I-Prim
admission I-Prim
to I-Prim
a I-Prim
nursing I-Prim
home I-Prim
or I-Prim
home I-Prim
for I-Prim
the I-Prim
elderly I-Prim
at I-Prim
12 I-Prim
months I-Prim
of I-Prim
follow-up I-Prim
. O

The O
primary O
outcome O
measure O
is O
perception B-Prim
of I-Prim
recovery I-Prim
measured I-Prim
on I-Prim
a I-Prim
7-point I-Prim
Likert I-Prim
scale I-Prim
ranging I-Prim
from I-Prim
" I-Prim
completely I-Prim
recovered I-Prim
" I-Prim
to I-Prim
" I-Prim
worse I-Prim
than I-Prim
ever I-Prim
" I-Prim
at I-Prim
12 I-Prim
months I-Prim
. O

Outcome O
measures O
and O
data O
collection O
The O
primary O
end O
point O
was O
improvement B-Prim
in I-Prim
oxygenation I-Prim
( I-Prim
improvement I-Prim
of I-Prim
PaO I-Prim
2 I-Prim
/ I-Prim
FiO I-Prim
2 I-Prim
( I-Prim
PF I-Prim
) I-Prim
ratio I-Prim
) I-Prim
. O

Primary O
outcomes O
are O
death B-Prim
from I-Prim
causes I-Prim
at I-Prim
study I-Prim
end I-Prim
( I-Prim
follow-up I-Prim
until I-Prim
at I-Prim
least I-Prim
46 I-Prim
weeks I-Prim
after I-Prim
randomization I-Prim
) I-Prim
. O

Primary O
and O
secondary O
outcomes O
will O
be O
evaluated O
pre- O
and O
post-intervention O
with O
a O
follow-up O
of O
12 O
months O
. O

The O
mean O
( O
standard O
deviation O
) O
scores O
of O
CRF O
, O
for O
the O
pre-specified O
primary O
outcome O
, O
CRF B-Prim
as I-Prim
measured I-Prim
by I-Prim
the I-Prim
BFI I-Prim
, O
were O
6.33 O
( O
1.39 O
) O
and O
6.00 O
( O
1.09 O
) O
at O
baseline O
for O
the O
treatment O
and O
control O
groups O
, O
respectively O
( O
See O
Table O
3 O
) O
. O

The O
primary O
endpoint O
was O
disease B-Prim
free I-Prim
survival I-Prim
( I-Prim
DFS I-Prim
) I-Prim
and O
the O
secondary O
endpoints O
overall B-Sec
survival I-Sec
and O
toxicity B-Sec
. O

After O
12 O
weeks O
, O
the O
intervention O
group O
showed O
statistically O
as O
well O
as O
clinically O
significant O
differences O
compared O
with O
the O
control O
group O
on O
the O
primary O
and O
secondary O
outcome O
measures O
. O

The O
primary O
efficacy O
measure O
was O
the B-Prim
mean I-Prim
number I-Prim
of I-Prim
oocytes I-Prim
retrieved I-Prim
; O
secondary O
efficacy O
measures O
included O
the B-Sec
total I-Sec
dose I-Sec
and I-Sec
duration I-Sec
of I-Sec
gonadotropin I-Sec
treatment I-Sec
; O
peak B-Sec
serum I-Sec
estradion I-Sec
levels I-Sec
; O
embryo B-Sec
transfer I-Sec
and I-Sec
implantation I-Sec
rates I-Sec
; O
chemical B-Sec
, I-Sec
clinical I-Sec
and I-Sec
continuing I-Sec
pregnancies I-Sec
; O
and O
live B-Sec
birth I-Sec
rates I-Sec
. O

We O
feel O
that O
this O
can O
be O
justified O
as O
our O
previous O
work O
has O
shown O
that O
less O
than O
8 O
% O
of O
children O
with O
X O
( O
T O
) O
had O
surgery O
within O
the O
first O
year O
following O
initial O
assessment O
when O
treated O
in O
a O
routine O
setting O
18 O
; O
in O
some O
centres O
, O
no O
children O
had O
surgery O
within O
2 O
years O
of O
diagnosis O
19 O
. O

The O
primary O
outcome O
measure O
is O
changes B-Prim
in I-Prim
regional I-Prim
cerebral I-Prim
blood I-Prim
flow I-Prim
from I-Prim
baseline I-Prim
in I-Prim
the I-Prim
arterial I-Prim
territories I-Prim
of I-Prim
the I-Prim
anterior I-Prim
cerebral I-Prim
artery I-Prim
, I-Prim
medial I-Prim
cerebral I-Prim
artery I-Prim
and I-Prim
the I-Prim
posterior I-Prim
cerebral I-Prim
artery I-Prim
, I-Prim
measured I-Prim
by I-Prim
CT I-Prim
perfusion I-Prim
scan I-Prim
. O

Analyses O
of O
primary O
and O
secondary O
outcomes O
will O
be O
by O
intention O
to O
treat O
including O
all O
those O
recruited O
, O
and O
will O
compare O
differences O
between O
MMHU O
and O
standard O
care O
: O
• O
Mean O
/ O
median O
days O
at O
home O
, O
and O
total O
length O
of O
hospital O
stay O
( O
and O
95 O
% O
confidence O
intervals O
for O
the O
differences O
) O
• O
Proportions O
dead O
, O
at O
home O
, O
in O
new O
care O
homes O
and O
readmitted O
( O
and O
95 O
% O
confidence O
intervals O
for O
the O
differences O
) O
• O
Mean O
/ O
median O
scaled O
outcomes O
for O
patients O
and O
carers O
( O
and O
95 O
% O
confidence O
intervals O
for O
the O
differences O
) O
. O

Statistical O
analysis O
An O
a O
priori O
analysis O
of O
sample O
size O
revealed O
that O
at O
least O
17 O
patients O
per O
group O
were O
required O
to O
demonstrate O
a O
minimum O
difference O
of O
20 O
% O
between O
groups O
in O
the O
primary O
endpoint O
with O
an O
estimated O
standard O
deviation O
of O
20 O
% O
, O
a O
test O
power O
of O
80 O
% O
, O
and O
an O
alpha O
error O
of O
5 O
% O
. O

Sensitivity O
analysis O
will O
test O
uncertainty O
in O
key O
parameters O
such O
as O
the O
selection O
of O
cost O
weights O
and O
statistical O
variation O
in O
quality O
of O
life O
scores O
. O

Statistical O
analysis O
Confirmatory O
analysis O
The O
confirmatory O
analysis O
of O
the O
primary O
efficacy O
endpoint O
will O
be O
conducted O
according O
to O
the O
intention-to-treat O
principle O
, O
ie O
, O
all O
randomised O
patients O
will O
be O
included O
and O
will O
be O
analysed O
in O
the O
treatment O
group O
where O
they O
were O
allocated O
to O
by O
randomisation O
. O

Main O
toddler O
outcomes O
include O
: O
a B-Prim
) I-Prim
increased I-Prim
fruit I-Prim
and I-Prim
vegetable I-Prim
consumption I-Prim
and I-Prim
decreased I-Prim
sweetened I-Prim
beverage I-Prim
consumption I-Prim
; O
and O
b B-Prim
) I-Prim
improved I-Prim
toddler-eating I-Prim
skills I-Prim
( I-Prim
self-feeding I-Prim
and I-Prim
self-serving I-Prim
) I-Prim
. O

If O
there O
was O
no O
data O
for O
the O
primary O
endpoint O
( O
sRaw B-Prim
) O
at O
week O
4 O
, O
the O
last O
observation O
from O
week O
2 O
was O
carried O
forward O
. O

The O
main O
outcome O
measure O
was O
Chlamydia B-Prim
screening I-Prim
rates I-Prim
. O

